Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
35700.0 | 2022-10-05 00:00:00 UTC | ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Shift From Loss To Profit | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-inc.s-nasdaq%3Aacad-shift-from-loss-to-profit | nan | nan | We feel now is a pretty good time to analyse ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) business as it appears the company may be on the cusp of a considerable accomplishment. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The US$2.9b market-cap company posted a loss in its most recent financial year of US$168m and a latest trailing-twelve-month loss of US$205m leading to an even wider gap between loss and breakeven. The most pressing concern for investors is ACADIA Pharmaceuticals' path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts’ expectations for the company.
Consensus from 20 of the American Biotechs analysts is that ACADIA Pharmaceuticals is on the verge of breakeven. They expect the company to post a final loss in 2023, before turning a profit of US$36m in 2024. Therefore, the company is expected to breakeven roughly 2 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 76% is expected, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.
NasdaqGS:ACAD Earnings Per Share Growth October 5th 2022
Underlying developments driving ACADIA Pharmaceuticals' growth isn’t the focus of this broad overview, however, take into account that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
One thing we’d like to point out is that ACADIA Pharmaceuticals has no debt on its balance sheet, which is rare for a loss-making biotech, which usually has a high level of debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.
Next Steps:
There are key fundamentals of ACADIA Pharmaceuticals which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at ACADIA Pharmaceuticals, take a look at ACADIA Pharmaceuticals' company page on Simply Wall St. We've also compiled a list of pertinent factors you should look at:
Valuation: What is ACADIA Pharmaceuticals worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether ACADIA Pharmaceuticals is currently mispriced by the market.
Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on ACADIA Pharmaceuticals’s board and the CEO’s background.
Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We feel now is a pretty good time to analyse ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) business as it appears the company may be on the cusp of a considerable accomplishment. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The most pressing concern for investors is ACADIA Pharmaceuticals' path to profitability – when will it breakeven? | We feel now is a pretty good time to analyse ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) business as it appears the company may be on the cusp of a considerable accomplishment. NasdaqGS:ACAD Earnings Per Share Growth October 5th 2022 Underlying developments driving ACADIA Pharmaceuticals' growth isn’t the focus of this broad overview, however, take into account that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. For a more comprehensive look at ACADIA Pharmaceuticals, take a look at ACADIA Pharmaceuticals' company page on Simply Wall St. We've also compiled a list of pertinent factors you should look at: Valuation: What is ACADIA Pharmaceuticals worth today? | We feel now is a pretty good time to analyse ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) business as it appears the company may be on the cusp of a considerable accomplishment. NasdaqGS:ACAD Earnings Per Share Growth October 5th 2022 Underlying developments driving ACADIA Pharmaceuticals' growth isn’t the focus of this broad overview, however, take into account that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. For a more comprehensive look at ACADIA Pharmaceuticals, take a look at ACADIA Pharmaceuticals' company page on Simply Wall St. We've also compiled a list of pertinent factors you should look at: Valuation: What is ACADIA Pharmaceuticals worth today? | The most pressing concern for investors is ACADIA Pharmaceuticals' path to profitability – when will it breakeven? We feel now is a pretty good time to analyse ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) business as it appears the company may be on the cusp of a considerable accomplishment. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. |
35701.0 | 2022-09-23 00:00:00 UTC | SPDR S&P Biotech ETF Experiences Big Outflow | ACAD | https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-outflow-2 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $329.5 million dollar outflow -- that's a 4.6% decrease week over week (from 91,620,000 to 87,400,000). Among the largest underlying components of XBI, in trading today CRISPR Therapeutics AG (Symbol: CRSP) is down about 2.5%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.8%, and ChemoCentryx, Inc. (Symbol: CCXI) is relatively unchanged. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average:
Looking at the chart above, XBI's low point in its 52 week range is $61.78 per share, with $134.79 as the 52 week high point — that compares with a last trade of $76.51. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XBI, in trading today CRISPR Therapeutics AG (Symbol: CRSP) is down about 2.5%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.8%, and ChemoCentryx, Inc. (Symbol: CCXI) is relatively unchanged. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $61.78 per share, with $134.79 as the 52 week high point — that compares with a last trade of $76.51. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XBI, in trading today CRISPR Therapeutics AG (Symbol: CRSP) is down about 2.5%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.8%, and ChemoCentryx, Inc. (Symbol: CCXI) is relatively unchanged. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $61.78 per share, with $134.79 as the 52 week high point — that compares with a last trade of $76.51. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of XBI, in trading today CRISPR Therapeutics AG (Symbol: CRSP) is down about 2.5%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.8%, and ChemoCentryx, Inc. (Symbol: CCXI) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $329.5 million dollar outflow -- that's a 4.6% decrease week over week (from 91,620,000 to 87,400,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $61.78 per share, with $134.79 as the 52 week high point — that compares with a last trade of $76.51. | Among the largest underlying components of XBI, in trading today CRISPR Therapeutics AG (Symbol: CRSP) is down about 2.5%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.8%, and ChemoCentryx, Inc. (Symbol: CCXI) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $329.5 million dollar outflow -- that's a 4.6% decrease week over week (from 91,620,000 to 87,400,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $61.78 per share, with $134.79 as the 52 week high point — that compares with a last trade of $76.51. |
35702.0 | 2022-09-12 00:00:00 UTC | Acadia Says FDA Accepts For Filing NDA Of Trofinetide For Rett Syndrome Treatment | ACAD | https://www.nasdaq.com/articles/acadia-says-fda-accepts-for-filing-nda-of-trofinetide-for-rett-syndrome-treatment | nan | nan | (RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) said that the U.S. Food and Drug Administration has accepted for filing its New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome.
The company noted that the FDA has granted a priority review and assigned a PDUFA or Prescription Drug User Fee Act action date of March 12, 2023. The FDA has also informed the company that at this time they are not planning to hold an Advisory Committee meeting.
Rett syndrome is a complex, multisystem neurodevelopmental disorder that includes a period of normal development followed by significant developmental regression with loss of language and hand function skills, impaired gait and development of hand stereotypes.
For More Such Health News, visit rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) said that the U.S. Food and Drug Administration has accepted for filing its New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The company noted that the FDA has granted a priority review and assigned a PDUFA or Prescription Drug User Fee Act action date of March 12, 2023. The FDA has also informed the company that at this time they are not planning to hold an Advisory Committee meeting. | (RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) said that the U.S. Food and Drug Administration has accepted for filing its New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. Rett syndrome is a complex, multisystem neurodevelopmental disorder that includes a period of normal development followed by significant developmental regression with loss of language and hand function skills, impaired gait and development of hand stereotypes. For More Such Health News, visit rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) said that the U.S. Food and Drug Administration has accepted for filing its New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The company noted that the FDA has granted a priority review and assigned a PDUFA or Prescription Drug User Fee Act action date of March 12, 2023. Rett syndrome is a complex, multisystem neurodevelopmental disorder that includes a period of normal development followed by significant developmental regression with loss of language and hand function skills, impaired gait and development of hand stereotypes. | (RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) said that the U.S. Food and Drug Administration has accepted for filing its New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The company noted that the FDA has granted a priority review and assigned a PDUFA or Prescription Drug User Fee Act action date of March 12, 2023. The FDA has also informed the company that at this time they are not planning to hold an Advisory Committee meeting. |
35703.0 | 2022-09-08 00:00:00 UTC | October 28th Options Now Available For Acadia Pharmaceuticals (ACAD) | ACAD | https://www.nasdaq.com/articles/october-28th-options-now-available-for-acadia-pharmaceuticals-acad | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the October 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new October 28th contracts and identified one put and one call contract of particular interest.
The put contract at the $15.00 strike price has a current bid of 5 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $15.00, but will also collect the premium, putting the cost basis of the shares at $14.95 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $17.28/share today.
Because the $15.00 strike represents an approximate 13% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.33% return on the cash commitment, or 2.43% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 85 cents. If an investor was to purchase shares of ACAD stock at the current price level of $17.28/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $18.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 9.09% if the stock gets called away at the October 28th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red:
Considering the fact that the $18.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 50%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 4.92% boost of extra return to the investor, or 35.91% annualized, which we refer to as the YieldBoost.
The implied volatility in the call contract example above is 198%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $17.28) to be 77%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the October 28th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the October 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new October 28th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 85 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the October 28th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 85 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the October 28th expiration. |
35704.0 | 2022-09-07 00:00:00 UTC | Acadia (ACAD) Down 0.6% Since Last Earnings Report: Can It Rebound? | ACAD | https://www.nasdaq.com/articles/acadia-acad-down-0.6-since-last-earnings-report%3A-can-it-rebound | nan | nan | A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have lost about 0.6% in that time frame, outperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Acadia due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Acadia's Q2 Earnings & Revenues Surpass Estimates
Acadia reported a second-quarter 2022 loss of 21 cents per share, narrower than the Zacks Consensus Estimate of a loss of 25 cents. In the year-ago quarter, the company had incurred a loss of 27 cents per share.
Total revenues, comprising net sales of Nuplazid, increased 17% year over year to $134.6 million in the second quarter, driven by Nuplazid demand growth. The top line surpassed the Zacks Consensus Estimate of $131 million. Nuplazid’s sales increased 16.5% sequentially in the reported quarter.
Quarter in Detail
Research and development (R&D) expenses were $75.6 million for the quarter, up 32.8% year over year, owing to increased costs related to pipeline development activities, especially ACP-044, ACP-319 and other early-stage pipeline candidates.
Selling, general and administrative (SG&A) expenses were $89.9 million, down 7.1% year over year, owing to reduced advertising and promotional costs as well as lower personnel expenses.
As of Jun 30, 2022, Acadia had cash, cash equivalents and investments worth $436.4 million compared with $446 million as of Mar 31, 2022.
2022 Guidance
Acadia updated the financial guidance for 2022.
The company now expects Nuplazid net sales in the range of $510-$540 million compared with the earlier projection of $510-$560 million for 2022. The Zacks Consensus Estimate for the metric is pegged at $530.98 million.
The company expects R&D expenses in the range of $340-$360 million compared with the $355-$375 million expected previously. SG&A expenses are expected to be $360-$380 million, unchanged from the previous guidance.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended upward during the past month.
The consensus estimate has shifted 9.29% due to these changes.
VGM Scores
Currently, Acadia has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Acadia has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Want to Know the #1 Semiconductor Stock for 2022?
Few people know how promising the semiconductor market is. Over the last couple of years, disruptions to the supply chain have caused shortages in several industries. The absence of one single semiconductor can stop all operations in certain industries.
This year, companies that create and produce this essential material will have incredible pricing power. For a limited time, Zacks is revealing the top semiconductor stock for 2022. You'll find it in our new Special Report, One Semiconductor Stock Stands to Gain the Most.
Today, it's yours free with no obligation.
>>Give me access to my free special report.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Will the recent negative trend continue leading up to its next earnings release, or is Acadia due for a breakout? A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD). Acadia's Q2 Earnings & Revenues Surpass Estimates Acadia reported a second-quarter 2022 loss of 21 cents per share, narrower than the Zacks Consensus Estimate of a loss of 25 cents. | Acadia's Q2 Earnings & Revenues Surpass Estimates Acadia reported a second-quarter 2022 loss of 21 cents per share, narrower than the Zacks Consensus Estimate of a loss of 25 cents. A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD). Will the recent negative trend continue leading up to its next earnings release, or is Acadia due for a breakout? | Acadia's Q2 Earnings & Revenues Surpass Estimates Acadia reported a second-quarter 2022 loss of 21 cents per share, narrower than the Zacks Consensus Estimate of a loss of 25 cents. VGM Scores Currently, Acadia has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy. A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD). | Acadia's Q2 Earnings & Revenues Surpass Estimates Acadia reported a second-quarter 2022 loss of 21 cents per share, narrower than the Zacks Consensus Estimate of a loss of 25 cents. A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD). Will the recent negative trend continue leading up to its next earnings release, or is Acadia due for a breakout? |
35705.0 | 2022-09-07 00:00:00 UTC | Add Up The Parts: IYY Could Be Worth $119 | ACAD | https://www.nasdaq.com/articles/add-up-the-parts%3A-iyy-could-be-worth-%24119 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Dow Jones U.S. ETF (Symbol: IYY), we found that the implied analyst target price for the ETF based upon its underlying holdings is $118.56 per unit.
With IYY trading at a recent price near $95.78 per unit, that means that analysts see 23.78% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IYY's underlying holdings with notable upside to their analyst target prices are Beam Therapeutics Inc (Symbol: BEAM), MicroStrategy Inc. (Symbol: MSTR), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Although BEAM has traded at a recent price of $52.93/share, the average analyst target is 70.27% higher at $90.12/share. Similarly, MSTR has 35.13% upside from the recent share price of $204.25 if the average analyst target price of $276.00/share is reached, and analysts on average are expecting ACAD to reach a target price of $20.76/share, which is 28.73% above the recent price of $16.13. Below is a twelve month price history chart comparing the stock performance of BEAM, MSTR, and ACAD:
Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
iShares Dow Jones U.S. ETF IYY $95.78 $118.56 23.78%
Beam Therapeutics Inc BEAM $52.93 $90.12 70.27%
MicroStrategy Inc. MSTR $204.25 $276.00 35.13%
Acadia Pharmaceuticals Inc ACAD $16.13 $20.76 28.73%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | iShares Dow Jones U.S. ETF IYY $95.78 $118.56 23.78% Beam Therapeutics Inc BEAM $52.93 $90.12 70.27% MicroStrategy Inc. MSTR $204.25 $276.00 35.13% Acadia Pharmaceuticals Inc ACAD $16.13 $20.76 28.73% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYY's underlying holdings with notable upside to their analyst target prices are Beam Therapeutics Inc (Symbol: BEAM), MicroStrategy Inc. (Symbol: MSTR), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, MSTR has 35.13% upside from the recent share price of $204.25 if the average analyst target price of $276.00/share is reached, and analysts on average are expecting ACAD to reach a target price of $20.76/share, which is 28.73% above the recent price of $16.13. | Three of IYY's underlying holdings with notable upside to their analyst target prices are Beam Therapeutics Inc (Symbol: BEAM), MicroStrategy Inc. (Symbol: MSTR), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, MSTR has 35.13% upside from the recent share price of $204.25 if the average analyst target price of $276.00/share is reached, and analysts on average are expecting ACAD to reach a target price of $20.76/share, which is 28.73% above the recent price of $16.13. iShares Dow Jones U.S. ETF IYY $95.78 $118.56 23.78% Beam Therapeutics Inc BEAM $52.93 $90.12 70.27% MicroStrategy Inc. MSTR $204.25 $276.00 35.13% Acadia Pharmaceuticals Inc ACAD $16.13 $20.76 28.73% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Similarly, MSTR has 35.13% upside from the recent share price of $204.25 if the average analyst target price of $276.00/share is reached, and analysts on average are expecting ACAD to reach a target price of $20.76/share, which is 28.73% above the recent price of $16.13. Three of IYY's underlying holdings with notable upside to their analyst target prices are Beam Therapeutics Inc (Symbol: BEAM), MicroStrategy Inc. (Symbol: MSTR), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Below is a twelve month price history chart comparing the stock performance of BEAM, MSTR, and ACAD: Below is a summary table of the current analyst target prices discussed above: | iShares Dow Jones U.S. ETF IYY $95.78 $118.56 23.78% Beam Therapeutics Inc BEAM $52.93 $90.12 70.27% MicroStrategy Inc. MSTR $204.25 $276.00 35.13% Acadia Pharmaceuticals Inc ACAD $16.13 $20.76 28.73% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYY's underlying holdings with notable upside to their analyst target prices are Beam Therapeutics Inc (Symbol: BEAM), MicroStrategy Inc. (Symbol: MSTR), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, MSTR has 35.13% upside from the recent share price of $204.25 if the average analyst target price of $276.00/share is reached, and analysts on average are expecting ACAD to reach a target price of $20.76/share, which is 28.73% above the recent price of $16.13. |
35706.0 | 2022-09-01 00:00:00 UTC | Interesting ACAD Put And Call Options For October 14th | ACAD | https://www.nasdaq.com/articles/interesting-acad-put-and-call-options-for-october-14th | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new October 14th contracts and identified one put and one call contract of particular interest.
The put contract at the $14.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $14.00, but will also collect the premium, putting the cost basis of the shares at $13.85 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $16.42/share today.
Because the $14.00 strike represents an approximate 15% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 1.07% return on the cash commitment, or 9.09% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $14.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 5 cents. If an investor was to purchase shares of ACAD stock at the current price level of $16.42/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $18.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 9.93% if the stock gets called away at the October 14th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red:
Considering the fact that the $18.00 strike represents an approximate 10% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 0.30% boost of extra return to the investor, or 2.58% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $16.42) to be 77%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 10% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 14th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 10% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 14th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $14.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 5 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 10% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 14th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $14.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 5 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 10% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 14th expiration. |
35707.0 | 2022-08-30 00:00:00 UTC | Novartis (NVS) Chronic Myeloid Leukemia Drug Approved by EC | ACAD | https://www.nasdaq.com/articles/novartis-nvs-chronic-myeloid-leukemia-drug-approved-by-ec | nan | nan | Novartis NVS announced that the European Commission (EC) has approved Scemblix (asciminib) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).
The approval was based on positive results from the phase III ASCEMBL study, in which Scemblix nearly doubled the major molecular response rate as compared to Bosulif (bosutinib), with a more than three times lower discontinuation rate due to adverse reactions at 24 weeks and confirmed at 96 weeks.
The approval was already in the cards as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) gave a positive opinion for the same in June.
Per the company, Scemblix is the first CML treatment that acts as a STAMP inhibitor, specifically targeting the ABL myristoyl pocket.
Last year, the FDA granted accelerated approval to Scemblix for adult patients with Ph+ CML-CP, previously treated with two or more TKIs based on MMR rate at 24 weeks, and full approval for adult patients with Ph+ CML-CP with the T315I mutation. Novartis has also shared the longer-term, 96-week efficacy and safety data with the FDA, which is currently under evaluation through a priority review.
Scemblix is being studied across multiple treatment lines for CML-CP, both as a monotherapy and in combination.
Shares of Novartis have lost 6% this year compared with the industry’s decline of 2.6%.
Image Source: Zacks Investment Research
The approval will strengthen NVS’ strong oncology portfolio. Further, the approval of new drugs bodes well for Novartis, which is looking to strengthen its core pharma business after announcing plans to spin off Sandoz, its generics and biosimilars division, into a new publicly traded standalone company last week.
In October 2021, Novartis announced the commencement of a strategic review of the Sandoz division. This was because industry-wide price competition among generic pharmaceutical companies and consolidation of buyers caused significant declines in sales and profits of Sandoz, particularly in the United States.
Earlier, the company had spun off its eye care division, Alcon, into a new company.
Novartis will focus on further strengthening its position in five core therapeutic areas (Hematology, Solid Tumors, Immunology, Neuroscience and Cardiovascular) and technology platforms (Gene Therapy, Cell Therapy, Radioligand Therapy, Targeted Protein Degradation and xRNA), and achieving a balanced geographic footprint.
Zacks Rank & Stocks to Consider
Novartis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in this space are Bolt Pharmaceuticals BOLT, Acadia Pharmaceuticals ACAD and Dynavax DVAX. All three carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss estimates for BOLT have narrowed to $2.25 from $2.87 in the past 60 days. BOLT surpassed earnings in three of the trailing four quarters, the average being 2.39%.
Loss estimates for ACAD have narrowed to $1.30 from $1.40 in the past 60 days. ACAD surpassed earnings in two of the trailing four quarters, the average being 6.83%.
Dynavax’s earnings estimates have increased to $1.73 from $1.14 for 2022 over the past 60 days. Earnings of Dynavax surpassed estimates in two of the trailing four quarters.
How to Profit from the Hot Electric Vehicle Industry
Global electric car sales in 2021 more than doubled their 2020 numbers. And today, the electric vehicle (EV) technology and very nature of the business is changing quickly. The next push for future technologies is happening now and investors who get in early could see exceptional profits.
See Zacks' Top Stocks to Profit from the EV Revolution >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
Dynavax Technologies Corporation (DVAX): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Bolt Biotherapeutics, Inc. (BOLT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in this space are Bolt Pharmaceuticals BOLT, Acadia Pharmaceuticals ACAD and Dynavax DVAX. Loss estimates for ACAD have narrowed to $1.30 from $1.40 in the past 60 days. ACAD surpassed earnings in two of the trailing four quarters, the average being 6.83%. | Some better-ranked stocks in this space are Bolt Pharmaceuticals BOLT, Acadia Pharmaceuticals ACAD and Dynavax DVAX. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Loss estimates for ACAD have narrowed to $1.30 from $1.40 in the past 60 days. | Some better-ranked stocks in this space are Bolt Pharmaceuticals BOLT, Acadia Pharmaceuticals ACAD and Dynavax DVAX. Loss estimates for ACAD have narrowed to $1.30 from $1.40 in the past 60 days. ACAD surpassed earnings in two of the trailing four quarters, the average being 6.83%. | Some better-ranked stocks in this space are Bolt Pharmaceuticals BOLT, Acadia Pharmaceuticals ACAD and Dynavax DVAX. Loss estimates for ACAD have narrowed to $1.30 from $1.40 in the past 60 days. ACAD surpassed earnings in two of the trailing four quarters, the average being 6.83%. |
35708.0 | 2022-08-30 00:00:00 UTC | Wall Street Analysts Believe Acadia (ACAD) Could Rally 26%: Here's is How to Trade | ACAD | https://www.nasdaq.com/articles/wall-street-analysts-believe-acadia-acad-could-rally-26%3A-heres-is-how-to-trade | nan | nan | Shares of Acadia Pharmaceuticals (ACAD) have gained 16.7% over the past four weeks to close the last trading session at $16.47, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $20.76 indicates a potential upside of 26.1%.
The average comprises 17 short-term price targets ranging from a low of $10 to a high of $42, with a standard deviation of $6.94. While the lowest estimate indicates a decline of 39.3% from the current price level, the most optimistic estimate points to a 155% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.
However, an impressive consensus price target is not the only factor that indicates a potential upside in ACAD. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.
Here's What You Should Know About Analysts' Price Targets
According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Why ACAD Could Witness a Solid Upside
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The Zacks Consensus Estimate for the current year has increased 7.1% over the past month, as 10 estimates have gone higher compared to no negative revision.
Moreover, ACAD currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, while the consensus price target may not be a reliable indicator of how much ACAD could gain, the direction of price movement it implies does appear to be a good guide.
How to Profit from the Hot Electric Vehicle Industry
Global electric car sales in 2021 more than doubled their 2020 numbers. And today, the electric vehicle (EV) technology and very nature of the business is changing quickly. The next push for future technologies is happening now and investors who get in early could see exceptional profits.
See Zacks' Top Stocks to Profit from the EV Revolution >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of Acadia Pharmaceuticals (ACAD) have gained 16.7% over the past four weeks to close the last trading session at $16.47, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. However, an impressive consensus price target is not the only factor that indicates a potential upside in ACAD. Why ACAD Could Witness a Solid Upside Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. | You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much ACAD could gain, the direction of price movement it implies does appear to be a good guide. Shares of Acadia Pharmaceuticals (ACAD) have gained 16.7% over the past four weeks to close the last trading session at $16.47, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. However, an impressive consensus price target is not the only factor that indicates a potential upside in ACAD. | You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much ACAD could gain, the direction of price movement it implies does appear to be a good guide. Shares of Acadia Pharmaceuticals (ACAD) have gained 16.7% over the past four weeks to close the last trading session at $16.47, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. However, an impressive consensus price target is not the only factor that indicates a potential upside in ACAD. | However, an impressive consensus price target is not the only factor that indicates a potential upside in ACAD. Shares of Acadia Pharmaceuticals (ACAD) have gained 16.7% over the past four weeks to close the last trading session at $16.47, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Why ACAD Could Witness a Solid Upside Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. |
35709.0 | 2022-08-09 00:00:00 UTC | Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates | ACAD | https://www.nasdaq.com/articles/acadias-acad-q2-earnings-revenues-surpass-estimates | nan | nan | Acadia Pharmaceuticals Inc. ACAD reported a second-quarter 2022 loss of 21 cents per share, narrower than the Zacks Consensus Estimate of a loss of 25 cents. In the year-ago quarter, the company had incurred a loss of 27 cents per share.
Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 17% year over year to $134.6 million in the second quarter, driven by Nuplazid demand growth. The top line surpassed the Zacks Consensus Estimate of $131 million. Nuplazid sales increased 16.5% sequentially in the reported quarter.
Nuplazid is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis.
Shares of Acadia have plunged 28.8% in the year so far compared with the industry’s 18% decline.
Image Source: Zacks Investment Research
Quarter in Detail
Research and development (R&D) expenses were $75.6 million for the quarter, up 32.8% year over year, owing to increased costs related to pipeline development activities, especially ACP-044, ACP-319 and other early-stage pipeline candidates.
Selling, general and administrative (SG&A) expenses were $89.9 million, down 7.1% year over year, owing to reduced advertising and promotional costs as well as lower personnel expenses.
As of Jun 30, 2022, Acadia had cash, cash equivalents and investments worth $436.4 million compared with $446 million as of Mar 31, 2022.
2022 Guidance
Acadia updated the financial guidance for 2022.
The company now expects Nuplazid net sales in the range of $510-$540 million compared with the earlier projection of $510-$560 million for 2022. The Zacks Consensus Estimate for the metric is pegged at $530.98 million.
The company expects R&D expenses in the range of $340-$360 million compared with the $355-$375 million expected previously. SG&A expenses are expected to be $360-$380 million, unchanged from the previous guidance.
Pipeline Updates
Last week, Acadia received a complete response letter (“CRL”) from the FDA for its resubmitted supplemental new drug application (“sNDA”) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).
The latest CRL was expected, as in June 2022, the FDA’s Psychopharmacologic Drugs Advisory Committee (“PDAC”) voted (nine-three) against the sNDA for pimavanserin for treating hallucinations and delusions associated with ADP.
Earlier, the FDA had asked the committee for advice and recommendations regarding the evidence that pimavanserin is effective for the given indication.
We remind investors that the FDA issued a CRL to the Nuplazid sNDA in April 2021.
Acadia submitted a new drug application or NDA to the FDA seeking approval of its pipeline candidate, trofinetide, for the treatment of Rett syndrome in adults and pediatric patients aged two years and above in July 2022.
Along with the earnings release, Acadia announced that it has decided to discontinue the development of ACP-044, a novel orally-administered non-opioid analgesic, which was evaluated for treating acute and chronic pain. The company also decided to discontinue the development of another candidate ACP-319.
Acadia Pharmaceuticals Inc. Price, Consensus and EPS Surprise
Acadia Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Acadia Pharmaceuticals Inc. Quote
Zacks Rank & Stocks to Consider
Acadia currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector include Bio-Techne Corporation TECH, Atara Biotherapeutics, Inc. ATRA and Precision BioSciences, Inc. DTIL, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Bio-Techne’s earnings estimates have been revised 0.2% upward for 2022 and 0.8% upward for 2023 in the past 60 days.
Earnings of Bio-Techne have surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. TECH delivered an earnings surprise of 3.30%, on average.
Atara Biotherapeutics’ loss per share estimates narrowed 0.6% for 2022 and 13.3% for 2023 in the past 60 days.
Earnings of Atara Biotherapeutics have surpassed estimates in two of the trailing four quarters and missed on the other two occasions. ATRA delivered an earnings surprise of -12.51%, on average.
Precision BioSciences’ loss per share estimates narrowed 5.7% for 2022 and 16.2% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.
Want to Know the #1 Semiconductor Stock for 2022?
Few people know how promising the semiconductor market is. Over the last couple of years, disruptions to the supply chain have caused shortages in several industries. The absence of one single semiconductor can stop all operations in certain industries.
This year, companies that create and produce this essential material will have incredible pricing power. For a limited time, Zacks is revealing the top semiconductor stock for 2022. You'll find it in our new Special Report, One Semiconductor Stock Stands to Gain the Most.
Today, it's yours free with no obligation.
>>Give me access to my free special report.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioTechne Corp (TECH): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Atara Biotherapeutics, Inc. (ATRA): Free Stock Analysis Report
Precision BioSciences, Inc. (DTIL): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Pipeline Updates Last week, Acadia received a complete response letter (“CRL”) from the FDA for its resubmitted supplemental new drug application (“sNDA”) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). Acadia submitted a new drug application or NDA to the FDA seeking approval of its pipeline candidate, trofinetide, for the treatment of Rett syndrome in adults and pediatric patients aged two years and above in July 2022. Acadia Pharmaceuticals Inc. ACAD reported a second-quarter 2022 loss of 21 cents per share, narrower than the Zacks Consensus Estimate of a loss of 25 cents. | Acadia Pharmaceuticals Inc. Price, Consensus and EPS Surprise Acadia Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). Acadia Pharmaceuticals Inc. ACAD reported a second-quarter 2022 loss of 21 cents per share, narrower than the Zacks Consensus Estimate of a loss of 25 cents. Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 17% year over year to $134.6 million in the second quarter, driven by Nuplazid demand growth. | Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 17% year over year to $134.6 million in the second quarter, driven by Nuplazid demand growth. Acadia Pharmaceuticals Inc. Price, Consensus and EPS Surprise Acadia Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). Acadia Pharmaceuticals Inc. ACAD reported a second-quarter 2022 loss of 21 cents per share, narrower than the Zacks Consensus Estimate of a loss of 25 cents. | Shares of Acadia have plunged 28.8% in the year so far compared with the industry’s 18% decline. Pipeline Updates Last week, Acadia received a complete response letter (“CRL”) from the FDA for its resubmitted supplemental new drug application (“sNDA”) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). Acadia Pharmaceuticals Inc. ACAD reported a second-quarter 2022 loss of 21 cents per share, narrower than the Zacks Consensus Estimate of a loss of 25 cents. |
35710.0 | 2022-08-08 00:00:00 UTC | Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-acad-reports-q2-loss-tops-revenue-estimates | nan | nan | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 16%. A quarter ago, it was expected that this drugmaker would post a loss of $0.49 per share when it actually produced a loss of $0.70, delivering a surprise of -42.86%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $134.56 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 2.82%. This compares to year-ago revenues of $115.22 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Acadia shares have lost about 29.6% since the beginning of the year versus the S&P 500's decline of -13%.
What's Next for Acadia?
While Acadia has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Acadia: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.20 on $139.9 million in revenues for the coming quarter and -$1.40 on $530.98 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Geron (GERN), another stock in the same industry, has yet to report results for the quarter ended June 2022. The results are expected to be released on August 11.
This drugmaker is expected to post quarterly loss of $0.09 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 5.3% higher over the last 30 days to the current level.
Geron's revenues are expected to be $0.12 million, up 5.5% from the year-ago quarter.
How to Profit from the Hot Electric Vehicle Industry
Global electric car sales in 2021 more than doubled their 2020 numbers. And today, the electric vehicle (EV) technology and very nature of the business is changing quickly. The next push for future technologies is happening now and investors who get in early could see exceptional profits.
See Zacks' Top Stocks to Profit from the EV Revolution >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Geron Corporation (GERN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.25. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $134.56 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 2.82%. Acadia shares have lost about 29.6% since the beginning of the year versus the S&P 500's decline of -13%. | Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $134.56 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 2.82%. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.25. | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.25. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $134.56 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 2.82%. Acadia shares have lost about 29.6% since the beginning of the year versus the S&P 500's decline of -13%. | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.25. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $134.56 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 2.82%. Acadia shares have lost about 29.6% since the beginning of the year versus the S&P 500's decline of -13%. |
35711.0 | 2022-08-03 00:00:00 UTC | Moderna (MRNA) Q2 Earnings and Revenues Beat Estimates | ACAD | https://www.nasdaq.com/articles/moderna-mrna-q2-earnings-and-revenues-beat-estimates | nan | nan | Moderna (MRNA) came out with quarterly earnings of $5.24 per share, beating the Zacks Consensus Estimate of $4.50 per share. This compares to earnings of $6.46 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 16.44%. A quarter ago, it was expected that this biotechnology company would post earnings of $5.18 per share when it actually produced earnings of $8.58, delivering a surprise of 65.64%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Moderna, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $4.75 billion for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 22.08%. This compares to year-ago revenues of $4.35 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Moderna shares have lost about 36.7% since the beginning of the year versus the S&P 500's decline of -14.2%.
What's Next for Moderna?
While Moderna has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Moderna: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $7.23 on $6 billion in revenues for the coming quarter and $27.16 on $22.46 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Acadia Pharmaceuticals (ACAD), another stock in the same industry, has yet to report results for the quarter ended June 2022. The results are expected to be released on August 8.
This drugmaker is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents a year-over-year change of +7.4%. The consensus EPS estimate for the quarter has been revised 0.3% higher over the last 30 days to the current level.
Acadia Pharmaceuticals' revenues are expected to be $130 million, up 12.8% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Moderna, Inc. (MRNA): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (ACAD), another stock in the same industry, has yet to report results for the quarter ended June 2022. Acadia Pharmaceuticals' revenues are expected to be $130 million, up 12.8% from the year-ago quarter. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report | ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Acadia Pharmaceuticals (ACAD), another stock in the same industry, has yet to report results for the quarter ended June 2022. Acadia Pharmaceuticals' revenues are expected to be $130 million, up 12.8% from the year-ago quarter. | Acadia Pharmaceuticals (ACAD), another stock in the same industry, has yet to report results for the quarter ended June 2022. Acadia Pharmaceuticals' revenues are expected to be $130 million, up 12.8% from the year-ago quarter. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report | Acadia Pharmaceuticals (ACAD), another stock in the same industry, has yet to report results for the quarter ended June 2022. Acadia Pharmaceuticals' revenues are expected to be $130 million, up 12.8% from the year-ago quarter. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report |
35712.0 | 2022-08-01 00:00:00 UTC | Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-acad-may-report-negative-earnings%3A-know-the-trend-ahead-of-next-2 | nan | nan | Wall Street expects a year-over-year increase in earnings on higher revenues when Acadia Pharmaceuticals (ACAD) reports results for the quarter ended June 2022. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on August 8, 2022, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on theearnings call it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus Estimate
This drugmaker is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents a year-over-year change of +7.4%.
Revenues are expected to be $130.61 million, up 13.4% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0.54% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Acadia?
For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -11.07%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Acadia will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Acadia would post a loss of $0.49 per share when it actually produced a loss of $0.70, delivering a surprise of -42.86%.
Over the last four quarters, the company has beaten consensus EPS estimates two times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Acadia doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry Player
Codexis (CDXS), another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $0.14 for the quarter ended June 2022. This estimate points to a year-over-year change of -100%. Revenues for the quarter are expected to be $37.93 million, up 49% from the year-ago quarter.
The consensus EPS estimate for Codexis has been revised 32.1% lower over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -7.14%.
This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that Codexis will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Want to Know the #1 Semiconductor Stock for 2022?
Few people know how promising the semiconductor market is. Over the last couple of years, disruptions to the supply chain have caused shortages in several industries. The absence of one single semiconductor can stop all operations in certain industries.
This year, companies that create and produce this essential material will have incredible pricing power. For a limited time, Zacks is revealing the top semiconductor stock for 2022. You'll find it in our new Special Report, One Semiconductor Stock Stands to Gain the Most.
Today, it's yours free with no obligation.
>>Give me access to my free special report.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Codexis, Inc. (CDXS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Wall Street expects a year-over-year increase in earnings on higher revenues when Acadia Pharmaceuticals (ACAD) reports results for the quarter ended June 2022. How Have the Numbers Shaped Up for Acadia? For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. | Wall Street expects a year-over-year increase in earnings on higher revenues when Acadia Pharmaceuticals (ACAD) reports results for the quarter ended June 2022. How Have the Numbers Shaped Up for Acadia? For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. | Wall Street expects a year-over-year increase in earnings on higher revenues when Acadia Pharmaceuticals (ACAD) reports results for the quarter ended June 2022. How Have the Numbers Shaped Up for Acadia? For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. | Wall Street expects a year-over-year increase in earnings on higher revenues when Acadia Pharmaceuticals (ACAD) reports results for the quarter ended June 2022. How Have the Numbers Shaped Up for Acadia? For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. |
35713.0 | 2022-07-28 00:00:00 UTC | Interesting ACAD Put And Call Options For September 9th | ACAD | https://www.nasdaq.com/articles/interesting-acad-put-and-call-options-for-september-9th | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the September 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new September 9th contracts and identified one put and one call contract of particular interest.
The put contract at the $12.00 strike price has a current bid of 25 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $12.00, but will also collect the premium, putting the cost basis of the shares at $11.75 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $14.50/share today.
Because the $12.00 strike represents an approximate 17% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 2.08% return on the cash commitment, or 17.68% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $12.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $15.00 strike price has a current bid of 25 cents. If an investor was to purchase shares of ACAD stock at the current price level of $14.50/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $15.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 5.17% if the stock gets called away at the September 9th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $15.00 strike highlighted in red:
Considering the fact that the $15.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 1.72% boost of extra return to the investor, or 14.64% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $14.50) to be 77%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $15.00 strike highlighted in red: Considering the fact that the $15.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the September 9th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $15.00 strike highlighted in red: Considering the fact that the $15.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the September 9th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $12.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $15.00 strike price has a current bid of 25 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $15.00 strike highlighted in red: Considering the fact that the $15.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the September 9th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $12.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $15.00 strike price has a current bid of 25 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $15.00 strike highlighted in red: Considering the fact that the $15.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the September 9th expiration. |
35714.0 | 2022-07-21 00:00:00 UTC | ACAD September 2nd Options Begin Trading | ACAD | https://www.nasdaq.com/articles/acad-september-2nd-options-begin-trading | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the September 2nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new September 2nd contracts and identified one put and one call contract of particular interest.
The put contract at the $15.00 strike price has a current bid of $1.35. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $15.00, but will also collect the premium, putting the cost basis of the shares at $13.65 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $15.15/share today.
Because the $15.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 9.00% return on the cash commitment, or 76.40% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $16.00 strike price has a current bid of $1.15. If an investor was to purchase shares of ACAD stock at the current price level of $15.15/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $16.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 13.20% if the stock gets called away at the September 2nd expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red:
Considering the fact that the $16.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 7.59% boost of extra return to the investor, or 64.43% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $15.15) to be 77%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red: Considering the fact that the $16.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the September 2nd expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red: Considering the fact that the $16.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the September 2nd expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $16.00 strike price has a current bid of $1.15. Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red: Considering the fact that the $16.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the September 2nd expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $16.00 strike price has a current bid of $1.15. Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red: Considering the fact that the $16.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the September 2nd expiration. |
35715.0 | 2022-07-19 00:00:00 UTC | Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate | ACAD | https://www.nasdaq.com/articles/acadia-acad-files-an-nda-for-its-rett-syndrome-candidate | nan | nan | Acadia Pharmaceuticals Inc. ACAD announced that it has submitted a new drug application or NDA to the FDA seeking approval of its pipeline candidate, trofinetide, for the treatment of Rett syndrome in adults and pediatric patients aged two years and above.
The regulatory filing was based on data from the pivotal phase III Lavender study, which evaluated the safety and efficacy of trofinetide versus placebo for treating Rett syndrome in girls and young women aged five to 20 years.
Rett syndrome is a rare neurological disorder for girls aged between five and 20 years.
Shares of Acadia have lost 35.7% so far this year compared with the industry’s decrease of 20.5%.
Image Source: Zacks Investment Research
In December 2021, ACAD announced positive top-line data from the pivotal phase III Lavender study evaluating trofinetide for the treatment of Rett syndrome.
The study met its co-primary endpoints by demonstrating statistically significant improvement over placebo in the Rett syndrome behavior questionnaire and the clinical global impression of progress at 12 weeks.
Also, treatment with trofinetide led to statistically significant improvement versus placebo in CSBS-DP-IT–Social, caregiver scale of ability to communicate — a key secondary endpoint.
In 2018, ACADIA entered into a license agreement with Australian biopharmaceutical company, Neuren Pharmaceuticals Limited, and obtained exclusive North American rights to develop and commercialize trofinetide for Rett syndrome and other indications.
If approved, trofinetide can become the second approved drug in Acadia’s portfolio of marketed drugs. Upon potential approval, trofinetide can lend a significant boost to the company and lower its sole dependence on Nuplazid (pimavanserin) for revenues.
Currently, Acadia’s top line solely comprises sales of its only marketed drug, Nuplazid, in the United States. The drug is approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Last month, the FDA’s Psychopharmacologic Drugs Advisory Committee (“PDAC”) voted (nine-three) against the supplemental new drug application (sNDA) for Nuplazid for treating hallucinations and delusions associated with Alzheimer's disease psychosis.
Earlier, the FDA had asked the committee for advice and recommendations regarding the evidence that pimavanserin is effective for the given indication. Though the FDA is not completely bound by the PDAC’s recommendations, it usually follows the same. The FDA’s decision date for the sNDA is Aug 4.
The FDA had issued a complete response letter to the sNDA for Nuplazid in April 2021.
Zacks Rank & Stocks to Consider
Acadia currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Anika Therapeutics, Inc. ANIK, Fate Therapeutics, Inc. FATE and Beam Therapeutics Inc. BEAM, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Anika Therapeutics’ loss per share has narrowed 14.4% for 2022 and 9.1% for 2023 in the past 60 days.
Earnings of Anika Therapeutics have surpassed estimates in each of the trailing four quarters. ANIK delivered an earnings surprise of 200.45%, on average.
Fate Therapeutics’ loss per share estimates narrowed 0.3% for 2022 and 0.5% for 2023 in the past 60 days.
Earnings of Fate Therapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. FATE delivered an earnings surprise of -0.72%, on average.
Beam Therapeutics’ loss per share estimates narrowed 0.7% for 2022 and 0.8% for 2023 in the past 60 days.
Earnings of Beam Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. BEAM delivered an earnings surprise of 1.80%, on average.
Want to Know the #1 Semiconductor Stock for 2022?
Few people know how promising the semiconductor market is. Over the last couple of years, disruptions to the supply chain have caused shortages in several industries. The absence of one single semiconductor can stop all operations in certain industries.
This year, companies that create and produce this essential material will have incredible pricing power. For a limited time, Zacks is revealing the top semiconductor stock for 2022. You'll find it in our new Special Report, One Semiconductor Stock Stands to Gain the Most.
Today, it's yours free with no obligation.
>>Give me access to my free special report.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Beam Therapeutics Inc. (BEAM): Free Stock Analysis Report
Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report
Fate Therapeutics, Inc. (FATE): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals Inc. ACAD announced that it has submitted a new drug application or NDA to the FDA seeking approval of its pipeline candidate, trofinetide, for the treatment of Rett syndrome in adults and pediatric patients aged two years and above. Image Source: Zacks Investment Research In December 2021, ACAD announced positive top-line data from the pivotal phase III Lavender study evaluating trofinetide for the treatment of Rett syndrome. Shares of Acadia have lost 35.7% so far this year compared with the industry’s decrease of 20.5%. | Image Source: Zacks Investment Research In December 2021, ACAD announced positive top-line data from the pivotal phase III Lavender study evaluating trofinetide for the treatment of Rett syndrome. Acadia Pharmaceuticals Inc. ACAD announced that it has submitted a new drug application or NDA to the FDA seeking approval of its pipeline candidate, trofinetide, for the treatment of Rett syndrome in adults and pediatric patients aged two years and above. Shares of Acadia have lost 35.7% so far this year compared with the industry’s decrease of 20.5%. | Acadia Pharmaceuticals Inc. ACAD announced that it has submitted a new drug application or NDA to the FDA seeking approval of its pipeline candidate, trofinetide, for the treatment of Rett syndrome in adults and pediatric patients aged two years and above. Shares of Acadia have lost 35.7% so far this year compared with the industry’s decrease of 20.5%. Image Source: Zacks Investment Research In December 2021, ACAD announced positive top-line data from the pivotal phase III Lavender study evaluating trofinetide for the treatment of Rett syndrome. | Acadia Pharmaceuticals Inc. ACAD announced that it has submitted a new drug application or NDA to the FDA seeking approval of its pipeline candidate, trofinetide, for the treatment of Rett syndrome in adults and pediatric patients aged two years and above. Shares of Acadia have lost 35.7% so far this year compared with the industry’s decrease of 20.5%. Image Source: Zacks Investment Research In December 2021, ACAD announced positive top-line data from the pivotal phase III Lavender study evaluating trofinetide for the treatment of Rett syndrome. |
35716.0 | 2022-07-08 00:00:00 UTC | Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why | ACAD | https://www.nasdaq.com/articles/acadia-acad-down-more-than-30-in-past-3-months%3A-heres-why | nan | nan | Shares of Acadia Pharmaceuticals Inc. ACAD have plunged 33.5% in the past three months compared with the industry’s decrease of 7.6%.
Image Source: Zacks Investment Research
The company’s sole marketed drug, Nuplazid (pimavanserin), is approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The drug is the first and the only FDA-approved treatment for the given indication.
In June 2022, the FDA’s Psychopharmacologic Drugs Advisory Committee (“PDAC”) voted (nine-three) against the supplemental new drug application (sNDA) for Nuplazid for treating hallucinations and delusions associated with Alzheimer's disease psychosis (“ADP”).
Earlier, the FDA had asked the committee for advice and recommendations regarding the evidence that pimavanserin is effective for the given indication. Though the FDA is not completely bound by the PDAC’s recommendations, it usually follows the same. The FDA’s decision date for the sNDA is Aug 4.
This might be a reason for ACAD’s shares to have remained down during this time frame.
We remind investors that the FDA had issued a complete response letter to the sNDA for Nuplazid in April 2021.
Nuplazid generated sales worth $115.5 million in the first quarter of 2022, reflecting an increase of 8% year over year. A potential label expansion is likely to boost sales of the drug in the days ahead.
This apart, Acadia has other promising pipeline candidates that are being developed for various other indications.
The company is planning to file a new drug application for trofinetide to treat Rett syndrome later in 2022. Currently, there are no approved medicines for the given indications.
In April 2022, Acadia announced top-line data from a phase II study evaluating the safety and efficacy of its investigational candidate, ACP-044, for the treatment of acute pain following bunionectomy surgery. The study failed to meet its primary endpoint. Shares of Acadia tanked on this news.
ACP-044 is also being evaluated in a phase II study for treating pain associated with osteoarthritis.
Acadia Pharmaceuticals Inc. Price
Acadia Pharmaceuticals Inc. price | Acadia Pharmaceuticals Inc. Quote
Zacks Rank & Stocks to Consider
Acadia currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Leap Therapeutics, Inc. LPTX, Aeglea BioTherapeutics, Inc. AGLE and Precision BioSciences, Inc. DTIL, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Aeglea BioTherapeutics’ loss per share estimates narrowed 12.7% for 2022 and 25.6% for 2023 in the past 60 days.
Earnings of Aeglea BioTherapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AGLE delivered an earnings surprise of 9.47%, on average.
Precision BioSciences’ loss per share estimates narrowed 26.2% for 2022 and 42.6% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Aeglea BioTherapeutics, Inc. (AGLE): Free Stock Analysis Report
Leap Therapeutics, Inc. (LPTX): Free Stock Analysis Report
Precision BioSciences, Inc. (DTIL): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In April 2022, Acadia announced top-line data from a phase II study evaluating the safety and efficacy of its investigational candidate, ACP-044, for the treatment of acute pain following bunionectomy surgery. Shares of Acadia Pharmaceuticals Inc. ACAD have plunged 33.5% in the past three months compared with the industry’s decrease of 7.6%. This might be a reason for ACAD’s shares to have remained down during this time frame. | Acadia Pharmaceuticals Inc. Price Acadia Pharmaceuticals Inc. price | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Shares of Acadia Pharmaceuticals Inc. ACAD have plunged 33.5% in the past three months compared with the industry’s decrease of 7.6%. | Acadia Pharmaceuticals Inc. Price Acadia Pharmaceuticals Inc. price | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). Shares of Acadia Pharmaceuticals Inc. ACAD have plunged 33.5% in the past three months compared with the industry’s decrease of 7.6%. This might be a reason for ACAD’s shares to have remained down during this time frame. | Shares of Acadia Pharmaceuticals Inc. ACAD have plunged 33.5% in the past three months compared with the industry’s decrease of 7.6%. This might be a reason for ACAD’s shares to have remained down during this time frame. This apart, Acadia has other promising pipeline candidates that are being developed for various other indications. |
35717.0 | 2022-07-07 00:00:00 UTC | ACAD August 26th Options Begin Trading | ACAD | https://www.nasdaq.com/articles/acad-august-26th-options-begin-trading | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the August 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new August 26th contracts and identified one put and one call contract of particular interest.
The put contract at the $15.00 strike price has a current bid of $1.30. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $15.00, but will also collect the premium, putting the cost basis of the shares at $13.70 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $15.47/share today.
Because the $15.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 8.67% return on the cash commitment, or 63.27% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $16.00 strike price has a current bid of $1.45. If an investor was to purchase shares of ACAD stock at the current price level of $15.47/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $16.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 12.80% if the stock gets called away at the August 26th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red:
Considering the fact that the $16.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 9.37% boost of extra return to the investor, or 68.42% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $15.47) to be 77%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red: Considering the fact that the $16.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the August 26th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red: Considering the fact that the $16.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the August 26th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $16.00 strike price has a current bid of $1.45. Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red: Considering the fact that the $16.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the August 26th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $16.00 strike price has a current bid of $1.45. Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red: Considering the fact that the $16.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the August 26th expiration. |
35718.0 | 2022-06-23 00:00:00 UTC | August 5th Options Now Available For Acadia Pharmaceuticals | ACAD | https://www.nasdaq.com/articles/august-5th-options-now-available-for-acadia-pharmaceuticals | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the August 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new August 5th contracts and identified one put and one call contract of particular interest.
The put contract at the $14.00 strike price has a current bid of $1.20. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $14.00, but will also collect the premium, putting the cost basis of the shares at $12.80 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $14.49/share today.
Because the $14.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 8.57% return on the cash commitment, or 72.76% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $14.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $15.00 strike price has a current bid of $1.00. If an investor was to purchase shares of ACAD stock at the current price level of $14.49/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $15.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 10.42% if the stock gets called away at the August 5th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $15.00 strike highlighted in red:
Considering the fact that the $15.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 6.90% boost of extra return to the investor, or 58.58% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $14.49) to be 77%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $15.00 strike highlighted in red: Considering the fact that the $15.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the August 5th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $15.00 strike highlighted in red: Considering the fact that the $15.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the August 5th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $14.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $15.00 strike price has a current bid of $1.00. Below is a chart showing ACAD's trailing twelve month trading history, with the $15.00 strike highlighted in red: Considering the fact that the $15.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the August 5th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $14.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $15.00 strike price has a current bid of $1.00. Below is a chart showing ACAD's trailing twelve month trading history, with the $15.00 strike highlighted in red: Considering the fact that the $15.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the August 5th expiration. |
35719.0 | 2022-06-21 00:00:00 UTC | Health Care Sector Update for 06/21/2022: HOTH,CVNY,VALN,PFE,ACAD | ACAD | https://www.nasdaq.com/articles/health-care-sector-update-for-06-21-2022%3A-hothcvnyvalnpfeacad | nan | nan | Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) both rising 2.8%.
The Nasdaq Biotechnology index was climbing 2.4%.
In company news, Hoth Therapeutics (HOTH) rose 4% after the biopharmaceuticals company Tuesday said it was cleared by regulators in Australia to begin the next phase of its BioLexa topical drug candidate to treat atopic dermatitis.
Valneva (VALN) soared 90% after saying Pfizer (PFE) will acquire an 8.1% equity stake in the specialty drug maker in exchange for a 90.5 million euros ($95 million) investment, part of a broader strategic partnership between the two companies for Valneva's VLA15 vaccine candidate for Lyme disease.
Convey Health Solutions (CNVY) more than doubled in price on Tuesday, recently climbing nearly 139%, after agreeing to a $1.1 billion buyout offer from private-equity investors TPG, which will pay $10.50 per share in cash for the workflow-management company, or 143% above Friday's closing price.
To the downside, Acadia (ACAD) plunged as much as 37% on Tuesday, sinking to its lowest share price since March 2013, after a US Food and Drug Administration advisory panel concluded the company's pimavanserin drug candidate did not effectively treat hallucinations and delusions in patients with Alzheimer's disease.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | To the downside, Acadia (ACAD) plunged as much as 37% on Tuesday, sinking to its lowest share price since March 2013, after a US Food and Drug Administration advisory panel concluded the company's pimavanserin drug candidate did not effectively treat hallucinations and delusions in patients with Alzheimer's disease. Valneva (VALN) soared 90% after saying Pfizer (PFE) will acquire an 8.1% equity stake in the specialty drug maker in exchange for a 90.5 million euros ($95 million) investment, part of a broader strategic partnership between the two companies for Valneva's VLA15 vaccine candidate for Lyme disease. Convey Health Solutions (CNVY) more than doubled in price on Tuesday, recently climbing nearly 139%, after agreeing to a $1.1 billion buyout offer from private-equity investors TPG, which will pay $10.50 per share in cash for the workflow-management company, or 143% above Friday's closing price. | To the downside, Acadia (ACAD) plunged as much as 37% on Tuesday, sinking to its lowest share price since March 2013, after a US Food and Drug Administration advisory panel concluded the company's pimavanserin drug candidate did not effectively treat hallucinations and delusions in patients with Alzheimer's disease. Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) both rising 2.8%. In company news, Hoth Therapeutics (HOTH) rose 4% after the biopharmaceuticals company Tuesday said it was cleared by regulators in Australia to begin the next phase of its BioLexa topical drug candidate to treat atopic dermatitis. | To the downside, Acadia (ACAD) plunged as much as 37% on Tuesday, sinking to its lowest share price since March 2013, after a US Food and Drug Administration advisory panel concluded the company's pimavanserin drug candidate did not effectively treat hallucinations and delusions in patients with Alzheimer's disease. Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) both rising 2.8%. Convey Health Solutions (CNVY) more than doubled in price on Tuesday, recently climbing nearly 139%, after agreeing to a $1.1 billion buyout offer from private-equity investors TPG, which will pay $10.50 per share in cash for the workflow-management company, or 143% above Friday's closing price. | To the downside, Acadia (ACAD) plunged as much as 37% on Tuesday, sinking to its lowest share price since March 2013, after a US Food and Drug Administration advisory panel concluded the company's pimavanserin drug candidate did not effectively treat hallucinations and delusions in patients with Alzheimer's disease. Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) both rising 2.8%. The Nasdaq Biotechnology index was climbing 2.4%. |
35720.0 | 2022-06-21 00:00:00 UTC | ACADIA Stock: Deep Discount or Trap for Investors? Analysts Weigh In | ACAD | https://www.nasdaq.com/articles/acadia-stock%3A-deep-discount-or-trap-for-investors-analysts-weigh-in | nan | nan | Investing in biotechs can be a risky business. Success hinges mostly on two criteria; promising data from clinical trials or regulatory approval. Get either of these wrong and the push back from the Street can be brutal.
Case in point: ACADIA Pharmaceuticals (ACAD) shares are down 33% following a negative decision made last Friday by the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC). The panel voted 9-3 against the approval of Nuplazid (pimavanserin) as a therapy for hallucinations and delusions associated with Alzheimer’s disease (ADP).
While the FDA is not required to follow the panel’s decision, in the majority of cases, its own decision usually reflects the one made by the committee.
Based on the briefing docs – which highlighted limited duration, not enough clinical significance, and issues relating to the design of the trial - and the FDA's sole focus on efficacy rather than the overall benefit/risk, J.P. Morgan’s Cory Kasimov anticipated an “uphill battle.”
“The ultimate outcome isn't overly surprising,” the analyst went on to say, before adding, “At this point, we suspect the only chance for Nuplazid in ADP is another trial, which the company has been reluctant to commit to (TBD if that changes).”
Kasimov believes investor focus will now turn to the anticipated mid-year submission of the NDA (new drug application) of trofinetide for the treatment of Rett syndrome. “However,” the 5-star analyst summed up, “with little else expected this year, we suspect it will be difficult for ACAD to outperform our broader coverage universe.”
Accordingly, the analyst downgraded his rating for ACAD from Overweight (i.e., Buy) to Neutral, and lowered his price target from $34 to $19. However, following Tuesday’s meltdown, the new target implies ~46% upside from current levels. (To watch Kasimov’s track record, click here)
So, that’s J.P. Morgan’s view. JMP analyst Jason Butler, on the other hand, remains upbeat on the general outlook for ACAD.
“As expected, the stock is under pressure this morning and at this valuation we view the stock as attractive based on the approved PDP indication alone and our confidence in continued growth,” Butler explained.
Unlike Kasimov, Butler sticks with an Outperform (i.e., Buy) rating although his price target is also reduced from $35 to $23. Nevertheless, should the target be met, investors will be sitting on returns of 76% in a year’s time. (To watch Butler’s track record, click here)
Overall, ACAD gets a Moderate Buy from the analyst consensus. The stock has 16 recent reviews, breaking down to 7 Buys, 8 Holds, and 1 Sell. The shares are selling for $13, and the average price target of $24 indicates a potential upside of ~84% over the next 12 months. (See ACAD stock forecast on TipRanks)
To find good ideas for biotech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Case in point: ACADIA Pharmaceuticals (ACAD) shares are down 33% following a negative decision made last Friday by the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC). “However,” the 5-star analyst summed up, “with little else expected this year, we suspect it will be difficult for ACAD to outperform our broader coverage universe.” Accordingly, the analyst downgraded his rating for ACAD from Overweight (i.e., Buy) to Neutral, and lowered his price target from $34 to $19. JMP analyst Jason Butler, on the other hand, remains upbeat on the general outlook for ACAD. | (See ACAD stock forecast on TipRanks) To find good ideas for biotech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Case in point: ACADIA Pharmaceuticals (ACAD) shares are down 33% following a negative decision made last Friday by the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC). “However,” the 5-star analyst summed up, “with little else expected this year, we suspect it will be difficult for ACAD to outperform our broader coverage universe.” Accordingly, the analyst downgraded his rating for ACAD from Overweight (i.e., Buy) to Neutral, and lowered his price target from $34 to $19. | “However,” the 5-star analyst summed up, “with little else expected this year, we suspect it will be difficult for ACAD to outperform our broader coverage universe.” Accordingly, the analyst downgraded his rating for ACAD from Overweight (i.e., Buy) to Neutral, and lowered his price target from $34 to $19. (See ACAD stock forecast on TipRanks) To find good ideas for biotech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Case in point: ACADIA Pharmaceuticals (ACAD) shares are down 33% following a negative decision made last Friday by the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC). | “However,” the 5-star analyst summed up, “with little else expected this year, we suspect it will be difficult for ACAD to outperform our broader coverage universe.” Accordingly, the analyst downgraded his rating for ACAD from Overweight (i.e., Buy) to Neutral, and lowered his price target from $34 to $19. (To watch Butler’s track record, click here) Overall, ACAD gets a Moderate Buy from the analyst consensus. Case in point: ACADIA Pharmaceuticals (ACAD) shares are down 33% following a negative decision made last Friday by the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC). |
35721.0 | 2022-06-21 00:00:00 UTC | Health Care Sector Update for 06/21/2022: CVNY, VALN, PFE, ACAD | ACAD | https://www.nasdaq.com/articles/health-care-sector-update-for-06-21-2022%3A-cvny-valn-pfe-acad | nan | nan | Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index rising 2.4% while the SPDR Health Care Select Sector ETF (XLV) was up 2.7%.
The Nasdaq Biotechnology index also was climbing 3.0%.
In company news, Convey Health Solutions (CNVY) more than doubled in price on Tuesday, recently climbing over 138%, after agreeing to a $1.1 billion buyout offer from private-equity investors TPG, which will pay $10.50 per share in cash for the workflow-management company, or 143% above Friday's closing price.
Valneva (VALN) soared 92% after saying Pfizer (PFE) will acquire an 8.1% equity stake in the specialty drug maker in exchange for a 90.5 million euros ($95 million) investment, part of a broader strategic partnership between the two companies for Valneva's VLA15 vaccine candidate for Lyme disease.
Acadia (ACAD) dropped as much as 37% on Tuesday, sinking to its lowest share price since March 2013, after a US Food and Drug Administration advisory panel concluded the company's pimavanserin drug candidate did not effectively treat hallucinations and delusions in patients with Alzheimer's disease.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia (ACAD) dropped as much as 37% on Tuesday, sinking to its lowest share price since March 2013, after a US Food and Drug Administration advisory panel concluded the company's pimavanserin drug candidate did not effectively treat hallucinations and delusions in patients with Alzheimer's disease. In company news, Convey Health Solutions (CNVY) more than doubled in price on Tuesday, recently climbing over 138%, after agreeing to a $1.1 billion buyout offer from private-equity investors TPG, which will pay $10.50 per share in cash for the workflow-management company, or 143% above Friday's closing price. Valneva (VALN) soared 92% after saying Pfizer (PFE) will acquire an 8.1% equity stake in the specialty drug maker in exchange for a 90.5 million euros ($95 million) investment, part of a broader strategic partnership between the two companies for Valneva's VLA15 vaccine candidate for Lyme disease. | Acadia (ACAD) dropped as much as 37% on Tuesday, sinking to its lowest share price since March 2013, after a US Food and Drug Administration advisory panel concluded the company's pimavanserin drug candidate did not effectively treat hallucinations and delusions in patients with Alzheimer's disease. Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index rising 2.4% while the SPDR Health Care Select Sector ETF (XLV) was up 2.7%. Valneva (VALN) soared 92% after saying Pfizer (PFE) will acquire an 8.1% equity stake in the specialty drug maker in exchange for a 90.5 million euros ($95 million) investment, part of a broader strategic partnership between the two companies for Valneva's VLA15 vaccine candidate for Lyme disease. | Acadia (ACAD) dropped as much as 37% on Tuesday, sinking to its lowest share price since March 2013, after a US Food and Drug Administration advisory panel concluded the company's pimavanserin drug candidate did not effectively treat hallucinations and delusions in patients with Alzheimer's disease. Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index rising 2.4% while the SPDR Health Care Select Sector ETF (XLV) was up 2.7%. In company news, Convey Health Solutions (CNVY) more than doubled in price on Tuesday, recently climbing over 138%, after agreeing to a $1.1 billion buyout offer from private-equity investors TPG, which will pay $10.50 per share in cash for the workflow-management company, or 143% above Friday's closing price. | Acadia (ACAD) dropped as much as 37% on Tuesday, sinking to its lowest share price since March 2013, after a US Food and Drug Administration advisory panel concluded the company's pimavanserin drug candidate did not effectively treat hallucinations and delusions in patients with Alzheimer's disease. Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index rising 2.4% while the SPDR Health Care Select Sector ETF (XLV) was up 2.7%. The Nasdaq Biotechnology index also was climbing 3.0%. |
35722.0 | 2022-06-21 00:00:00 UTC | Why Acadia Pharmaceuticals Stock Is Crashing Today | ACAD | https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-stock-is-crashing-today | nan | nan | What happened
Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) were crashing 35.4% as of 11 a.m. ET on Tuesday. The steep decline came after a Food and Drug Administration (FDA) advisory committee voted 9-3 against recommending approval of pimavanserin in treating Alzheimer's disease psychosis.
This vote was reported on June 17. But the trading of Acadia stock was halted that day because of the FDA advisory committee's deliberations. Trading of the biotech stock didn't resume until today since the stock market was closed on Monday for the federal Juneteenth holiday.
So what
The FDA's Psychopharmacologic Drugs Advisory Committee (PDAC) determined that the data for pimavanserin didn't sufficiently demonstrate that it was effective in treating hallucinations and delusions experienced by patients with Alzheimer's disease psychosis. CEO Steve Davis said that the company was "disappointed" with the advisory committee's vote.
Acadia still has a chance of winning approval. The FDA doesn't have to go along with the PDAC's recommendation. Davis said that Acadia will cooperate closely with the FDA as the agency completes its review.
However, the odds certainly appear to be stacked against Acadia at this point. An FDA rejection would seriously hurt the company's growth prospects. It already markets pimavanserin under the brand name Nuplazid for treating Parkinson's disease psychosis. The addition of a second indication would significantly expand the drug's addressable market.
Now what
The FDA set a PDUFA date of Aug. 4 for its approval decision on pimavanserin in treating Alzheimer's disease psychosis. Acadia's next steps will hinge on the outcome of the agency's review.
10 stocks we like better than Acadia Pharmaceuticals
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2022
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) were crashing 35.4% as of 11 a.m. But the trading of Acadia stock was halted that day because of the FDA advisory committee's deliberations. Acadia still has a chance of winning approval. | What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) were crashing 35.4% as of 11 a.m. But the trading of Acadia stock was halted that day because of the FDA advisory committee's deliberations. Acadia still has a chance of winning approval. | What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) were crashing 35.4% as of 11 a.m. But the trading of Acadia stock was halted that day because of the FDA advisory committee's deliberations. Acadia still has a chance of winning approval. | What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) were crashing 35.4% as of 11 a.m. But the trading of Acadia stock was halted that day because of the FDA advisory committee's deliberations. Acadia still has a chance of winning approval. |
35723.0 | 2022-06-20 00:00:00 UTC | FDA Panel Votes Against Acadia (ACAD) sNDA for Nuplazid | ACAD | https://www.nasdaq.com/articles/fda-panel-votes-against-acadia-acad-snda-for-nuplazid | nan | nan | Acadia Pharmaceuticals Inc. ACAD announced that the FDA’s Psychopharmacologic Drugs Advisory Committee (“PDAC”) has not voted in favor of the supplemental new drug application (sNDA) for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis (“ADP”).
The PDAC voted nine to three, thus not supporting the claim that pimavanserin is effective in the treatment of hallucinations and delusions for the ADP patient population. Earlier, the FDA had asked the committee for advice and recommendations regarding the evidence that pimavanserin is effective for the given indication.
The FDA’s decision date for the sNDA is Aug 4. Though the FDA is not completely bound by the PDAC’s recommendations, it usually follows the same.
Shares of Acadia have lost 16.4% so far this year compared with the industry’s decline of 28.1%.
Image Source: Zacks Investment Research
In a separate press release, Acadia announced that the Nasdaq halted trading ACAD’s common shares on Jun 17, ahead of the PDAC’s review of the resubmitted sNDA for Nuplazid for the treatment of hallucinations and delusions associated with ADP.
Acadia shares are expected to be down when it resumes trading on Monday, Jun 20.
Last week, shares of Acadia gained briefly after the FDA issued the briefing documents ahead of its Advisory Committee meeting on Jun 17.
We remind investors that the FDA had issued a complete response letter ("CRL") to the sNDA for Nuplazid in April 2021.
The CRL indicated that the FDA had decided that Nuplazid could not be approved in its then-present form as it lacked statistical significance in some of the subgroups of dementia. Moreover, there was an insufficient number of patients with certain less common dementia subtypes, which was considered as a lack of substantial evidence of effectiveness to support approval. The CRL also stated that the phase II Alzheimer’s disease psychosis study, a supportive study in the sNDA filing, was inadequate and not well controlled.
Nuplazid is currently approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The drug generated sales worth $115.5 million in the first quarter of 2022, reflecting an increase of 8% year over year. A potential label expansion is likely to boost sales of the drug in the days ahead.
Zacks Rank & Stocks to Consider
Acadia currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Leap Therapeutics, Inc. LPTX, Aeglea BioTherapeutics, Inc. AGLE and Precision BioSciences, Inc. DTIL, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Aeglea BioTherapeutics’ loss per share estimates narrowed 19.4% for 2022 and 37.5% for 2023 in the past 60 days.
Earnings of Aeglea BioTherapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AGLE delivered an earnings surprise of 9.47%, on average
Precision BioSciences’ loss per share estimates narrowed 21.7% for 2022 and 31.4% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?
From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Aeglea BioTherapeutics, Inc. (AGLE): Free Stock Analysis Report
Leap Therapeutics, Inc. (LPTX): Free Stock Analysis Report
Precision BioSciences, Inc. (DTIL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Image Source: Zacks Investment Research In a separate press release, Acadia announced that the Nasdaq halted trading ACAD’s common shares on Jun 17, ahead of the PDAC’s review of the resubmitted sNDA for Nuplazid for the treatment of hallucinations and delusions associated with ADP. Last week, shares of Acadia gained briefly after the FDA issued the briefing documents ahead of its Advisory Committee meeting on Jun 17. Acadia Pharmaceuticals Inc. ACAD announced that the FDA’s Psychopharmacologic Drugs Advisory Committee (“PDAC”) has not voted in favor of the supplemental new drug application (sNDA) for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis (“ADP”). | ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Acadia Pharmaceuticals Inc. ACAD announced that the FDA’s Psychopharmacologic Drugs Advisory Committee (“PDAC”) has not voted in favor of the supplemental new drug application (sNDA) for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis (“ADP”). Shares of Acadia have lost 16.4% so far this year compared with the industry’s decline of 28.1%. | Acadia Pharmaceuticals Inc. ACAD announced that the FDA’s Psychopharmacologic Drugs Advisory Committee (“PDAC”) has not voted in favor of the supplemental new drug application (sNDA) for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis (“ADP”). Image Source: Zacks Investment Research In a separate press release, Acadia announced that the Nasdaq halted trading ACAD’s common shares on Jun 17, ahead of the PDAC’s review of the resubmitted sNDA for Nuplazid for the treatment of hallucinations and delusions associated with ADP. Shares of Acadia have lost 16.4% so far this year compared with the industry’s decline of 28.1%. | Acadia Pharmaceuticals Inc. ACAD announced that the FDA’s Psychopharmacologic Drugs Advisory Committee (“PDAC”) has not voted in favor of the supplemental new drug application (sNDA) for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis (“ADP”). Image Source: Zacks Investment Research In a separate press release, Acadia announced that the Nasdaq halted trading ACAD’s common shares on Jun 17, ahead of the PDAC’s review of the resubmitted sNDA for Nuplazid for the treatment of hallucinations and delusions associated with ADP. Shares of Acadia have lost 16.4% so far this year compared with the industry’s decline of 28.1%. |
35724.0 | 2022-06-16 00:00:00 UTC | Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA | ACAD | https://www.nasdaq.com/articles/acadia-acad-up-on-fda-briefing-document-for-nuplazid-snda | nan | nan | Shares of ACADIA Pharmaceuticals Inc. ACAD gained 15.5% on Wednesday after the FDA issued briefing documents related to the resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis (“ADP”).
The regulatory body issued the briefing documents ahead of its Advisory Committee meeting, which is scheduled to review the resubmitted supplemental new drug application (sNDA) for pimavanserin on Jun 17, 2022.
Per the FDA briefing document, the agency decided that the study was designed with features that could allow the latter to be considered an adequate and well-controlled one, suitable for regulatory decision making. Investors are upbeat about the likely positive outcome of the meeting. This might have been a catalyst for the stock price to go up.
Shares of Acadia have lost 19.6% so far this year compared with the industry’s decrease of 28.8%.
Image Source: Zacks Investment Research
In March 2022, Acadia received the action date from the FDA related to its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with ADP.
The regulatory body has set a target action date of Aug 4, 2022.
During the first quarter of 2022, Acadia resubmitted the sNDA to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with ADP.
The resubmitted sNDA was based on positive data from two placebo-controlled studies — the pivotal phase III HARMONY study and the -019 study. Both studies have prospectively met their primary endpoints.
The FDA had issued a complete response letter to the sNDA for Nuplazid in April 2021.
The CRL indicated that the FDA had completed its review of the application and had decided that it could not be approved in its then-present form as it lacked statistical significance in some of the subgroups of dementia. Moreover, there was an insufficient number of patients with certain less common dementia subtypes, which was considered as a lack of substantial evidence of effectiveness to support approval. The CRL also stated that the phase II Alzheimer’s disease psychosis study, a supportive study in the sNDA filing, was inadequate and not well controlled.
Nuplazid is currently approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Nuplazid generated sales worth $115.5 million in the first quarter of 2022, reflecting an increase of 8% year-over-year. A potential label expansion is likely to boost sales of the drug in the days ahead. However, if the FDA again declines to approve the sNDA for pimavanserinfor treating hallucinations and delusions associated with ADP, it will be a major setback for the company.
ACADIA Pharmaceuticals Inc. Price
ACADIA Pharmaceuticals Inc. price | ACADIA Pharmaceuticals Inc. Quote
Zacks Rank & Stocks to Consider
Acadia currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Leap Therapeutics, Inc. LPTX, Galapagos NV GLPG and Precision BioSciences, Inc. DTIL, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Galapagos’ loss per share estimates narrowed 32.5% for 2022 and 31.1% for 2023 in the past 60 days.
Earnings of Galapagos have surpassed estimates in each of the trailing three quarters. GLPG delivered an earnings surprise of 40.80%, on average.
Precision BioSciences’ loss per share estimates narrowed 21.7% for 2022 and 31.4% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.
Special Report: The Top 5 IPOs for Your Portfolio
Today, you have a chance to get in on the ground floor of one of the best investment opportunities of the year. As the world continues to benefit from an ever-evolving internet, a handful of innovative tech companies are on the brink of reaping immense rewards - and you can put yourself in a position to cash in. One is set to disrupt the online communication industry. Brilliantly designed for creating online communities, this stock is poised to explode when made public. With the strength of our economy and record amounts of cash flooding into IPOs, you don’t want to miss this opportunity.
>>See Zacks’ Hottest IPOs Now
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Galapagos NV (GLPG): Free Stock Analysis Report
Leap Therapeutics, Inc. (LPTX): Free Stock Analysis Report
Precision BioSciences, Inc. (DTIL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of ACADIA Pharmaceuticals Inc. ACAD gained 15.5% on Wednesday after the FDA issued briefing documents related to the resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis (“ADP”). Image Source: Zacks Investment Research In March 2022, Acadia received the action date from the FDA related to its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with ADP. Shares of Acadia have lost 19.6% so far this year compared with the industry’s decrease of 28.8%. | Shares of ACADIA Pharmaceuticals Inc. ACAD gained 15.5% on Wednesday after the FDA issued briefing documents related to the resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis (“ADP”). ACADIA Pharmaceuticals Inc. Price ACADIA Pharmaceuticals Inc. price | ACADIA Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). Shares of Acadia have lost 19.6% so far this year compared with the industry’s decrease of 28.8%. | Shares of ACADIA Pharmaceuticals Inc. ACAD gained 15.5% on Wednesday after the FDA issued briefing documents related to the resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis (“ADP”). Image Source: Zacks Investment Research In March 2022, Acadia received the action date from the FDA related to its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with ADP. ACADIA Pharmaceuticals Inc. Price ACADIA Pharmaceuticals Inc. price | ACADIA Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). | Shares of ACADIA Pharmaceuticals Inc. ACAD gained 15.5% on Wednesday after the FDA issued briefing documents related to the resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis (“ADP”). ACADIA Pharmaceuticals Inc. Price ACADIA Pharmaceuticals Inc. price | ACADIA Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). Shares of Acadia have lost 19.6% so far this year compared with the industry’s decrease of 28.8%. |
35725.0 | 2022-06-16 00:00:00 UTC | Acadia (ACAD) Surges 15.5%: Is This an Indication of Further Gains? | ACAD | https://www.nasdaq.com/articles/acadia-acad-surges-15.5%3A-is-this-an-indication-of-further-gains | nan | nan | Acadia Pharmaceuticals (ACAD) shares rallied 15.5% in the last trading session to close at $18.77. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 4.7% loss over the past four weeks.
Shares of the company rallied after the FDA issued briefing documents related to the resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis (“ADP”). Per the FDA briefing document, the agency decided that the study was designed with features which could allow it to be considered an adequate and well-controlled one, suitable for regulatory decision making.
This drugmaker is expected to post quarterly loss of $0.24 per share in its upcoming report, which represents a year-over-year change of +11.1%. Revenues are expected to be $131.19 million, up 13.9% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Acadia, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ACAD going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Acadia belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Akoya Biosciences (AKYA), closed the last trading session 3.3% higher at $10.42. Over the past month, AKYA has returned 11.7%.
Akoya's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.34. Compared to the company's year-ago EPS, this represents a change of -70%. Akoya currently boasts a Zacks Rank of #3 (Hold).
Special Report: The Top 5 IPOs for Your Portfolio
Today, you have a chance to get in on the ground floor of one of the best investment opportunities of the year. As the world continues to benefit from an ever-evolving internet, a handful of innovative tech companies are on the brink of reaping immense rewards - and you can put yourself in a position to cash in. One is set to disrupt the online communication industry. Brilliantly designed for creating online communities, this stock is poised to explode when made public. With the strength of our economy and record amounts of cash flooding into IPOs, you don’t want to miss this opportunity.
>>See Zacks’ Hottest IPOs Now
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Akoya Biosciences, Inc. (AKYA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (ACAD) shares rallied 15.5% in the last trading session to close at $18.77. For Acadia, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. So, make sure to keep an eye on ACAD going forward to see if this recent jump can turn into more strength down the road. | ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Acadia Pharmaceuticals (ACAD) shares rallied 15.5% in the last trading session to close at $18.77. For Acadia, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. | You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Acadia belongs to the Zacks Medical - Biomedical and Genetics industry. Acadia Pharmaceuticals (ACAD) shares rallied 15.5% in the last trading session to close at $18.77. For Acadia, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. | ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Acadia Pharmaceuticals (ACAD) shares rallied 15.5% in the last trading session to close at $18.77. For Acadia, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. |
35726.0 | 2022-06-15 00:00:00 UTC | Why Acadia Pharmaceuticals Spiked Today | ACAD | https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-spiked-today | nan | nan | What happened
Acadia Pharmaceuticals' (NASDAQ: ACAD) stock was up more than 14.3% as of 12:03 p.m. ET on Wednesday thanks to a sheaf of documents released by the Food and Drug Administration (FDA) about the company's submission requesting a new indication for its Parkinson's-disease-associated psychosis therapy, Nuplazid.
Last year, the FDA ruled that there wasn't sufficient evidence in favor of Nuplazid's efficacy for the new indication, which is for psychosis in patients with Alzheimer's disease, so the company submitted a pair of new analyses. The newly released documents appear to show that regulators are at least willing to entertain a formal public evaluation of the merit of the two analyses, which is what's driving the rise in the share price.
So what
Nuplazid is Acadia's only approved drug, and it helped the company to bring in trailing-12-month revenue of more than $493 million. But the company still isn't profitable, so there's pressure for it to squeeze more money out of the drug's sunk research and development costs by trying to commercialize Nuplazid for additional indications.
If regulators ultimately decide not to bite the second time around, it'll be another major setback. Nonetheless, revenue from the current set of indications for Nuplazid is still growing, so it won't be a life-or-death situation for the company either way.
Now what
Acadia's resubmitted application will go before a non-binding FDA advisory committee on June 17. Then, on Aug. 3, the FDA's binding committee will hold the final vote.
If the advisory committee votes to approve the drug, it'll catalyze further growth, but the binding committee's vote will result in a far larger move -- and not necessarily upward.
10 stocks we like better than Acadia Pharmaceuticals
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2022
Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Acadia Pharmaceuticals' (NASDAQ: ACAD) stock was up more than 14.3% as of 12:03 p.m. So what Nuplazid is Acadia's only approved drug, and it helped the company to bring in trailing-12-month revenue of more than $493 million. Now what Acadia's resubmitted application will go before a non-binding FDA advisory committee on June 17. | What happened Acadia Pharmaceuticals' (NASDAQ: ACAD) stock was up more than 14.3% as of 12:03 p.m. So what Nuplazid is Acadia's only approved drug, and it helped the company to bring in trailing-12-month revenue of more than $493 million. Now what Acadia's resubmitted application will go before a non-binding FDA advisory committee on June 17. | 10 stocks we like better than Acadia Pharmaceuticals When our award-winning analyst team has a stock tip, it can pay to listen. What happened Acadia Pharmaceuticals' (NASDAQ: ACAD) stock was up more than 14.3% as of 12:03 p.m. So what Nuplazid is Acadia's only approved drug, and it helped the company to bring in trailing-12-month revenue of more than $493 million. | What happened Acadia Pharmaceuticals' (NASDAQ: ACAD) stock was up more than 14.3% as of 12:03 p.m. So what Nuplazid is Acadia's only approved drug, and it helped the company to bring in trailing-12-month revenue of more than $493 million. Now what Acadia's resubmitted application will go before a non-binding FDA advisory committee on June 17. |
35727.0 | 2022-06-15 00:00:00 UTC | Health Care Sector Update for 06/15/2022: ACAD,AMN,OSH,ATNF | ACAD | https://www.nasdaq.com/articles/health-care-sector-update-for-06-15-2022%3A-acadamnoshatnf | nan | nan | Health care stocks were trading higher this afternoon, with the NYSE Health Care Index rising 1.5% and the SPDR Health Care Select Sector ETF (XLV) up 1.2%.
The Nasdaq Biotechnology index was climbing 2.5%.
In company news, ACADIA Pharmaceuticals (ACAD) streaked almost 16% higher after briefing documents prepared for an upcoming advisory panel meeting indicates the US Food and Drug Administration has "no key safety issue" with the company's pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease. The FDA's psychopharmacologic drugs advisory committee will review the company's resubmitted supplemental new drug application for pimavanserin and forward its recommendations to the full agency.
AMN Healthcare Services (AMN) rose 2.9% after the hospital staffing services company Wednesday authorized an additional $250 million for stock buybacks.
Among decliners, Oak Street Health (OSH) dropped 1.7% following a double downgrade Wednesday of the primary care company by BofA Securities to underperform from buy, coupled with an $8 reduction in its price target for the stock to $18.
180 Life Sciences (ATNF) slumped over 34%, earlier sinking nearly 40% to a record low of $0.81 a share, after saying UK and US regulators were unlikely to accept the endpoints proposed by the company to evaluate its adalimumab drug candidate as a prospective treatment for early-stage Dupuytren's disease - a progressive condition that causes fingers to irreversibly curl into the palm and is currently only treatable through surgery.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, ACADIA Pharmaceuticals (ACAD) streaked almost 16% higher after briefing documents prepared for an upcoming advisory panel meeting indicates the US Food and Drug Administration has "no key safety issue" with the company's pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease. Among decliners, Oak Street Health (OSH) dropped 1.7% following a double downgrade Wednesday of the primary care company by BofA Securities to underperform from buy, coupled with an $8 reduction in its price target for the stock to $18. 180 Life Sciences (ATNF) slumped over 34%, earlier sinking nearly 40% to a record low of $0.81 a share, after saying UK and US regulators were unlikely to accept the endpoints proposed by the company to evaluate its adalimumab drug candidate as a prospective treatment for early-stage Dupuytren's disease - a progressive condition that causes fingers to irreversibly curl into the palm and is currently only treatable through surgery. | In company news, ACADIA Pharmaceuticals (ACAD) streaked almost 16% higher after briefing documents prepared for an upcoming advisory panel meeting indicates the US Food and Drug Administration has "no key safety issue" with the company's pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease. Health care stocks were trading higher this afternoon, with the NYSE Health Care Index rising 1.5% and the SPDR Health Care Select Sector ETF (XLV) up 1.2%. AMN Healthcare Services (AMN) rose 2.9% after the hospital staffing services company Wednesday authorized an additional $250 million for stock buybacks. | In company news, ACADIA Pharmaceuticals (ACAD) streaked almost 16% higher after briefing documents prepared for an upcoming advisory panel meeting indicates the US Food and Drug Administration has "no key safety issue" with the company's pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease. Health care stocks were trading higher this afternoon, with the NYSE Health Care Index rising 1.5% and the SPDR Health Care Select Sector ETF (XLV) up 1.2%. 180 Life Sciences (ATNF) slumped over 34%, earlier sinking nearly 40% to a record low of $0.81 a share, after saying UK and US regulators were unlikely to accept the endpoints proposed by the company to evaluate its adalimumab drug candidate as a prospective treatment for early-stage Dupuytren's disease - a progressive condition that causes fingers to irreversibly curl into the palm and is currently only treatable through surgery. | In company news, ACADIA Pharmaceuticals (ACAD) streaked almost 16% higher after briefing documents prepared for an upcoming advisory panel meeting indicates the US Food and Drug Administration has "no key safety issue" with the company's pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease. Health care stocks were trading higher this afternoon, with the NYSE Health Care Index rising 1.5% and the SPDR Health Care Select Sector ETF (XLV) up 1.2%. The Nasdaq Biotechnology index was climbing 2.5%. |
35728.0 | 2022-06-15 00:00:00 UTC | Noteworthy Wednesday Option Activity: ACAD, VST, OLED | ACAD | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-acad-vst-oled | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total of 34,497 contracts have traded so far, representing approximately 3.4 million underlying shares. That amounts to about 209% of ACAD's average daily trading volume over the past month of 1.7 million shares. Particularly high volume was seen for the $16 strike put option expiring June 24, 2022, with 4,454 contracts trading so far today, representing approximately 445,400 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $16 strike highlighted in orange:
Vistra Corp (Symbol: VST) saw options trading volume of 73,014 contracts, representing approximately 7.3 million underlying shares or approximately 135.6% of VST's average daily trading volume over the past month, of 5.4 million shares. Especially high volume was seen for the $25 strike call option expiring July 15, 2022, with 33,519 contracts trading so far today, representing approximately 3.4 million underlying shares of VST. Below is a chart showing VST's trailing twelve month trading history, with the $25 strike highlighted in orange:
And Universal Display Corp (Symbol: OLED) options are showing a volume of 3,975 contracts thus far today. That number of contracts represents approximately 397,500 underlying shares, working out to a sizeable 111.7% of OLED's average daily trading volume over the past month, of 355,930 shares. Particularly high volume was seen for the $150 strike call option expiring December 16, 2022, with 3,449 contracts trading so far today, representing approximately 344,900 underlying shares of OLED. Below is a chart showing OLED's trailing twelve month trading history, with the $150 strike highlighted in orange:
For the various different available expirations for ACAD options, VST options, or OLED options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $16 strike put option expiring June 24, 2022, with 4,454 contracts trading so far today, representing approximately 445,400 underlying shares of ACAD. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total of 34,497 contracts have traded so far, representing approximately 3.4 million underlying shares. That amounts to about 209% of ACAD's average daily trading volume over the past month of 1.7 million shares. | Below is a chart showing ACAD's trailing twelve month trading history, with the $16 strike highlighted in orange: Vistra Corp (Symbol: VST) saw options trading volume of 73,014 contracts, representing approximately 7.3 million underlying shares or approximately 135.6% of VST's average daily trading volume over the past month, of 5.4 million shares. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total of 34,497 contracts have traded so far, representing approximately 3.4 million underlying shares. That amounts to about 209% of ACAD's average daily trading volume over the past month of 1.7 million shares. | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total of 34,497 contracts have traded so far, representing approximately 3.4 million underlying shares. Below is a chart showing ACAD's trailing twelve month trading history, with the $16 strike highlighted in orange: Vistra Corp (Symbol: VST) saw options trading volume of 73,014 contracts, representing approximately 7.3 million underlying shares or approximately 135.6% of VST's average daily trading volume over the past month, of 5.4 million shares. That amounts to about 209% of ACAD's average daily trading volume over the past month of 1.7 million shares. | Below is a chart showing ACAD's trailing twelve month trading history, with the $16 strike highlighted in orange: Vistra Corp (Symbol: VST) saw options trading volume of 73,014 contracts, representing approximately 7.3 million underlying shares or approximately 135.6% of VST's average daily trading volume over the past month, of 5.4 million shares. Below is a chart showing OLED's trailing twelve month trading history, with the $150 strike highlighted in orange: For the various different available expirations for ACAD options, VST options, or OLED options, visit StockOptionsChannel.com. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total of 34,497 contracts have traded so far, representing approximately 3.4 million underlying shares. |
35729.0 | 2022-06-06 00:00:00 UTC | Notable Monday Option Activity: RWT, ORA, ACAD | ACAD | https://www.nasdaq.com/articles/notable-monday-option-activity%3A-rwt-ora-acad | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Redwood Trust Inc (Symbol: RWT), where a total volume of 5,725 contracts has been traded thus far today, a contract volume which is representative of approximately 572,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 51.8% of RWT's average daily trading volume over the past month, of 1.1 million shares. Particularly high volume was seen for the $10 strike call option expiring January 20, 2023, with 4,922 contracts trading so far today, representing approximately 492,200 underlying shares of RWT. Below is a chart showing RWT's trailing twelve month trading history, with the $10 strike highlighted in orange:
Ormat Technologies Inc (Symbol: ORA) options are showing a volume of 1,620 contracts thus far today. That number of contracts represents approximately 162,000 underlying shares, working out to a sizeable 50.6% of ORA's average daily trading volume over the past month, of 320,405 shares. Particularly high volume was seen for the $70 strike put option expiring December 16, 2022, with 600 contracts trading so far today, representing approximately 60,000 underlying shares of ORA. Below is a chart showing ORA's trailing twelve month trading history, with the $70 strike highlighted in orange:
And Acadia Pharmaceuticals Inc (Symbol: ACAD) saw options trading volume of 8,422 contracts, representing approximately 842,200 underlying shares or approximately 49.3% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Especially high volume was seen for the $30 strike call option expiring June 24, 2022, with 3,530 contracts trading so far today, representing approximately 353,000 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $30 strike highlighted in orange:
For the various different available expirations for RWT options, ORA options, or ACAD options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $30 strike call option expiring June 24, 2022, with 3,530 contracts trading so far today, representing approximately 353,000 underlying shares of ACAD. Below is a chart showing ORA's trailing twelve month trading history, with the $70 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) saw options trading volume of 8,422 contracts, representing approximately 842,200 underlying shares or approximately 49.3% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Below is a chart showing ACAD's trailing twelve month trading history, with the $30 strike highlighted in orange: For the various different available expirations for RWT options, ORA options, or ACAD options, visit StockOptionsChannel.com. | Below is a chart showing ORA's trailing twelve month trading history, with the $70 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) saw options trading volume of 8,422 contracts, representing approximately 842,200 underlying shares or approximately 49.3% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Below is a chart showing ACAD's trailing twelve month trading history, with the $30 strike highlighted in orange: For the various different available expirations for RWT options, ORA options, or ACAD options, visit StockOptionsChannel.com. Especially high volume was seen for the $30 strike call option expiring June 24, 2022, with 3,530 contracts trading so far today, representing approximately 353,000 underlying shares of ACAD. | Below is a chart showing ORA's trailing twelve month trading history, with the $70 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) saw options trading volume of 8,422 contracts, representing approximately 842,200 underlying shares or approximately 49.3% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Especially high volume was seen for the $30 strike call option expiring June 24, 2022, with 3,530 contracts trading so far today, representing approximately 353,000 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $30 strike highlighted in orange: For the various different available expirations for RWT options, ORA options, or ACAD options, visit StockOptionsChannel.com. | Below is a chart showing ORA's trailing twelve month trading history, with the $70 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) saw options trading volume of 8,422 contracts, representing approximately 842,200 underlying shares or approximately 49.3% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Especially high volume was seen for the $30 strike call option expiring June 24, 2022, with 3,530 contracts trading so far today, representing approximately 353,000 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $30 strike highlighted in orange: For the various different available expirations for RWT options, ORA options, or ACAD options, visit StockOptionsChannel.com. |
35730.0 | 2022-06-02 00:00:00 UTC | July 22nd Options Now Available For Acadia Pharmaceuticals (ACAD) | ACAD | https://www.nasdaq.com/articles/july-22nd-options-now-available-for-acadia-pharmaceuticals-acad | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the July 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new July 22nd contracts and identified one put and one call contract of particular interest.
The put contract at the $12.00 strike price has a current bid of 40 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $12.00, but will also collect the premium, putting the cost basis of the shares at $11.60 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $16.29/share today.
Because the $12.00 strike represents an approximate 26% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 3.33% return on the cash commitment, or 24.33% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $12.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $17.00 strike price has a current bid of 60 cents. If an investor was to purchase shares of ACAD stock at the current price level of $16.29/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $17.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 8.04% if the stock gets called away at the July 22nd expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $17.00 strike highlighted in red:
Considering the fact that the $17.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 3.68% boost of extra return to the investor, or 26.89% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $16.29) to be 63%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $17.00 strike highlighted in red: Considering the fact that the $17.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the July 22nd expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $17.00 strike highlighted in red: Considering the fact that the $17.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the July 22nd expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $12.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $17.00 strike price has a current bid of 60 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $17.00 strike highlighted in red: Considering the fact that the $17.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the July 22nd expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $12.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $17.00 strike price has a current bid of 60 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $17.00 strike highlighted in red: Considering the fact that the $17.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the July 22nd expiration. |
35731.0 | 2022-05-27 00:00:00 UTC | Noteworthy Friday Option Activity: LMND, WDC, ACAD | ACAD | https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-lmnd-wdc-acad | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Lemonade Inc (Symbol: LMND), where a total volume of 6,752 contracts has been traded thus far today, a contract volume which is representative of approximately 675,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 46.9% of LMND's average daily trading volume over the past month, of 1.4 million shares. Especially high volume was seen for the $19 strike put option expiring June 17, 2022, with 755 contracts trading so far today, representing approximately 75,500 underlying shares of LMND. Below is a chart showing LMND's trailing twelve month trading history, with the $19 strike highlighted in orange:
Western Digital Corp (Symbol: WDC) saw options trading volume of 23,587 contracts, representing approximately 2.4 million underlying shares or approximately 46.5% of WDC's average daily trading volume over the past month, of 5.1 million shares. Especially high volume was seen for the $62.50 strike call option expiring June 17, 2022, with 2,583 contracts trading so far today, representing approximately 258,300 underlying shares of WDC. Below is a chart showing WDC's trailing twelve month trading history, with the $62.50 strike highlighted in orange:
And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 7,695 contracts thus far today. That number of contracts represents approximately 769,500 underlying shares, working out to a sizeable 45.7% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Particularly high volume was seen for the $20 strike call option expiring June 24, 2022, with 3,171 contracts trading so far today, representing approximately 317,100 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $20 strike highlighted in orange:
For the various different available expirations for LMND options, WDC options, or ACAD options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $20 strike call option expiring June 24, 2022, with 3,171 contracts trading so far today, representing approximately 317,100 underlying shares of ACAD. Below is a chart showing WDC's trailing twelve month trading history, with the $62.50 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 7,695 contracts thus far today. That number of contracts represents approximately 769,500 underlying shares, working out to a sizeable 45.7% of ACAD's average daily trading volume over the past month, of 1.7 million shares. | Below is a chart showing WDC's trailing twelve month trading history, with the $62.50 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 7,695 contracts thus far today. That number of contracts represents approximately 769,500 underlying shares, working out to a sizeable 45.7% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Particularly high volume was seen for the $20 strike call option expiring June 24, 2022, with 3,171 contracts trading so far today, representing approximately 317,100 underlying shares of ACAD. | Particularly high volume was seen for the $20 strike call option expiring June 24, 2022, with 3,171 contracts trading so far today, representing approximately 317,100 underlying shares of ACAD. Below is a chart showing WDC's trailing twelve month trading history, with the $62.50 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 7,695 contracts thus far today. That number of contracts represents approximately 769,500 underlying shares, working out to a sizeable 45.7% of ACAD's average daily trading volume over the past month, of 1.7 million shares. | Below is a chart showing ACAD's trailing twelve month trading history, with the $20 strike highlighted in orange: For the various different available expirations for LMND options, WDC options, or ACAD options, visit StockOptionsChannel.com. Below is a chart showing WDC's trailing twelve month trading history, with the $62.50 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 7,695 contracts thus far today. That number of contracts represents approximately 769,500 underlying shares, working out to a sizeable 45.7% of ACAD's average daily trading volume over the past month, of 1.7 million shares. |
35732.0 | 2022-05-27 00:00:00 UTC | Biotech Stocks Facing FDA Decision In June 2022 | ACAD | https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-in-june-2022 | nan | nan | (RTTNews) - As another month comes to a close, it's time to take a look back at some of the healthcare sector news that made headlines in May and look ahead to what's in store on the regulatory front in June.
Just when the world was heaving a sigh of relief at the declining number of new COVID-19 cases and deaths since the end of March 2022, a fresh outbreak of monkeypox that began in early May has become the new global concern.
On May 19, Bavarian Nordic A/S (BVNRY.OB) secured a contract with an undisclosed European country to supply its IMVANEX smallpox vaccine in response to the emerging outbreak of monkeypox. Smallpox vaccine appears to be at least 85 percent effective in preventing monkeypox, according to studies.
Hyundai Bioscience, as recently as May 25, announced that it is planning to submit a request for a fast track processing to the FDA for investigational drug CP-COV03, an oral antiviral medicine for the treatment of monkeypox, which it developed as a treatment for COVID-19.
As of May 25, 2022, there were 219 confirmed cases of monkeypox reported from countries where the disease is not considered endemic, including 118 cases in the European Union, according to the European Centre for Disease Prevention and Control.
Now, let's take a look at the stocks awaiting FDA decision in June.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - As another month comes to a close, it's time to take a look back at some of the healthcare sector news that made headlines in May and look ahead to what's in store on the regulatory front in June. Just when the world was heaving a sigh of relief at the declining number of new COVID-19 cases and deaths since the end of March 2022, a fresh outbreak of monkeypox that began in early May has become the new global concern. On May 19, Bavarian Nordic A/S (BVNRY.OB) secured a contract with an undisclosed European country to supply its IMVANEX smallpox vaccine in response to the emerging outbreak of monkeypox. | On May 19, Bavarian Nordic A/S (BVNRY.OB) secured a contract with an undisclosed European country to supply its IMVANEX smallpox vaccine in response to the emerging outbreak of monkeypox. Smallpox vaccine appears to be at least 85 percent effective in preventing monkeypox, according to studies. As of May 25, 2022, there were 219 confirmed cases of monkeypox reported from countries where the disease is not considered endemic, including 118 cases in the European Union, according to the European Centre for Disease Prevention and Control. | (RTTNews) - As another month comes to a close, it's time to take a look back at some of the healthcare sector news that made headlines in May and look ahead to what's in store on the regulatory front in June. Hyundai Bioscience, as recently as May 25, announced that it is planning to submit a request for a fast track processing to the FDA for investigational drug CP-COV03, an oral antiviral medicine for the treatment of monkeypox, which it developed as a treatment for COVID-19. As of May 25, 2022, there were 219 confirmed cases of monkeypox reported from countries where the disease is not considered endemic, including 118 cases in the European Union, according to the European Centre for Disease Prevention and Control. | (RTTNews) - As another month comes to a close, it's time to take a look back at some of the healthcare sector news that made headlines in May and look ahead to what's in store on the regulatory front in June. Just when the world was heaving a sigh of relief at the declining number of new COVID-19 cases and deaths since the end of March 2022, a fresh outbreak of monkeypox that began in early May has become the new global concern. On May 19, Bavarian Nordic A/S (BVNRY.OB) secured a contract with an undisclosed European country to supply its IMVANEX smallpox vaccine in response to the emerging outbreak of monkeypox. |
35733.0 | 2022-05-26 00:00:00 UTC | ACAD July 8th Options Begin Trading | ACAD | https://www.nasdaq.com/articles/acad-july-8th-options-begin-trading | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the July 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new July 8th contracts and identified one put and one call contract of particular interest.
The put contract at the $15.00 strike price has a current bid of 30 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $15.00, but will also collect the premium, putting the cost basis of the shares at $14.70 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $15.83/share today.
Because the $15.00 strike represents an approximate 5% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 2.00% return on the cash commitment, or 16.98% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $16.00 strike price has a current bid of 50 cents. If an investor was to purchase shares of ACAD stock at the current price level of $15.83/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $16.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 4.23% if the stock gets called away at the July 8th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red:
Considering the fact that the $16.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 3.16% boost of extra return to the investor, or 26.81% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $15.83) to be 62%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red: Considering the fact that the $16.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the July 8th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red: Considering the fact that the $16.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the July 8th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $16.00 strike price has a current bid of 50 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red: Considering the fact that the $16.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the July 8th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $16.00 strike price has a current bid of 50 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red: Considering the fact that the $16.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the July 8th expiration. |
35734.0 | 2022-05-18 00:00:00 UTC | ACADIA Pharmaceuticals: No Upturn in Sight | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals%3A-no-upturn-in-sight | nan | nan | ACADIA Pharmaceuticals (ACAD) is a biotechnology developer of breakthrough therapies in neuroscience.
Specifically, ACADIA markets Nuplazid for hallucinations and delusions associated with Parkinson's disease. Nuplazid is an antipsychotic, the first and only drug (the company says) approved to treat psychosis in schizophrenia and other psychotic disorders.
As more schizophrenic patients are enrolled in a Phase 3 trial evaluating Nuplazid for the negative symptoms of this serious mental illness, the company is working to develop Nuplazid for Alzheimer's psychosis.
ACADIA is also developing a treatment for patients with Rett syndrome. Rett syndrome is a rare genetic neurological disorder that causes a progressive loss of motor skills and speech and primarily affects females.
The company's headquarters are in San Diego, California. I am bearish on ACADIA Pharmaceuticals for the next few months.
Current Market Downtrend
The overall market is just a whisper away from the technical bear market.
Healthcare stocks have also suffered from the high level of risk aversion currently prevailing in financial markets, having fallen more than 11% year-to-date. ACADIA shares have fallen about 27%, underperforming the benchmark index for the U.S. market significantly.
The market is currently facing severe headwinds from Russian aggression in Ukraine, rising inflation, and concerns about the steady supply of Russian oil and gas.
Fueled by the introduction of tighter monetary policies by central banks to curb rising inflation, the risk of a recession is compounding this turmoil.
Timid Rebound Opportunity Nipped
Regarding ACADIA's Supplemental New Drug Application for Nuplazid to treat hallucinations and delusions in Alzheimer's patients, the U.S. Food and Drug Administration will take action around August 4.
FDA approval could potentially bode well for the stock price as it would restore some excitement that traders have been losing.
However, with analysts believing ACADIA's earnings will deteriorate this year, forecasting a 33% rise in net losses, the company is likely to delay its upbeat earnings report beyond 2022, undoing any optimistic findings from the regulator.
Q1-2022 Results
Market headwinds impacted ACADIA's stock price, but not its first-quarter 2022 revenue. Revenue rose about 8% year-over-year to nearly $116 million, thanks to higher Nuplazid net sales.
Despite the increase in net sales, ACADIA's earnings for the first quarter of 2022 were still negative as the company posted a new net loss of $0.70, missing average estimates by $0.13. Net loss was lower for the corresponding period in 2021, as it was $0.42 per common share.
The net loss appears to have deteriorated due to the impact of costs from certain collaboration agreements, combined with higher non-cash share-based fees.
Research and development expenses increased 126.3% year-over-year to $129 million, while selling, general and administrative expenses decreased 13.4% to nearly $97 million in the first quarter of 2022.
Looking ahead, ACADIA is forecasting revenue from the sale of Nuplazid to be between $510 million and $560 million, versus analysts' median forecast of $533.09 million.
Balance Sheet
As of March 31, 2022, ACADIA's financial position appears to be rock solid, with cash and short-term investments totaling $446 million and total debt (consisting primarily of operating lease liabilities) of approximately $60 million.
However, investors should be aware that since the bottom line is still a net loss, ACADIA earns negative returns on each investment. Therefore, it does not recover the cost of raising the necessary capital for that investment.
The situation is evident in this comparison: ACADIA's weighted average cost of capital is 7%, while its return on invested capital is -22%.
ACADIA is destroying rather than creating value, and its current balance sheet could lose much of its financial flexibility if the above relationship doesn't reverse.
The likelihood of that happening this year is very slim, which is certainly not good for the stock price.
Wall Street's Take
In the past three months, 16 Wall Street analysts have issued a 12-month price target for ACAD. The company has a Moderate Buy consensus rating based on seven Buys, nine Holds, and zero Sell ratings.
The average ACADIA Pharmaceuticals price target is $29.07, implying 70.5% upside potential.
Valuation
ACADIA has a market cap of $2.75 billion and a 52-week range of $15.16 to $28.06.
The stock has a price/earnings ratio of -12.8, a price/book ratio of 6.2, a price/sales ratio of 5.6, and a price-to-free-cash-flow ratio of -19.4.
Conclusion
Persistent headwinds and expectations for a larger net loss this year leave ACADIA with little chance of breaking out of its current bearish trend. The share price has traded very weakly since early 2022.
Discover new investment ideas with data you can trust.
Read full Disclaimer & Disclosure
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Conclusion Persistent headwinds and expectations for a larger net loss this year leave ACADIA with little chance of breaking out of its current bearish trend. ACADIA Pharmaceuticals (ACAD) is a biotechnology developer of breakthrough therapies in neuroscience. Specifically, ACADIA markets Nuplazid for hallucinations and delusions associated with Parkinson's disease. | However, with analysts believing ACADIA's earnings will deteriorate this year, forecasting a 33% rise in net losses, the company is likely to delay its upbeat earnings report beyond 2022, undoing any optimistic findings from the regulator. Q1-2022 Results Market headwinds impacted ACADIA's stock price, but not its first-quarter 2022 revenue. However, investors should be aware that since the bottom line is still a net loss, ACADIA earns negative returns on each investment. | However, with analysts believing ACADIA's earnings will deteriorate this year, forecasting a 33% rise in net losses, the company is likely to delay its upbeat earnings report beyond 2022, undoing any optimistic findings from the regulator. Despite the increase in net sales, ACADIA's earnings for the first quarter of 2022 were still negative as the company posted a new net loss of $0.70, missing average estimates by $0.13. Looking ahead, ACADIA is forecasting revenue from the sale of Nuplazid to be between $510 million and $560 million, versus analysts' median forecast of $533.09 million. | I am bearish on ACADIA Pharmaceuticals for the next few months. ACADIA Pharmaceuticals (ACAD) is a biotechnology developer of breakthrough therapies in neuroscience. Specifically, ACADIA markets Nuplazid for hallucinations and delusions associated with Parkinson's disease. |
35735.0 | 2022-05-17 00:00:00 UTC | Analysts Predict 43% Gains Ahead For FBT | ACAD | https://www.nasdaq.com/articles/analysts-predict-43-gains-ahead-for-fbt | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $189.69 per unit.
With FBT trading at a recent price near $132.57 per unit, that means that analysts see 43.09% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FBT's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioNTech SE (Symbol: BNTX), and FibroGen Inc (Symbol: FGEN). Although ACAD has traded at a recent price of $16.60/share, the average analyst target is 79.72% higher at $29.83/share. Similarly, BNTX has 59.19% upside from the recent share price of $151.20 if the average analyst target price of $240.70/share is reached, and analysts on average are expecting FGEN to reach a target price of $14.50/share, which is 56.93% above the recent price of $9.24. Below is a twelve month price history chart comparing the stock performance of ACAD, BNTX, and FGEN:
Combined, ACAD, BNTX, and FGEN represent 9.31% of the First Trust NYSE Arca Biotechnology Index Fund ETF. Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
First Trust NYSE Arca Biotechnology Index Fund ETF FBT $132.57 $189.69 43.09%
Acadia Pharmaceuticals Inc ACAD $16.60 $29.83 79.72%
BioNTech SE BNTX $151.20 $240.70 59.19%
FibroGen Inc FGEN $9.24 $14.50 56.93%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of ACAD, BNTX, and FGEN: Combined, ACAD, BNTX, and FGEN represent 9.31% of the First Trust NYSE Arca Biotechnology Index Fund ETF. First Trust NYSE Arca Biotechnology Index Fund ETF FBT $132.57 $189.69 43.09% Acadia Pharmaceuticals Inc ACAD $16.60 $29.83 79.72% BioNTech SE BNTX $151.20 $240.70 59.19% FibroGen Inc FGEN $9.24 $14.50 56.93% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of FBT's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioNTech SE (Symbol: BNTX), and FibroGen Inc (Symbol: FGEN). | Three of FBT's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioNTech SE (Symbol: BNTX), and FibroGen Inc (Symbol: FGEN). First Trust NYSE Arca Biotechnology Index Fund ETF FBT $132.57 $189.69 43.09% Acadia Pharmaceuticals Inc ACAD $16.60 $29.83 79.72% BioNTech SE BNTX $151.20 $240.70 59.19% FibroGen Inc FGEN $9.24 $14.50 56.93% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Although ACAD has traded at a recent price of $16.60/share, the average analyst target is 79.72% higher at $29.83/share. | Three of FBT's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioNTech SE (Symbol: BNTX), and FibroGen Inc (Symbol: FGEN). Although ACAD has traded at a recent price of $16.60/share, the average analyst target is 79.72% higher at $29.83/share. Below is a twelve month price history chart comparing the stock performance of ACAD, BNTX, and FGEN: Combined, ACAD, BNTX, and FGEN represent 9.31% of the First Trust NYSE Arca Biotechnology Index Fund ETF. | Although ACAD has traded at a recent price of $16.60/share, the average analyst target is 79.72% higher at $29.83/share. Three of FBT's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioNTech SE (Symbol: BNTX), and FibroGen Inc (Symbol: FGEN). Below is a twelve month price history chart comparing the stock performance of ACAD, BNTX, and FGEN: Combined, ACAD, BNTX, and FGEN represent 9.31% of the First Trust NYSE Arca Biotechnology Index Fund ETF. |
35736.0 | 2022-05-09 00:00:00 UTC | Acadia Pharmaceuticals is Now Oversold (ACAD) | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-is-now-oversold-acad | nan | nan | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $16.85 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 34.7. A bullish investor could look at ACAD's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares:
Looking at the chart above, ACAD's low point in its 52 week range is $15.6792 per share, with $28.055 as the 52 week high point — that compares with a last trade of $16.85.
Find out what 9 other oversold stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $16.85 per share. A bullish investor could look at ACAD's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $15.6792 per share, with $28.055 as the 52 week high point — that compares with a last trade of $16.85. | A bullish investor could look at ACAD's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $15.6792 per share, with $28.055 as the 52 week high point — that compares with a last trade of $16.85. In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $16.85 per share. | In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $16.85 per share. A bullish investor could look at ACAD's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $15.6792 per share, with $28.055 as the 52 week high point — that compares with a last trade of $16.85. | In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $16.85 per share. A bullish investor could look at ACAD's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $15.6792 per share, with $28.055 as the 52 week high point — that compares with a last trade of $16.85. |
35737.0 | 2022-05-05 00:00:00 UTC | Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates | ACAD | https://www.nasdaq.com/articles/acadia-acad-q1-earnings-revenues-fall-shy-of-estimates | nan | nan | Acadia Pharmaceuticals Inc. ACAD reported first-quarter 2022 loss of 70 cents per share, wider than the Zacks Consensus Estimate of a loss of 49 cents. In the year-ago quarter, the company had incurred a loss of 42 cents per share.
Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 8% year over year to $115.5 million in the first quarter, driven by Nuplazid demand growth. The top line, however, missed the Zacks Consensus Estimate of $124 million. Nuplazid sales declined 11.7% sequentially in the reported quarter.
Nuplazid is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis.
Shares of Acadia were up 3% in after-market trading on Wednesday, despite the weaker-than-expected earnings announcement. The stock has plunged 14.8% in the year so far compared with the industry’s 21.2% decline.
Image Source: Zacks Investment Research
Quarter in Detail
Research and development (R&D) expenses were $128.9 million for the quarter, significantly up from the year-ago quarter. This was due to an upfront payment of $60 million made to Stoke Therapeutics STOK under the collaboration agreement.
In January 2022, Acadia entered into a license and collaboration agreement with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for treating neurodevelopmental diseases of the central nervous system.
Acadia and Stoke will share all costs and profits equally for the SYNGAP1 program worldwide.
Selling, general and administrative (SG&A) expenses were $96.7 million, down 13.4% year over year, owing to reduced advertising and promotional costs as well as lower personnel expenses.
As of Mar 31, 2022, Acadia had cash, cash equivalents and investments worth $446 million compared with $520.7 million as of Dec 31, 2021.
2022 Guidance
Acadia reiterated the financial guidance for 2022 it had provided earlier this year.
The company expects Nuplazid net sales of $510-$560 million for 2022. The Zacks Consensus Estimate for the metric is pegged at $542.4 million.
The company expects R&D expenses of $355-$375 million while SG&A expenses are expected to be $360-$380 million in 2022.
Pipeline Updates
In March 2022, Acadia received the action date from the FDA related to its resubmitted supplemental new drug application (sNDA) for pimavanserin to treat hallucinations and delusions associated with Alzheimer’s disease psychosis.
The regulatory body has set a target action date of Aug 4, 2022.
Earlier this month, Acadia announced that the FDA’s Advisory Committee meeting to review the resubmission of the sNDA for pimavanserin is scheduled take place on Jun 17, 2022.
The FDA had issued a complete response letter to the sNDA for Nuplazid in April 2021.
Acadia has other promising pipeline candidates that are progressing well.
Last month, the company announced top-line data from a phase II study evaluating the safety and efficacy of its investigational candidate, ACP-044, for the treatment of acute pain following bunionectomy surgery. The study failed to meet its primary endpoint. Shares of Acadia tanked on this news.
Acadia is planning to file a new drug application for trofinetide to treat Rett syndrome around mid-2022.
Acadia Pharmaceuticals Inc. Price, Consensus and EPS Surprise
Acadia Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Acadia Pharmaceuticals Inc. Quote
Zacks Rank & Stocks to Consider
Acadia currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Vertex Pharmaceuticals Incorporated VRTX and Voyager Therapeutics, Inc. VYGR, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Vertex’s earnings estimates have been revised 0.3% upward for 2022 and 0.2% upward for 2023 over the past 60 days. The VRTX stock has rallied 24.6% year to date.
Earnings of Vertex surpassed estimates in each of the trailing four quarters.
Voyager Therapeutics’ loss per share estimates have narrowed 38.6% for 2022 and 29% for 2023 over the past 60 days. The VYGR stock has skyrocketed 214.4% year to date.
Earnings of Voyager Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Voyager Therapeutics, Inc. (VYGR): Free Stock Analysis Report
Stoke Therapeutics, Inc. (STOK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In January 2022, Acadia entered into a license and collaboration agreement with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for treating neurodevelopmental diseases of the central nervous system. Pipeline Updates In March 2022, Acadia received the action date from the FDA related to its resubmitted supplemental new drug application (sNDA) for pimavanserin to treat hallucinations and delusions associated with Alzheimer’s disease psychosis. Acadia Pharmaceuticals Inc. ACAD reported first-quarter 2022 loss of 70 cents per share, wider than the Zacks Consensus Estimate of a loss of 49 cents. | Acadia Pharmaceuticals Inc. Price, Consensus and EPS Surprise Acadia Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). Acadia Pharmaceuticals Inc. ACAD reported first-quarter 2022 loss of 70 cents per share, wider than the Zacks Consensus Estimate of a loss of 49 cents. Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 8% year over year to $115.5 million in the first quarter, driven by Nuplazid demand growth. | Acadia Pharmaceuticals Inc. ACAD reported first-quarter 2022 loss of 70 cents per share, wider than the Zacks Consensus Estimate of a loss of 49 cents. Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 8% year over year to $115.5 million in the first quarter, driven by Nuplazid demand growth. Acadia Pharmaceuticals Inc. Price, Consensus and EPS Surprise Acadia Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). | Pipeline Updates In March 2022, Acadia received the action date from the FDA related to its resubmitted supplemental new drug application (sNDA) for pimavanserin to treat hallucinations and delusions associated with Alzheimer’s disease psychosis. Acadia Pharmaceuticals Inc. ACAD reported first-quarter 2022 loss of 70 cents per share, wider than the Zacks Consensus Estimate of a loss of 49 cents. Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 8% year over year to $115.5 million in the first quarter, driven by Nuplazid demand growth. |
35738.0 | 2022-05-05 00:00:00 UTC | ABC Boosts EPS Outlook, ADPT Sees 20-26% Revenue Growth, ANAB To Report HARP Data In Q3 | ACAD | https://www.nasdaq.com/articles/abc-boosts-eps-outlook-adpt-sees-20-26-revenue-growth-anab-to-report-harp-data-in-q3 | nan | nan | (RTTNews) - The following are some of biotech companies that provided an update on their pipeline progress and reported quarterly results.
1. AmerisourceBergen Corporation (ABC) has boosted its earnings outlook for fiscal year 2022 to reflect stronger than expected performance of several of its businesses.
The company now expects adjusted EPS to be in the range of $10.80 to $11.05 for fiscal year 2022, up from its previous outlook range of $10.60 to $10.90 and above analysts' consensus estimate of $10.79 per share.
Adjusted EPS was $3.22 in the second quarter ended March 31, 2022, on revenue of $57.7 billion. This compares with adjusted EPS of $2.53 and revenue of $49.15 billion in the year-ago quarter.
Analysts polled by Thomson Reuters were expecting the company to earn $2.93 per share on revenue of $57.27 billion for the quarter.
ABC closed Wednesday's trading at $156.79, up 4.00%.
2. Acadia Pharmaceuticals Inc. (ACAD) has a regulatory catalyst to watch next month.
The company's supplemental New Drug Application for Pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis is under FDA review, with a decision expected on June 17, 2022.
The FDA had declined to approve Pimavanserin for expanded use in the above indication last April, citing "a lack of statistical significance in some of the subgroups of dementia, and insufficient numbers of patients with certain less common dementia subtypes as lack of substantial evidence of effectiveness to support approval".
Pimavanserin is already approved in the U.S. under the brand name Nuplazid for the treatment of hallucinations and delusions associated with Parkinson's disease.
Net sales of Nuplazid were $115.5 million for the three months ended March 31, 2022, compared to $106.6 million in the year-ago period.
Looking ahead to 2022, the company expects the drug to generate net sales of $510 to $560 million. Net sales of Nuplazid were $484.1 million in 2021.
ACAD closed Wednesday's trading at $19.89, up 0.40%.
3. Adaptive Biotechnologies Corp. (ADPT), which reported better-than-expected first quarter results, continues to expect revenue for 2022 to grow in the range of nearly 20-26% year-over-year.
Looking ahead to 2022, the company has reiterated its revenue outlook in the range of $185 million to $195 million. Revenue reported in 2021 was $154.3 million.
Wall Street analysts' consensus revenue estimate for the year is $189.38 million.
Net loss attributable to the company widened to $62.7 million or $0.44 per share for the first quarter of 2022 from $40.6 million or $0.29 per share for the same period in 2021. Revenue was $38.6 million for the first quarter of 2022, representing a 0.5% increase from the first quarter in the prior year.
Analysts polled by Thomson Reuters were expecting a loss of $0.45 per share on revenue of $37.71 million for Q1, 2022.
ADPT closed Wednesday's trading at $9.25, up 3.35%.
4. Aligos Therapeutics Inc. (ALGS), a clinical-stage biopharmaceutical company developing novel therapeutics for viral and liver diseases, has a couple of events planned for the second half of this year.
-- A phase I trial of ALG-000184 after single and multiple doses in healthy volunteers and chronic hepatitis B patients is underway. The company plans to share top line results for 28 day and 12-week cohorts of this trial in the second quarter and fourth quarter of 2022, respectively. -- A phase I proof of concept study of ALG-055009 in healthy volunteers and subjects with hyperlipidemia is ongoing, with topline results slated for release in the third quarter of 2022.
As of March 31, 2022, the company's cash, cash equivalents and marketable securities totaled $183.2 million.
ALGS closed Wednesday's trading at $1.24, down 0.80%.
5. AnaptysBio Inc. (ANAB) has a clinical trial catalyst to watch next quarter.
A phase II trial of lead drug candidate Imsidolimab in moderate-to-severe hidradenitis suppurativa, dubbed HARP, is underway. Topline data from this study is expected in the third quarter of 2022.
Imsidolimab is also under a phase III trial in generalized pustular psoriasis, dubbed GEMINI-1, with topline data anticipated in Q4 2023.
Rosnilimab and ANB032 are the other clinical drug candidates in the pipeline.
-- Rosnilimab is under a phase II clinical trial in moderate-to-severe alopecia areata, known as AZURE, with top-line data expected in the first half of 2023. -- ANB032 is being developed for treatment of inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. This compound is expected to advance into phase II testing in the second half of this year.
ANAB closed Wednesday's trading at $24.33, down 0.57%.
6. Apellis Pharmaceuticals Inc. (APLS) expects to submit the New Drug Application for intravitreal Pegcetacoplan in geographic atrophy secondary to age-related macular degeneration this quarter.
The company plans to seek approval for intravitreal Pegcetacoplan in Europe in the second half of 2022.
A phase II registrational study with systemic Pegcetacoplan for amyotrophic lateral sclerosis, dubbed MERIDIAN, is ongoing, with top-line results expected in mid-2023.
A phase III study of systemic Pegcetacoplan for Immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy is expected to be initiated in the second quarter of 2022.
APLS closed Wednesday's trading at $45.95, up 3.00%.
7. BioAtla Inc. (BCAB) has two catalysts to watch in the coming months.
An interim update from a phase II trial of Mecbotamab Vedotin in AXL-positive Non-Small Cell Lung Carcinoma is anticipated on or around 2Q22 earnings call.
The company expects to provide an interim update from its phase II trial of Ozuriftamab Vedotin in patients with ROR2-positive NSCLC in the second half of 2022.
As of March 31, 2022, cash and cash equivalents were $219.4 million.
BCAB closed Wednesday's trading at $4.08, up 6.53%.
8. Frequency Therapeutics Inc. (FREQ), a clinical-stage regenerative medicine, expects to achieve a few milestones in the coming months.
A phase IIb trial of FX-322 in individuals with acquired sensorineural hearing loss is underway, with data expected in Q4 2022 or Q1 2023.
The second investigational therapeutic candidate for sensorineural hearing loss is FX-345, which is currently under IND-enabling studies. An IND application for FX-345 is expected to be filed in the second half of 2022.
FREQ closed Wednesday's trading at $1.30, up 4.00%.
9. PetIQ Inc. (PETQ), a pet medication and wellness company, has reported better-than-expected results for the first quarter of 2022, and has reiterated its revenue outlook for the year.
Adjusted net income for the first quarter of 2022 increased to $18.3 million or $0.62 per share on net sales of $275.7 million. This compares with adjusted net income of $11.0 million or $0.41 per share and net sales of $254.3 million in the year-earlier quarter.
Wall Street analysts were looking for earnings of $0.37 per share and sales of $269.34 million for the quarter.
For full-year 2022, the company continues to expect net sales of approximately $985 million representing an increase of 5.6% compared to 2021.
Analysts, on average, expect the company to report net sales of $985.77 million for the year.
PETQ closed Wednesday's trading at $19.97, up 1.42%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals Inc. (ACAD) has a regulatory catalyst to watch next month. ACAD closed Wednesday's trading at $19.89, up 0.40%. The company's supplemental New Drug Application for Pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis is under FDA review, with a decision expected on June 17, 2022. | Acadia Pharmaceuticals Inc. (ACAD) has a regulatory catalyst to watch next month. ACAD closed Wednesday's trading at $19.89, up 0.40%. Analysts polled by Thomson Reuters were expecting the company to earn $2.93 per share on revenue of $57.27 billion for the quarter. | Acadia Pharmaceuticals Inc. (ACAD) has a regulatory catalyst to watch next month. ACAD closed Wednesday's trading at $19.89, up 0.40%. Net loss attributable to the company widened to $62.7 million or $0.44 per share for the first quarter of 2022 from $40.6 million or $0.29 per share for the same period in 2021. | Acadia Pharmaceuticals Inc. (ACAD) has a regulatory catalyst to watch next month. ACAD closed Wednesday's trading at $19.89, up 0.40%. Net sales of Nuplazid were $115.5 million for the three months ended March 31, 2022, compared to $106.6 million in the year-ago period. |
35739.0 | 2022-05-04 00:00:00 UTC | Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-acad-reports-q1-loss-lags-revenue-estimates | nan | nan | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -42.86%. A quarter ago, it was expected that this drugmaker would post a loss of $0.24 per share when it actually produced a loss of $0.27, delivering a surprise of -12.50%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $115.47 million for the quarter ended March 2022, missing the Zacks Consensus Estimate by 6.68%. This compares to year-ago revenues of $106.55 million. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Acadia shares have lost about 15.1% since the beginning of the year versus the S&P 500's decline of -12.4%.
What's Next for Acadia?
While Acadia has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Acadia: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.27 on $135.91 million in revenues for the coming quarter and -$1.32 on $542.43 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Intercept Pharmaceuticals (ICPT), has yet to report results for the quarter ended March 2022. The results are expected to be released on May 6.
This drugmaker is expected to post quarterly loss of $0.89 per share in its upcoming report, which represents a year-over-year change of +27.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Intercept Pharmaceuticals' revenues are expected to be $90.86 million, up 11.3% from the year-ago quarter.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.49. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $115.47 million for the quarter ended March 2022, missing the Zacks Consensus Estimate by 6.68%. Acadia shares have lost about 15.1% since the beginning of the year versus the S&P 500's decline of -12.4%. | Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $115.47 million for the quarter ended March 2022, missing the Zacks Consensus Estimate by 6.68%. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.49. | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.49. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $115.47 million for the quarter ended March 2022, missing the Zacks Consensus Estimate by 6.68%. Acadia shares have lost about 15.1% since the beginning of the year versus the S&P 500's decline of -12.4%. | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.49. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $115.47 million for the quarter ended March 2022, missing the Zacks Consensus Estimate by 6.68%. Acadia shares have lost about 15.1% since the beginning of the year versus the S&P 500's decline of -12.4%. |
35740.0 | 2022-05-02 00:00:00 UTC | Notable Monday Option Activity: MAT, MPWR, ACAD | ACAD | https://www.nasdaq.com/articles/notable-monday-option-activity%3A-mat-mpwr-acad | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Mattel Inc (Symbol: MAT), where a total of 19,618 contracts have traded so far, representing approximately 2.0 million underlying shares. That amounts to about 67.3% of MAT's average daily trading volume over the past month of 2.9 million shares. Especially high volume was seen for the $27 strike call option expiring June 17, 2022, with 13,672 contracts trading so far today, representing approximately 1.4 million underlying shares of MAT. Below is a chart showing MAT's trailing twelve month trading history, with the $27 strike highlighted in orange:
Monolithic Power Systems Inc (Symbol: MPWR) options are showing a volume of 3,114 contracts thus far today. That number of contracts represents approximately 311,400 underlying shares, working out to a sizeable 67.2% of MPWR's average daily trading volume over the past month, of 463,500 shares. Especially high volume was seen for the $340 strike put option expiring May 20, 2022, with 1,364 contracts trading so far today, representing approximately 136,400 underlying shares of MPWR. Below is a chart showing MPWR's trailing twelve month trading history, with the $340 strike highlighted in orange:
And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 10,649 contracts thus far today. That number of contracts represents approximately 1.1 million underlying shares, working out to a sizeable 62.8% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Especially high volume was seen for the $22 strike call option expiring June 17, 2022, with 2,503 contracts trading so far today, representing approximately 250,300 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $22 strike highlighted in orange:
For the various different available expirations for MAT options, MPWR options, or ACAD options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $22 strike call option expiring June 17, 2022, with 2,503 contracts trading so far today, representing approximately 250,300 underlying shares of ACAD. Below is a chart showing MPWR's trailing twelve month trading history, with the $340 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 10,649 contracts thus far today. That number of contracts represents approximately 1.1 million underlying shares, working out to a sizeable 62.8% of ACAD's average daily trading volume over the past month, of 1.7 million shares. | That number of contracts represents approximately 1.1 million underlying shares, working out to a sizeable 62.8% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Below is a chart showing MPWR's trailing twelve month trading history, with the $340 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 10,649 contracts thus far today. Especially high volume was seen for the $22 strike call option expiring June 17, 2022, with 2,503 contracts trading so far today, representing approximately 250,300 underlying shares of ACAD. | That number of contracts represents approximately 1.1 million underlying shares, working out to a sizeable 62.8% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Below is a chart showing MPWR's trailing twelve month trading history, with the $340 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 10,649 contracts thus far today. Especially high volume was seen for the $22 strike call option expiring June 17, 2022, with 2,503 contracts trading so far today, representing approximately 250,300 underlying shares of ACAD. | Below is a chart showing ACAD's trailing twelve month trading history, with the $22 strike highlighted in orange: For the various different available expirations for MAT options, MPWR options, or ACAD options, visit StockOptionsChannel.com. Below is a chart showing MPWR's trailing twelve month trading history, with the $340 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 10,649 contracts thus far today. That number of contracts represents approximately 1.1 million underlying shares, working out to a sizeable 62.8% of ACAD's average daily trading volume over the past month, of 1.7 million shares. |
35741.0 | 2022-05-02 00:00:00 UTC | Zymeworks Inc. (ZYME) Surges 23.2%: Is This an Indication of Further Gains? | ACAD | https://www.nasdaq.com/articles/zymeworks-inc.-zyme-surges-23.2%3A-is-this-an-indication-of-further-gains | nan | nan | Zymeworks Inc. (ZYME) shares rallied 23.2% in the last trading session to close at $6.11. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 24.3% loss over the past four weeks.
Last month, the company announced that it has completed enrollment in the pivotal HERIZON-BTC-01 study, evaluating the antitumor activity of lead candidate, zanidatamab monotherapy in patients with previously treated advanced/metastatic HER2-amplified biliary tract cancers, including gallbladder cancer and cholangiocarcinoma. Efficacy and safety data from the same are expected in early 2023. This might have been driving the share price rally.
This company is expected to post quarterly loss of $0.97 per share in its upcoming report, which represents a year-over-year change of -11.5%. Revenues are expected to be $3.76 million, up 487.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Zymeworks Inc., the consensus EPS estimate for the quarter has been revised 16.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on ZYME going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Zymeworks Inc. is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Acadia Pharmaceuticals (ACAD), finished the last trading session 2.7% lower at $18.44. ACAD has returned -21.7% over the past month.
Acadia's consensus EPS estimate for the upcoming report has changed +7.3% over the past month to -$0.49. Compared to the company's year-ago EPS, this represents a change of -16.7%. Acadia currently boasts a Zacks Rank of #3 (Hold).
Just Released: Zacks' 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +25.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Zymeworks Inc. (ZYME): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One other stock in the same industry, Acadia Pharmaceuticals (ACAD), finished the last trading session 2.7% lower at $18.44. ACAD has returned -21.7% over the past month. Acadia's consensus EPS estimate for the upcoming report has changed +7.3% over the past month to -$0.49. | ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report One other stock in the same industry, Acadia Pharmaceuticals (ACAD), finished the last trading session 2.7% lower at $18.44. ACAD has returned -21.7% over the past month. | One other stock in the same industry, Acadia Pharmaceuticals (ACAD), finished the last trading session 2.7% lower at $18.44. ACAD has returned -21.7% over the past month. Acadia's consensus EPS estimate for the upcoming report has changed +7.3% over the past month to -$0.49. | Acadia's consensus EPS estimate for the upcoming report has changed +7.3% over the past month to -$0.49. One other stock in the same industry, Acadia Pharmaceuticals (ACAD), finished the last trading session 2.7% lower at $18.44. ACAD has returned -21.7% over the past month. |
35742.0 | 2022-04-27 00:00:00 UTC | Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for | ACAD | https://www.nasdaq.com/articles/analysts-estimate-acadia-pharmaceuticals-acad-to-report-a-decline-in-earnings%3A-what-to-2 | nan | nan | Acadia Pharmaceuticals (ACAD) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2022. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 4. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This drugmaker is expected to post quarterly loss of $0.46 per share in its upcoming report, which represents a year-over-year change of -9.5%.
Revenues are expected to be $123.33 million, up 15.8% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 5.17% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Acadia?
For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -48.15%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Acadia will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Acadia would post a loss of $0.24 per share when it actually produced a loss of $0.27, delivering a surprise of -12.50%.
Over the last four quarters, the company has beaten consensus EPS estimates three times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Acadia doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (ACAD) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2022. How Have the Numbers Shaped Up for Acadia? For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. | Acadia Pharmaceuticals (ACAD) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2022. How Have the Numbers Shaped Up for Acadia? For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. | Acadia Pharmaceuticals (ACAD) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2022. How Have the Numbers Shaped Up for Acadia? For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. | Acadia Pharmaceuticals (ACAD) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2022. How Have the Numbers Shaped Up for Acadia? For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. |
35743.0 | 2022-04-20 00:00:00 UTC | Notable Wednesday Option Activity: ACAD, W, SCCO | ACAD | https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-acad-w-scco | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total of 8,563 contracts have traded so far, representing approximately 856,300 underlying shares. That amounts to about 58.2% of ACAD's average daily trading volume over the past month of 1.5 million shares. Particularly high volume was seen for the $25 strike call option expiring June 17, 2022, with 2,501 contracts trading so far today, representing approximately 250,100 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $25 strike highlighted in orange:
Wayfair Inc (Symbol: W) saw options trading volume of 13,372 contracts, representing approximately 1.3 million underlying shares or approximately 57.8% of W's average daily trading volume over the past month, of 2.3 million shares. Particularly high volume was seen for the $105 strike call option expiring August 19, 2022, with 3,534 contracts trading so far today, representing approximately 353,400 underlying shares of W. Below is a chart showing W's trailing twelve month trading history, with the $105 strike highlighted in orange:
And Southern Copper Corp (Symbol: SCCO) options are showing a volume of 4,769 contracts thus far today. That number of contracts represents approximately 476,900 underlying shares, working out to a sizeable 55.9% of SCCO's average daily trading volume over the past month, of 853,590 shares. Especially high volume was seen for the $75 strike call option expiring May 20, 2022, with 3,835 contracts trading so far today, representing approximately 383,500 underlying shares of SCCO. Below is a chart showing SCCO's trailing twelve month trading history, with the $75 strike highlighted in orange:
For the various different available expirations for ACAD options, W options, or SCCO options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $25 strike call option expiring June 17, 2022, with 2,501 contracts trading so far today, representing approximately 250,100 underlying shares of ACAD. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total of 8,563 contracts have traded so far, representing approximately 856,300 underlying shares. That amounts to about 58.2% of ACAD's average daily trading volume over the past month of 1.5 million shares. | Particularly high volume was seen for the $25 strike call option expiring June 17, 2022, with 2,501 contracts trading so far today, representing approximately 250,100 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $25 strike highlighted in orange: Wayfair Inc (Symbol: W) saw options trading volume of 13,372 contracts, representing approximately 1.3 million underlying shares or approximately 57.8% of W's average daily trading volume over the past month, of 2.3 million shares. Below is a chart showing SCCO's trailing twelve month trading history, with the $75 strike highlighted in orange: For the various different available expirations for ACAD options, W options, or SCCO options, visit StockOptionsChannel.com. | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total of 8,563 contracts have traded so far, representing approximately 856,300 underlying shares. Below is a chart showing ACAD's trailing twelve month trading history, with the $25 strike highlighted in orange: Wayfair Inc (Symbol: W) saw options trading volume of 13,372 contracts, representing approximately 1.3 million underlying shares or approximately 57.8% of W's average daily trading volume over the past month, of 2.3 million shares. That amounts to about 58.2% of ACAD's average daily trading volume over the past month of 1.5 million shares. | Below is a chart showing ACAD's trailing twelve month trading history, with the $25 strike highlighted in orange: Wayfair Inc (Symbol: W) saw options trading volume of 13,372 contracts, representing approximately 1.3 million underlying shares or approximately 57.8% of W's average daily trading volume over the past month, of 2.3 million shares. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total of 8,563 contracts have traded so far, representing approximately 856,300 underlying shares. That amounts to about 58.2% of ACAD's average daily trading volume over the past month of 1.5 million shares. |
35744.0 | 2022-04-19 00:00:00 UTC | Pre-market Movers: AXSM, SST, SAVA, ENSV, SMCI… | ACAD | https://www.nasdaq.com/articles/pre-market-movers%3A-axsm-sst-sava-ensv-smci... | nan | nan | (RTTNews) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.50 A.M. ET).
In the Green
Axsome Therapeutics, Inc. (AXSM) is up over 34% at $43.89 Super Micro Computer, Inc. (SMCI) is up over 15% at $42.20 4D pharma plc (LBPS) is up over 13% at $5.27 BARK, Inc. (BARK) is up over 13% at $3.76 American Campus Communities, Inc. (ACC) is up over 12% at $65.00 Sharps Technology, Inc. (STSS) is up over 12% at $2.37 Zendesk, Inc. (ZEN) is up over 6% at $129.87 Banco Bradesco S.A. (BBD) is up over 5% at $4.41 ARC Document Solutions, Inc. (ARC) is up over 5% at $4.00 Fresh Vine Wine, Inc. (VINE) is up over 5% at $3.74
In the Red
System1, Inc. (SST) is down over 27% at $14.75 Cassava Sciences, Inc. (SAVA) is down over 18% at $20.55 Enservco Corporation (ENSV) is down over 16% at $3.04 NETGEAR, Inc. (NTGR) is down over 12% at $20.31 Indonesia Energy Corporation Limited (INDO) is down over 9% at $23.40 Origin Agritech Limited (SEED) is down over 8% at $7.36 ACADIA Pharmaceuticals Inc. (ACAD) is down over 7% at $20.70 Ecopetrol S.A. (EC) is down over 6% at $18.08 IsoPlexis Corporation (ISO) is down over 6% at $2.30
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the Green Axsome Therapeutics, Inc. (AXSM) is up over 34% at $43.89 Super Micro Computer, Inc. (SMCI) is up over 15% at $42.20 4D pharma plc (LBPS) is up over 13% at $5.27 BARK, Inc. (BARK) is up over 13% at $3.76 American Campus Communities, Inc. (ACC) is up over 12% at $65.00 Sharps Technology, Inc. (STSS) is up over 12% at $2.37 Zendesk, Inc. (ZEN) is up over 6% at $129.87 Banco Bradesco S.A. (BBD) is up over 5% at $4.41 ARC Document Solutions, Inc. (ARC) is up over 5% at $4.00 Fresh Vine Wine, Inc. (VINE) is up over 5% at $3.74 In the Red System1, Inc. (SST) is down over 27% at $14.75 Cassava Sciences, Inc. (SAVA) is down over 18% at $20.55 Enservco Corporation (ENSV) is down over 16% at $3.04 NETGEAR, Inc. (NTGR) is down over 12% at $20.31 Indonesia Energy Corporation Limited (INDO) is down over 9% at $23.40 Origin Agritech Limited (SEED) is down over 8% at $7.36 ACADIA Pharmaceuticals Inc. (ACAD) is down over 7% at $20.70 Ecopetrol S.A. (EC) is down over 6% at $18.08 IsoPlexis Corporation (ISO) is down over 6% at $2.30 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.50 A.M. ET). | In the Green Axsome Therapeutics, Inc. (AXSM) is up over 34% at $43.89 Super Micro Computer, Inc. (SMCI) is up over 15% at $42.20 4D pharma plc (LBPS) is up over 13% at $5.27 BARK, Inc. (BARK) is up over 13% at $3.76 American Campus Communities, Inc. (ACC) is up over 12% at $65.00 Sharps Technology, Inc. (STSS) is up over 12% at $2.37 Zendesk, Inc. (ZEN) is up over 6% at $129.87 Banco Bradesco S.A. (BBD) is up over 5% at $4.41 ARC Document Solutions, Inc. (ARC) is up over 5% at $4.00 Fresh Vine Wine, Inc. (VINE) is up over 5% at $3.74 In the Red System1, Inc. (SST) is down over 27% at $14.75 Cassava Sciences, Inc. (SAVA) is down over 18% at $20.55 Enservco Corporation (ENSV) is down over 16% at $3.04 NETGEAR, Inc. (NTGR) is down over 12% at $20.31 Indonesia Energy Corporation Limited (INDO) is down over 9% at $23.40 Origin Agritech Limited (SEED) is down over 8% at $7.36 ACADIA Pharmaceuticals Inc. (ACAD) is down over 7% at $20.70 Ecopetrol S.A. (EC) is down over 6% at $18.08 IsoPlexis Corporation (ISO) is down over 6% at $2.30 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.50 A.M. ET). | In the Green Axsome Therapeutics, Inc. (AXSM) is up over 34% at $43.89 Super Micro Computer, Inc. (SMCI) is up over 15% at $42.20 4D pharma plc (LBPS) is up over 13% at $5.27 BARK, Inc. (BARK) is up over 13% at $3.76 American Campus Communities, Inc. (ACC) is up over 12% at $65.00 Sharps Technology, Inc. (STSS) is up over 12% at $2.37 Zendesk, Inc. (ZEN) is up over 6% at $129.87 Banco Bradesco S.A. (BBD) is up over 5% at $4.41 ARC Document Solutions, Inc. (ARC) is up over 5% at $4.00 Fresh Vine Wine, Inc. (VINE) is up over 5% at $3.74 In the Red System1, Inc. (SST) is down over 27% at $14.75 Cassava Sciences, Inc. (SAVA) is down over 18% at $20.55 Enservco Corporation (ENSV) is down over 16% at $3.04 NETGEAR, Inc. (NTGR) is down over 12% at $20.31 Indonesia Energy Corporation Limited (INDO) is down over 9% at $23.40 Origin Agritech Limited (SEED) is down over 8% at $7.36 ACADIA Pharmaceuticals Inc. (ACAD) is down over 7% at $20.70 Ecopetrol S.A. (EC) is down over 6% at $18.08 IsoPlexis Corporation (ISO) is down over 6% at $2.30 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.50 A.M. ET). | In the Green Axsome Therapeutics, Inc. (AXSM) is up over 34% at $43.89 Super Micro Computer, Inc. (SMCI) is up over 15% at $42.20 4D pharma plc (LBPS) is up over 13% at $5.27 BARK, Inc. (BARK) is up over 13% at $3.76 American Campus Communities, Inc. (ACC) is up over 12% at $65.00 Sharps Technology, Inc. (STSS) is up over 12% at $2.37 Zendesk, Inc. (ZEN) is up over 6% at $129.87 Banco Bradesco S.A. (BBD) is up over 5% at $4.41 ARC Document Solutions, Inc. (ARC) is up over 5% at $4.00 Fresh Vine Wine, Inc. (VINE) is up over 5% at $3.74 In the Red System1, Inc. (SST) is down over 27% at $14.75 Cassava Sciences, Inc. (SAVA) is down over 18% at $20.55 Enservco Corporation (ENSV) is down over 16% at $3.04 NETGEAR, Inc. (NTGR) is down over 12% at $20.31 Indonesia Energy Corporation Limited (INDO) is down over 9% at $23.40 Origin Agritech Limited (SEED) is down over 8% at $7.36 ACADIA Pharmaceuticals Inc. (ACAD) is down over 7% at $20.70 Ecopetrol S.A. (EC) is down over 6% at $18.08 IsoPlexis Corporation (ISO) is down over 6% at $2.30 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.50 A.M. ET). |
35745.0 | 2022-04-13 00:00:00 UTC | After Hours Most Active for Apr 13, 2022 : WBD, VALE, PBR, TMUS, ACAD, PM, BAC, AAPL, CMCSA, MTOR, PDBC, PG | ACAD | https://www.nasdaq.com/articles/after-hours-most-active-for-apr-13-2022-%3A-wbd-vale-pbr-tmus-acad-pm-bac-aapl-cmcsa-mtor | nan | nan | The NASDAQ 100 After Hours Indicator is down -1.97 to 14,215.32. The total After hours volume is currently 69,982,085 shares traded.
The following are the most active stocks for the after hours session:
Warner Bros. Discovery, Inc. (WBD) is unchanged at $26.00, with 6,148,650 shares traded. WBD's current last sale is 61.9% of the target price of $42.
VALE S.A. (VALE) is +0.01 at $19.92, with 4,310,066 shares traded. VALE's current last sale is 92.65% of the target price of $21.5.
Petroleo Brasileiro S.A.- Petrobras (PBR) is +0.07 at $16.03, with 3,798,321 shares traded. PBR's current last sale is 98.65% of the target price of $16.25.
T-Mobile US, Inc. (TMUS) is unchanged at $134.85, with 2,164,607 shares traded. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2022. The consensus EPS forecast is $0.74. As reported by Zacks, the current mean recommendation for TMUS is in the "buy range".
ACADIA Pharmaceuticals Inc. (ACAD) is unchanged at $24.43, with 2,144,598 shares traded. ACAD's current last sale is 80.1% of the target price of $30.5.
Philip Morris International Inc (PM) is unchanged at $101.20, with 1,733,455 shares traded. As reported by Zacks, the current mean recommendation for PM is in the "buy range".
Bank of America Corporation (BAC) is +0.03 at $38.85, with 1,601,568 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2022. The consensus EPS forecast is $0.84. BAC is scheduled to provide an earnings report on 4/18/2022, for the fiscal quarter ending Mar2022. The consensus earnings per share forecast is 0.76 per share, which represents a 86 percent increase over the EPS one Year Ago
Apple Inc. (AAPL) is -0.1 at $170.30, with 1,408,737 shares traded. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
Comcast Corporation (CMCSA) is unchanged at $47.91, with 1,398,375 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2022. The consensus EPS forecast is $0.92. As reported by Zacks, the current mean recommendation for CMCSA is in the "buy range".
Meritor, Inc. (MTOR) is unchanged at $35.55, with 1,365,277 shares traded. As reported by Zacks, the current mean recommendation for MTOR is in the "buy range".
Invesco Optimum Yield Diversified Commodity Strategy No K-1 ET (PDBC) is +0.01 at $18.88, with 1,363,016 shares traded. This represents a 42.81% increase from its 52 Week Low.
Procter & Gamble Company (The) (PG) is unchanged at $159.46, with 1,311,055 shares traded.PG is scheduled to provide an earnings report on 4/20/2022, for the fiscal quarter ending Mar2022. The consensus earnings per share forecast is 1.29 per share, which represents a 126 percent increase over the EPS one Year Ago
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. (ACAD) is unchanged at $24.43, with 2,144,598 shares traded. ACAD's current last sale is 80.1% of the target price of $30.5. Invesco Optimum Yield Diversified Commodity Strategy No K-1 ET (PDBC) is +0.01 at $18.88, with 1,363,016 shares traded. | ACADIA Pharmaceuticals Inc. (ACAD) is unchanged at $24.43, with 2,144,598 shares traded. ACAD's current last sale is 80.1% of the target price of $30.5. The consensus earnings per share forecast is 0.76 per share, which represents a 86 percent increase over the EPS one Year Ago | ACADIA Pharmaceuticals Inc. (ACAD) is unchanged at $24.43, with 2,144,598 shares traded. ACAD's current last sale is 80.1% of the target price of $30.5. The consensus earnings per share forecast is 0.76 per share, which represents a 86 percent increase over the EPS one Year Ago | ACADIA Pharmaceuticals Inc. (ACAD) is unchanged at $24.43, with 2,144,598 shares traded. ACAD's current last sale is 80.1% of the target price of $30.5. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2022. |
35746.0 | 2022-04-12 00:00:00 UTC | We Did The Math IYY Can Go To $129 | ACAD | https://www.nasdaq.com/articles/we-did-the-math-iyy-can-go-to-%24129 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Dow Jones U.S. ETF (Symbol: IYY), we found that the implied analyst target price for the ETF based upon its underlying holdings is $128.79 per unit.
With IYY trading at a recent price near $108.26 per unit, that means that analysts see 18.97% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IYY's underlying holdings with notable upside to their analyst target prices are Blue Owl Capital Inc (Symbol: OWL), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Chegg Inc (Symbol: CHGG). Although OWL has traded at a recent price of $13.34/share, the average analyst target is 35.87% higher at $18.12/share. Similarly, ACAD has 27.48% upside from the recent share price of $23.62 if the average analyst target price of $30.11/share is reached, and analysts on average are expecting CHGG to reach a target price of $44.70/share, which is 26.66% above the recent price of $35.29. Below is a twelve month price history chart comparing the stock performance of OWL, ACAD, and CHGG:
Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
iShares Dow Jones U.S. ETF IYY $108.26 $128.79 18.97%
Blue Owl Capital Inc OWL $13.34 $18.12 35.87%
Acadia Pharmaceuticals Inc ACAD $23.62 $30.11 27.48%
Chegg Inc CHGG $35.29 $44.70 26.66%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | iShares Dow Jones U.S. ETF IYY $108.26 $128.79 18.97% Blue Owl Capital Inc OWL $13.34 $18.12 35.87% Acadia Pharmaceuticals Inc ACAD $23.62 $30.11 27.48% Chegg Inc CHGG $35.29 $44.70 26.66% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYY's underlying holdings with notable upside to their analyst target prices are Blue Owl Capital Inc (Symbol: OWL), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Chegg Inc (Symbol: CHGG). Similarly, ACAD has 27.48% upside from the recent share price of $23.62 if the average analyst target price of $30.11/share is reached, and analysts on average are expecting CHGG to reach a target price of $44.70/share, which is 26.66% above the recent price of $35.29. | Three of IYY's underlying holdings with notable upside to their analyst target prices are Blue Owl Capital Inc (Symbol: OWL), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Chegg Inc (Symbol: CHGG). Similarly, ACAD has 27.48% upside from the recent share price of $23.62 if the average analyst target price of $30.11/share is reached, and analysts on average are expecting CHGG to reach a target price of $44.70/share, which is 26.66% above the recent price of $35.29. iShares Dow Jones U.S. ETF IYY $108.26 $128.79 18.97% Blue Owl Capital Inc OWL $13.34 $18.12 35.87% Acadia Pharmaceuticals Inc ACAD $23.62 $30.11 27.48% Chegg Inc CHGG $35.29 $44.70 26.66% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Similarly, ACAD has 27.48% upside from the recent share price of $23.62 if the average analyst target price of $30.11/share is reached, and analysts on average are expecting CHGG to reach a target price of $44.70/share, which is 26.66% above the recent price of $35.29. Three of IYY's underlying holdings with notable upside to their analyst target prices are Blue Owl Capital Inc (Symbol: OWL), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Chegg Inc (Symbol: CHGG). Below is a twelve month price history chart comparing the stock performance of OWL, ACAD, and CHGG: Below is a summary table of the current analyst target prices discussed above: | iShares Dow Jones U.S. ETF IYY $108.26 $128.79 18.97% Blue Owl Capital Inc OWL $13.34 $18.12 35.87% Acadia Pharmaceuticals Inc ACAD $23.62 $30.11 27.48% Chegg Inc CHGG $35.29 $44.70 26.66% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYY's underlying holdings with notable upside to their analyst target prices are Blue Owl Capital Inc (Symbol: OWL), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Chegg Inc (Symbol: CHGG). Similarly, ACAD has 27.48% upside from the recent share price of $23.62 if the average analyst target price of $30.11/share is reached, and analysts on average are expecting CHGG to reach a target price of $44.70/share, which is 26.66% above the recent price of $35.29. |
35747.0 | 2022-04-07 00:00:00 UTC | ACAD May 27th Options Begin Trading | ACAD | https://www.nasdaq.com/articles/acad-may-27th-options-begin-trading | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the May 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new May 27th contracts and identified one put and one call contract of particular interest.
The put contract at the $27.00 strike price has a current bid of $1.15. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $27.00, but will also collect the premium, putting the cost basis of the shares at $25.85 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $27.17/share today.
Because the $27.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 4.26% return on the cash commitment, or 31.09% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $27.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $28.00 strike price has a current bid of $1.15. If an investor was to purchase shares of ACAD stock at the current price level of $27.17/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $28.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 7.29% if the stock gets called away at the May 27th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red:
Considering the fact that the $28.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 4.23% boost of extra return to the investor, or 30.90% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 254 trading day closing values as well as today's price of $27.17) to be 58%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the May 27th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the May 27th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $27.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $28.00 strike price has a current bid of $1.15. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the May 27th expiration. | At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new May 27th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the May 27th expiration. |
35748.0 | 2022-03-31 00:00:00 UTC | ACAD May 13th Options Begin Trading | ACAD | https://www.nasdaq.com/articles/acad-may-13th-options-begin-trading | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the May 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new May 13th contracts and identified one put and one call contract of particular interest.
The put contract at the $20.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $20.00, but will also collect the premium, putting the cost basis of the shares at $19.85 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $24.02/share today.
Because the $20.00 strike represents an approximate 17% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.75% return on the cash commitment, or 6.37% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $27.00 strike price has a current bid of 50 cents. If an investor was to purchase shares of ACAD stock at the current price level of $24.02/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $27.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 14.49% if the stock gets called away at the May 13th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $27.00 strike highlighted in red:
Considering the fact that the $27.00 strike represents an approximate 12% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 2.08% boost of extra return to the investor, or 17.67% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $24.02) to be 61%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $27.00 strike highlighted in red: Considering the fact that the $27.00 strike represents an approximate 12% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the May 13th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $27.00 strike highlighted in red: Considering the fact that the $27.00 strike represents an approximate 12% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the May 13th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $27.00 strike price has a current bid of 50 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $27.00 strike highlighted in red: Considering the fact that the $27.00 strike represents an approximate 12% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the May 13th expiration. | At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new May 13th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $27.00 strike highlighted in red: Considering the fact that the $27.00 strike represents an approximate 12% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the May 13th expiration. |
35749.0 | 2022-03-30 00:00:00 UTC | Why Is Acadia (ACAD) Up 1% Since Last Earnings Report? | ACAD | https://www.nasdaq.com/articles/why-is-acadia-acad-up-1-since-last-earnings-report | nan | nan | It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have added about 1% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Acadia’s Q4 Earnings & Revenues Fall Shy of Estimates
Acadia reported a fourth-quarter 2021 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 24 cents. In the year-ago quarter, the company incurred a loss of 42 cents per share.
Total revenues, comprising net sales of Nuplazid increased 8% year over year to $130.8 million for the fourth quarter, driven by volume growth. The top line, however, missed the Zacks Consensus Estimate of $135 million. Nuplazid sales fell below market expectation in the reported quarter.
Quarter in Detail
Research and development (R&D) expenses were $67.1 million for the quarter, up 8.1% from the year-ago quarter.
Selling, general and administrative (SG&A) expenses were $105.8 million, down 12.4% year over year.
As of Dec 31, 2021, Acadia had cash, cash equivalents and investments worth $520.7 million compared with $540.3 million as of Sep 30, 2021.
2022 Guidance
Acadia expects Nuplazid net sales of $510-$560 million for 2022. The company expects R&D expenses of $355-$375 million, while SG&A expenses are expected to be $360-$380 million in 2022.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -38.97% due to these changes.
VGM Scores
At this time, Acadia has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. Notably, Acadia has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?
From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). Acadia’s Q4 Earnings & Revenues Fall Shy of Estimates Acadia reported a fourth-quarter 2021 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 24 cents. | Acadia’s Q4 Earnings & Revenues Fall Shy of Estimates Acadia reported a fourth-quarter 2021 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 24 cents. 2022 Guidance Acadia expects Nuplazid net sales of $510-$560 million for 2022. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report | Acadia’s Q4 Earnings & Revenues Fall Shy of Estimates Acadia reported a fourth-quarter 2021 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 24 cents. VGM Scores At this time, Acadia has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy. It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). | It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Acadia’s Q4 Earnings & Revenues Fall Shy of Estimates Acadia reported a fourth-quarter 2021 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 24 cents. |
35750.0 | 2022-03-14 00:00:00 UTC | Notable Monday Option Activity: LVS, ACAD, SIRI | ACAD | https://www.nasdaq.com/articles/notable-monday-option-activity%3A-lvs-acad-siri | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Las Vegas Sands Corp (Symbol: LVS), where a total of 80,757 contracts have traded so far, representing approximately 8.1 million underlying shares. That amounts to about 94% of LVS's average daily trading volume over the past month of 8.6 million shares. Particularly high volume was seen for the $25 strike put option expiring April 14, 2022, with 5,058 contracts trading so far today, representing approximately 505,800 underlying shares of LVS. Below is a chart showing LVS's trailing twelve month trading history, with the $25 strike highlighted in orange:
Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 11,985 contracts thus far today. That number of contracts represents approximately 1.2 million underlying shares, working out to a sizeable 85.3% of ACAD's average daily trading volume over the past month, of 1.4 million shares. Especially high volume was seen for the $25 strike call option expiring June 17, 2022, with 3,466 contracts trading so far today, representing approximately 346,600 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $25 strike highlighted in orange:
And Sirius XM Holdings Inc (Symbol: SIRI) saw options trading volume of 201,617 contracts, representing approximately 20.2 million underlying shares or approximately 82.7% of SIRI's average daily trading volume over the past month, of 24.4 million shares. Particularly high volume was seen for the $6.50 strike call option expiring April 08, 2022, with 50,063 contracts trading so far today, representing approximately 5.0 million underlying shares of SIRI. Below is a chart showing SIRI's trailing twelve month trading history, with the $6.50 strike highlighted in orange:
For the various different available expirations for LVS options, ACAD options, or SIRI options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $25 strike call option expiring June 17, 2022, with 3,466 contracts trading so far today, representing approximately 346,600 underlying shares of ACAD. Below is a chart showing LVS's trailing twelve month trading history, with the $25 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 11,985 contracts thus far today. That number of contracts represents approximately 1.2 million underlying shares, working out to a sizeable 85.3% of ACAD's average daily trading volume over the past month, of 1.4 million shares. | Below is a chart showing LVS's trailing twelve month trading history, with the $25 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 11,985 contracts thus far today. Below is a chart showing ACAD's trailing twelve month trading history, with the $25 strike highlighted in orange: And Sirius XM Holdings Inc (Symbol: SIRI) saw options trading volume of 201,617 contracts, representing approximately 20.2 million underlying shares or approximately 82.7% of SIRI's average daily trading volume over the past month, of 24.4 million shares. That number of contracts represents approximately 1.2 million underlying shares, working out to a sizeable 85.3% of ACAD's average daily trading volume over the past month, of 1.4 million shares. | Below is a chart showing ACAD's trailing twelve month trading history, with the $25 strike highlighted in orange: And Sirius XM Holdings Inc (Symbol: SIRI) saw options trading volume of 201,617 contracts, representing approximately 20.2 million underlying shares or approximately 82.7% of SIRI's average daily trading volume over the past month, of 24.4 million shares. Below is a chart showing LVS's trailing twelve month trading history, with the $25 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 11,985 contracts thus far today. That number of contracts represents approximately 1.2 million underlying shares, working out to a sizeable 85.3% of ACAD's average daily trading volume over the past month, of 1.4 million shares. | Below is a chart showing ACAD's trailing twelve month trading history, with the $25 strike highlighted in orange: And Sirius XM Holdings Inc (Symbol: SIRI) saw options trading volume of 201,617 contracts, representing approximately 20.2 million underlying shares or approximately 82.7% of SIRI's average daily trading volume over the past month, of 24.4 million shares. Below is a chart showing SIRI's trailing twelve month trading history, with the $6.50 strike highlighted in orange: For the various different available expirations for LVS options, ACAD options, or SIRI options, visit StockOptionsChannel.com. Below is a chart showing LVS's trailing twelve month trading history, with the $25 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 11,985 contracts thus far today. |
35751.0 | 2022-03-10 00:00:00 UTC | Acadia (ACAD) Stock Up on FDA's Action Date for Nuplazid sNDA | ACAD | https://www.nasdaq.com/articles/acadia-acad-stock-up-on-fdas-action-date-for-nuplazid-snda | nan | nan | Acadia Pharmaceuticals Inc. ACAD announced that it has received the action date from the FDA related to its resubmitted supplemental New Drug Application (sNDA) for pimavanserin to treat hallucinations and delusions associated with Alzheimer’s disease psychosis (“ADP”).
The regulatory body has set a target action date of Aug 4, 2022. The FDA’s Division of Psychiatry plans to hold an advisory committee meeting owing to its review of the sNDA.
Shares of Acadia were up 10.2% on Wednesday following the announcement of the above news. In fact, the stock has rallied 10.5% so far this year against the industry’s decline of 19.4%.
Image Source: Zacks Investment Research
Last month, Acadia resubmitted the sNDA to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with ADP.
The resubmitted sNDA was based on positive data from two placebo-controlled studies — the pivotal phase III HARMONY study and the -019 study. Both studies have prospectively met their primary endpoints.
In April 2021, the FDA issued a complete response letter (“CRL”) to the sNDA for Nuplazid for the treatment of hallucinations and delusions associated with dementia-related psychosis or DRP.
The CRL indicated that the FDA had completed its review of the application and had decided that it could not be approved in its then-present form as it lacked statistical significance in some of the subgroups of dementia. Moreover, there was an insufficient number of patients with certain less common dementia subtypes, which was considered as a lack of substantial evidence of effectiveness to support approval. The CRL also stated that the phase II Alzheimer’s disease psychosis study, a supportive study in the sNDA filing, was inadequate and not well controlled.
Pimavanserin is currently approved under the trade name Nuplazid in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
In 2021, Nuplazid recorded sales worth $484.1 million, reflecting an increase of 10% year over year. A potential label expansion is likely to boost sales of the drug in 2022 and beyond.
Zacks Rank & Stocks to Consider
Acadia currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Athersys, Inc. ATHX, Kaleido Biosciences, Inc. KLDO and Vertex Pharmaceuticals Incorporated VRTX, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Athersys’ earnings estimates have been revised 21.7% upward for 2022 over the past 60 days.
Earnings of Athersys have surpassed estimates in one of the trailing four quarters and missed the same on the other three occasions.
Kaleido Biosciences’ loss per share estimates have narrowed 11.3% for 2022 over the past 60 days.
Earnings of Kaleido Biosciences have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.
Vertex’s earnings estimates have been revised 8.4% upward for 2022 over the past 60 days. The VRTX stock has gained 9% year to date.
Vertex’s earnings have surpassed estimates in each of the trailing four quarters.
Just Released: Zacks' 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +25.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Athersys, Inc. (ATHX): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Kaleido Biosciences, Inc. (KLDO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals Inc. ACAD announced that it has received the action date from the FDA related to its resubmitted supplemental New Drug Application (sNDA) for pimavanserin to treat hallucinations and delusions associated with Alzheimer’s disease psychosis (“ADP”). Shares of Acadia were up 10.2% on Wednesday following the announcement of the above news. Image Source: Zacks Investment Research Last month, Acadia resubmitted the sNDA to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with ADP. | Acadia Pharmaceuticals Inc. ACAD announced that it has received the action date from the FDA related to its resubmitted supplemental New Drug Application (sNDA) for pimavanserin to treat hallucinations and delusions associated with Alzheimer’s disease psychosis (“ADP”). Shares of Acadia were up 10.2% on Wednesday following the announcement of the above news. Image Source: Zacks Investment Research Last month, Acadia resubmitted the sNDA to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with ADP. | Acadia Pharmaceuticals Inc. ACAD announced that it has received the action date from the FDA related to its resubmitted supplemental New Drug Application (sNDA) for pimavanserin to treat hallucinations and delusions associated with Alzheimer’s disease psychosis (“ADP”). Shares of Acadia were up 10.2% on Wednesday following the announcement of the above news. Image Source: Zacks Investment Research Last month, Acadia resubmitted the sNDA to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with ADP. | Acadia Pharmaceuticals Inc. ACAD announced that it has received the action date from the FDA related to its resubmitted supplemental New Drug Application (sNDA) for pimavanserin to treat hallucinations and delusions associated with Alzheimer’s disease psychosis (“ADP”). Shares of Acadia were up 10.2% on Wednesday following the announcement of the above news. Image Source: Zacks Investment Research Last month, Acadia resubmitted the sNDA to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with ADP. |
35752.0 | 2022-03-09 00:00:00 UTC | Health Care Sector Update for 03/09/2022: BLI,ACAD,BFLY,CYTO | ACAD | https://www.nasdaq.com/articles/health-care-sector-update-for-03-09-2022%3A-bliacadbflycyto | nan | nan | Health care stocks extended their Wednesday gains, with the NYSE Health Care Index rising 2.5% this afternoon and the SPDR Health Care Select Sector ETF (XLV) up 2.1%.
The Nasdaq Biotechnology index also was climbing 3.1%.
In company news, Berkeley Lights (BLI) climbed 6.4% after it said it hired Siddhartha Kadia from privately held EAG Laboratories to be its new CEO, succeeding Eric Hobbs, who is becoming president of the digital cell biology company's antibody therapeutics business. The company also said Kurt Wood would step down as chief financial officer on April 1 to pursue an opportunity outside of the biotech industry.
Acadia Pharmaceuticals (ACAD) rose over 10% after it said the US Food and Drug Administration set an Aug. 4 deadline for the agency to complete its review of the company's supplemental new drug application for the pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease.
Butterfly Network (BFLY) was rising 8.3% after it said it received a $5 million grant from the Bill & Melinda Gates Foundation to improve maternal and fetal health in Sub-Saharan Africa. Separately, FUJIFILM Sonosite said it has filed a patent infringement lawsuit seeking damages from Butterfly for allegedly infringing on the Japanese medical device company's patents for its ultrasound imaging technologies.
Altamira Therapeutics (CYTO) added 2.4%, giving back most of an early 5% advance that followed the company saying it has secured regulatory approvals to begin a clinical study to evaluate the ability of its Bentrio drug-free nasal spray to ease COVID-19 symptoms and reduced coronavisus-related hospital admissions.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (ACAD) rose over 10% after it said the US Food and Drug Administration set an Aug. 4 deadline for the agency to complete its review of the company's supplemental new drug application for the pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease. The company also said Kurt Wood would step down as chief financial officer on April 1 to pursue an opportunity outside of the biotech industry. Butterfly Network (BFLY) was rising 8.3% after it said it received a $5 million grant from the Bill & Melinda Gates Foundation to improve maternal and fetal health in Sub-Saharan Africa. | Acadia Pharmaceuticals (ACAD) rose over 10% after it said the US Food and Drug Administration set an Aug. 4 deadline for the agency to complete its review of the company's supplemental new drug application for the pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease. Health care stocks extended their Wednesday gains, with the NYSE Health Care Index rising 2.5% this afternoon and the SPDR Health Care Select Sector ETF (XLV) up 2.1%. The Nasdaq Biotechnology index also was climbing 3.1%. | Acadia Pharmaceuticals (ACAD) rose over 10% after it said the US Food and Drug Administration set an Aug. 4 deadline for the agency to complete its review of the company's supplemental new drug application for the pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease. Health care stocks extended their Wednesday gains, with the NYSE Health Care Index rising 2.5% this afternoon and the SPDR Health Care Select Sector ETF (XLV) up 2.1%. In company news, Berkeley Lights (BLI) climbed 6.4% after it said it hired Siddhartha Kadia from privately held EAG Laboratories to be its new CEO, succeeding Eric Hobbs, who is becoming president of the digital cell biology company's antibody therapeutics business. | Acadia Pharmaceuticals (ACAD) rose over 10% after it said the US Food and Drug Administration set an Aug. 4 deadline for the agency to complete its review of the company's supplemental new drug application for the pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease. Health care stocks extended their Wednesday gains, with the NYSE Health Care Index rising 2.5% this afternoon and the SPDR Health Care Select Sector ETF (XLV) up 2.1%. The Nasdaq Biotechnology index also was climbing 3.1%. |
35753.0 | 2022-03-09 00:00:00 UTC | Health Care Sector Update for 03/09/2022: ACAD,BFLY,CYTO | ACAD | https://www.nasdaq.com/articles/health-care-sector-update-for-03-09-2022%3A-acadbflycyto | nan | nan | Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index rising 2.1% while the SPDR Health Care Select Sector ETF (XLV) was up 1.9%.
The Nasdaq Biotechnology index was climbing 2.9%.
In company news, Acadia Pharmaceuticals (ACAD) rose over 10% after saying the US Food and Drug Administration has set an Aug. 4 deadline for the agency to complete its review of the company's supplemental new drug application for the pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease.
Butterfly Network (BFLY) was rising 8.1% after saying it received a $5 million grant from the Bill & Melinda Gates Foundation to improve maternal and fetal health in Sub-Saharan Africa. Separately, FUJIFILM Sonosite said it has filed a patent infringement lawsuit seeking damages from Butterfly for allegedly infringing on the Japanese medical device company's patents for its ultrasound imaging technologies.
Altamira Therapeutics (CYTO) has turned 6.2% lower, giving back an early 5% advance that followed the company saying it has secured regulatory approvals to begin a clinical study to evaluate the ability of its Bentrio drug-free nasal spray to ease COVID-19 symptoms and reduced coronavisus-related hospital admissions.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, Acadia Pharmaceuticals (ACAD) rose over 10% after saying the US Food and Drug Administration has set an Aug. 4 deadline for the agency to complete its review of the company's supplemental new drug application for the pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease. Butterfly Network (BFLY) was rising 8.1% after saying it received a $5 million grant from the Bill & Melinda Gates Foundation to improve maternal and fetal health in Sub-Saharan Africa. Separately, FUJIFILM Sonosite said it has filed a patent infringement lawsuit seeking damages from Butterfly for allegedly infringing on the Japanese medical device company's patents for its ultrasound imaging technologies. | In company news, Acadia Pharmaceuticals (ACAD) rose over 10% after saying the US Food and Drug Administration has set an Aug. 4 deadline for the agency to complete its review of the company's supplemental new drug application for the pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease. Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index rising 2.1% while the SPDR Health Care Select Sector ETF (XLV) was up 1.9%. The Nasdaq Biotechnology index was climbing 2.9%. | In company news, Acadia Pharmaceuticals (ACAD) rose over 10% after saying the US Food and Drug Administration has set an Aug. 4 deadline for the agency to complete its review of the company's supplemental new drug application for the pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease. Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index rising 2.1% while the SPDR Health Care Select Sector ETF (XLV) was up 1.9%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, Acadia Pharmaceuticals (ACAD) rose over 10% after saying the US Food and Drug Administration has set an Aug. 4 deadline for the agency to complete its review of the company's supplemental new drug application for the pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease. Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index rising 2.1% while the SPDR Health Care Select Sector ETF (XLV) was up 1.9%. The Nasdaq Biotechnology index was climbing 2.9%. |
35754.0 | 2022-03-07 00:00:00 UTC | Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? | ACAD | https://www.nasdaq.com/articles/should-you-invest-in-the-first-trust-nyse-arca-biotechnology-etf-fbt-0 | nan | nan | The First Trust NYSE Arca Biotechnology ETF (FBT) was launched on 06/19/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity market.
Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.
Additionally, sector ETFs offer convenient ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 11, placing it in bottom 31%.
Index Details
The fund is sponsored by First Trust Advisors. It has amassed assets over $1.46 billion, making it one of the larger ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. FBT seeks to match the performance of the NYSE Arca Biotechnology Index before fees and expenses.
The NYSE Arca Biotechnology Index is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
Costs
Investors should also pay attention to an ETF's expense ratio. Lower cost products will produce better results than those with a higher cost, assuming all other metrics remain the same.
Annual operating expenses for this ETF are 0.55%, making it on par with most peer products in the space.
It has a 12-month trailing dividend yield of 1.54%.
Sector Exposure and Top Holdings
While ETFs offer diversified exposure, which minimizes single stock risk, a deep look into a fund's holdings is a valuable exercise. And, most ETFs are very transparent products that disclose their holdings on a daily basis.
This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio.
Looking at individual holdings, Acadia Pharmaceuticals Inc. (ACAD) accounts for about 3.97% of total assets, followed by Sarepta Therapeutics, Inc. (SRPT) and Neurocrine Biosciences, Inc. (NBIX).
The top 10 holdings account for about 36.91% of total assets under management.
Performance and Risk
Year-to-date, the First Trust NYSE Arca Biotechnology ETF has lost about -11.98% so far, and is down about -7.76% over the last 12 months (as of 03/07/2022). FBT has traded between $140.40 and $176.20 in this past 52-week period.
The ETF has a beta of 0.90 and standard deviation of 25.20% for the trailing three-year period, making it a high risk choice in the space. With about 31 holdings, it has more concentrated exposure than peers.
Alternatives
First Trust NYSE Arca Biotechnology ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, FBT is a reasonable option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.
SPDR S&P Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index and the iShares Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index. SPDR S&P Biotech ETF has $6.37 billion in assets, iShares Biotechnology ETF has $7.89 billion. XBI has an expense ratio of 0.35% and IBB charges 0.45%.
Bottom Line
To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.
Get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
First Trust NYSE Arca Biotechnology ETF (FBT): ETF Research Reports
iShares Biotechnology ETF (IBB): ETF Research Reports
Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis Report
Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
SPDR S&P Biotech ETF (XBI): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at individual holdings, Acadia Pharmaceuticals Inc. (ACAD) accounts for about 3.97% of total assets, followed by Sarepta Therapeutics, Inc. (SRPT) and Neurocrine Biosciences, Inc. (NBIX). ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report The First Trust NYSE Arca Biotechnology ETF (FBT) was launched on 06/19/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity market. | Looking at individual holdings, Acadia Pharmaceuticals Inc. (ACAD) accounts for about 3.97% of total assets, followed by Sarepta Therapeutics, Inc. (SRPT) and Neurocrine Biosciences, Inc. (NBIX). ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report The First Trust NYSE Arca Biotechnology ETF (FBT) was launched on 06/19/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity market. | Looking at individual holdings, Acadia Pharmaceuticals Inc. (ACAD) accounts for about 3.97% of total assets, followed by Sarepta Therapeutics, Inc. (SRPT) and Neurocrine Biosciences, Inc. (NBIX). ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Alternatives First Trust NYSE Arca Biotechnology ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. | Looking at individual holdings, Acadia Pharmaceuticals Inc. (ACAD) accounts for about 3.97% of total assets, followed by Sarepta Therapeutics, Inc. (SRPT) and Neurocrine Biosciences, Inc. (NBIX). ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report The First Trust NYSE Arca Biotechnology ETF (FBT) was launched on 06/19/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity market. |
35755.0 | 2022-03-04 00:00:00 UTC | Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? | ACAD | https://www.nasdaq.com/articles/is-first-trust-nyse-arca-biotechnology-etf-fbt-a-strong-etf-right-now-0 | nan | nan | A smart beta exchange traded fund, the First Trust NYSE Arca Biotechnology ETF (FBT) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific segment of the market, and the ETF industry has traditionally been dominated by products based on this strategy.
A good option for investors who believe in market efficiency, market cap weighted indexes offer a low-cost, convenient, and transparent way of replicating market returns.
On the other hand, some investors who believe that it is possible to beat the market by superior stock selection opt to invest in another class of funds that track non-cap weighted strategies--popularly known as smart beta.
By attempting to pick stocks that have a better chance of risk-return performance, non-cap weighted indexes are based on certain fundamental characteristics, or a combination of such.
While this space offers a number of choices to investors, including simplest equal-weighting, fundamental weighting and volatility/momentum based weighting methodologies, not all these strategies have been able to deliver superior results.
Fund Sponsor & Index
The fund is sponsored by First Trust Advisors. It has amassed assets over $1.48 billion, making it one of the larger ETFs in the Health Care ETFs. FBT, before fees and expenses, seeks to match the performance of the NYSE Arca Biotechnology Index.
The NYSE Arca Biotechnology Index is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
Cost & Other Expenses
Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF's expense ratio.
With on par with most peer products in the space, this ETF has annual operating expenses of 0.55%.
The fund has a 12-month trailing dividend yield of 1.52%.
Sector Exposure and Top Holdings
Even though ETFs offer diversified exposure that minimizes single stock risk, investors should also look at the actual holdings inside the fund. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.
FBT's heaviest allocation is in the Healthcare sector, which is about 100% of the portfolio.
Looking at individual holdings, Acadia Pharmaceuticals Inc. (ACAD) accounts for about 3.97% of total assets, followed by Sarepta Therapeutics, Inc. (SRPT) and Neurocrine Biosciences, Inc. (NBIX).
Its top 10 holdings account for approximately 36.91% of FBT's total assets under management.
Performance and Risk
The ETF has lost about -10.95% and is down about -8.86% so far this year and in the past one year (as of 03/04/2022), respectively. FBT has traded between $140.40 and $176.20 during this last 52-week period.
The fund has a beta of 0.90 and standard deviation of 25.20% for the trailing three-year period, which makes FBT a high risk choice in this particular space. With about 31 holdings, it has more concentrated exposure than peers.
Alternatives
First Trust NYSE Arca Biotechnology ETF is a reasonable option for investors seeking to outperform the Health Care ETFs segment of the market. However, there are other ETFs in the space which investors could consider.
SPDR S&P Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index and the iShares Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index. SPDR S&P Biotech ETF has $6.61 billion in assets, iShares Biotechnology ETF has $7.97 billion. XBI has an expense ratio of 0.35% and IBB charges 0.45%.
Investors looking for cheaper and lower-risk options should consider traditional market cap weighted ETFs that aim to match the returns of the Health Care ETFs.
Bottom Line
To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
First Trust NYSE Arca Biotechnology ETF (FBT): ETF Research Reports
iShares Biotechnology ETF (IBB): ETF Research Reports
Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis Report
Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
SPDR S&P Biotech ETF (XBI): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at individual holdings, Acadia Pharmaceuticals Inc. (ACAD) accounts for about 3.97% of total assets, followed by Sarepta Therapeutics, Inc. (SRPT) and Neurocrine Biosciences, Inc. (NBIX). ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report On the other hand, some investors who believe that it is possible to beat the market by superior stock selection opt to invest in another class of funds that track non-cap weighted strategies--popularly known as smart beta. | Looking at individual holdings, Acadia Pharmaceuticals Inc. (ACAD) accounts for about 3.97% of total assets, followed by Sarepta Therapeutics, Inc. (SRPT) and Neurocrine Biosciences, Inc. (NBIX). ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report A smart beta exchange traded fund, the First Trust NYSE Arca Biotechnology ETF (FBT) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market. | Looking at individual holdings, Acadia Pharmaceuticals Inc. (ACAD) accounts for about 3.97% of total assets, followed by Sarepta Therapeutics, Inc. (SRPT) and Neurocrine Biosciences, Inc. (NBIX). ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report A smart beta exchange traded fund, the First Trust NYSE Arca Biotechnology ETF (FBT) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market. | Looking at individual holdings, Acadia Pharmaceuticals Inc. (ACAD) accounts for about 3.97% of total assets, followed by Sarepta Therapeutics, Inc. (SRPT) and Neurocrine Biosciences, Inc. (NBIX). ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report A smart beta exchange traded fund, the First Trust NYSE Arca Biotechnology ETF (FBT) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market. |
35756.0 | 2022-03-01 00:00:00 UTC | Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates | ACAD | https://www.nasdaq.com/articles/acadia-acad-q4-earnings-revenues-fall-shy-of-estimates | nan | nan | Acadia Pharmaceuticals Inc. ACAD reported a fourth-quarter 2021 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 24 cents. In the year-ago quarter, the company incurred a loss of 42 cents per share.
Total revenues, comprising net sales of Acadia's only marketed drug Nuplazid (pimavanserin), increased 8% year over year to $130.8 million for the fourth quarter, driven by Nuplazid volume growth. The top line, however, missed the Zacks Consensus Estimate of $135 million. Nuplazid sales fell below market expectation in the reported quarter.
Nuplazid is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis.
Shares of Acadia were down 7.7% in after-market trading on Monday, following the weaker-than-expected earnings announcement. The stock has plunged 46.1% in the past year compared with the industry’s 36.6% decline.
Image Source: Zacks Investment Research
Full-Year Results
For 2021, Acadia generated total revenues of $484.1 million compared with $441.8 million recorded in 2020.
For the year, the company reported a loss of $1.05 per share compared with a net loss of $1.79 per share in 2020.
Quarter in Detail
Research and development (R&D) expenses were $67.1 million for the quarter, up 8.1% from the year-ago quarter.
Selling, general and administrative (SG&A) expenses were $105.8 million, down 12.4% year over year.
As of Dec 31, 2021, Acadia had cash, cash equivalents and investments worth $520.7 million compared with $540.3 million as of Sep 30, 2021.
2022 Guidance
Acadia expects Nuplazid net sales of $510-$560 million for 2022. The Zacks Consensus Estimate for the metric is pegged at $557.9 million.
The company expects R&D expenses of $355-$375 million, while SG&A expenses are expected to be $360-$380 million in 2022.
Pipeline Updates
In February 2022, Acadia resubmitted the supplemental new drug application (“sNDA”) to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.
The FDA had issued a complete response letter (“CRL”) to the sNDA for Nuplazid in April 2021.
Acadia has other promising pipeline candidates that are progressing well.
In December 2021, the company announced positive top-line data from the phase III Lavender study, which evaluated the safety and efficacy of its pipeline candidate, trofinetide, for the treatment of Rett syndrome. The study met its co-primary endpoints.
Acadia expects to file a new drug application (“NDA”) for trofinetide to treat Rett syndrome around mid-2022.
The company is evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery in a phase II study. Top-line data from the study is anticipated later in the first quarter of 2022.
In January 2022, Acadia entered a collaboration agreement with Stoke Therapeutics, Inc. STOK to discover, develop and commercialize novel RNA-based medicines for treating neurodevelopmental diseases of the central nervous system (“CNS”). The collaboration looks like a good strategic fit for Acadia to boost its pipeline of candidates being developed for treating various CNS disorders.
The partnership is looking to leverage Stoke’s RNA-based capabilities with Acadia’s expertise in neuroscience drug development for discovering multiple RNA-based treatments in severe and rare genetic neurodevelopmental diseases, including SYNGAP1 syndrome, Rett syndrome and an undisclosed neurodevelopmental target.
Acadia and Stoke will share all costs and profits equally for the SYNGAP1 program worldwide.
Acadia Pharmaceuticals Inc. Price, Consensus and EPS Surprise
Acadia Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Acadia Pharmaceuticals Inc. Quote
Zacks Rank & Stocks to Consider
Acadia currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Dynavax Technologies Corporation DVAX and Kaleido Biosciences, Inc. KLDO, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Dynavax’s earnings estimates have been revised 10.3% upward for 2022 over the past 60 days. The stock has rallied 42.1% in the past year.
Earnings of Dynavax have surpassed estimates in each of the trailing four quarters.
Kaleido Biosciences’ loss per share estimates have narrowed 11.3% for 2022 over the past 60 days.
Earnings of Kaleido Biosciences have surpassed estimates in three of the trailing four quarters and missed the same once.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Dynavax Technologies Corporation (DVAX): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Kaleido Biosciences, Inc. (KLDO): Free Stock Analysis Report
Stoke Therapeutics, Inc. (STOK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Pipeline Updates In February 2022, Acadia resubmitted the supplemental new drug application (“sNDA”) to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis. In January 2022, Acadia entered a collaboration agreement with Stoke Therapeutics, Inc. STOK to discover, develop and commercialize novel RNA-based medicines for treating neurodevelopmental diseases of the central nervous system (“CNS”). Acadia Pharmaceuticals Inc. ACAD reported a fourth-quarter 2021 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 24 cents. | Acadia Pharmaceuticals Inc. Price, Consensus and EPS Surprise Acadia Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). Acadia Pharmaceuticals Inc. ACAD reported a fourth-quarter 2021 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 24 cents. Total revenues, comprising net sales of Acadia's only marketed drug Nuplazid (pimavanserin), increased 8% year over year to $130.8 million for the fourth quarter, driven by Nuplazid volume growth. | Acadia Pharmaceuticals Inc. ACAD reported a fourth-quarter 2021 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 24 cents. Total revenues, comprising net sales of Acadia's only marketed drug Nuplazid (pimavanserin), increased 8% year over year to $130.8 million for the fourth quarter, driven by Nuplazid volume growth. Acadia Pharmaceuticals Inc. Price, Consensus and EPS Surprise Acadia Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). | Acadia Pharmaceuticals Inc. ACAD reported a fourth-quarter 2021 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 24 cents. Total revenues, comprising net sales of Acadia's only marketed drug Nuplazid (pimavanserin), increased 8% year over year to $130.8 million for the fourth quarter, driven by Nuplazid volume growth. Shares of Acadia were down 7.7% in after-market trading on Monday, following the weaker-than-expected earnings announcement. |
35757.0 | 2022-02-28 00:00:00 UTC | Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-acad-reports-q4-loss-lags-revenue-estimates | nan | nan | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -12.50%. A quarter ago, it was expected that this drugmaker would post a loss of $0.27 per share when it actually produced a loss of $0.09, delivering a surprise of 66.67%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $130.76 million for the quarter ended December 2021, missing the Zacks Consensus Estimate by 3.09%. This compares to year-ago revenues of $121.01 million. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Acadia shares have added about 9.9% since the beginning of the year versus the S&P 500's decline of -8%.
What's Next for Acadia?
While Acadia has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Acadia: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.29 on $126.3 million in revenues for the coming quarter and -$0.96 on $557.91 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Seres Therapeutics (MCRB), has yet to report results for the quarter ended December 2021. The results are expected to be released on March 1.
This drug developer is expected to post quarterly loss of $0.45 per share in its upcoming report, which represents a year-over-year change of -150%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Seres Therapeutics' revenues are expected to be $19.48 million, up 11% from the year-ago quarter.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?
Last year's 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys
Access Zacks Top 10 Stocks for 2022 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Seres Therapeutics, Inc. (MCRB): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.24. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $130.76 million for the quarter ended December 2021, missing the Zacks Consensus Estimate by 3.09%. Acadia shares have added about 9.9% since the beginning of the year versus the S&P 500's decline of -8%. | Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $130.76 million for the quarter ended December 2021, missing the Zacks Consensus Estimate by 3.09%. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.24. | Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.24. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $130.76 million for the quarter ended December 2021, missing the Zacks Consensus Estimate by 3.09%. Acadia shares have added about 9.9% since the beginning of the year versus the S&P 500's decline of -8%. | While Acadia has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.24. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $130.76 million for the quarter ended December 2021, missing the Zacks Consensus Estimate by 3.09%. |
35758.0 | 2022-02-24 00:00:00 UTC | Interesting ACAD Put And Call Options For April 8th | ACAD | https://www.nasdaq.com/articles/interesting-acad-put-and-call-options-for-april-8th | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new April 8th contracts and identified one put and one call contract of particular interest.
The put contract at the $24.00 strike price has a current bid of $1.65. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $24.00, but will also collect the premium, putting the cost basis of the shares at $22.35 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $24.85/share today.
Because the $24.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 6.87% return on the cash commitment, or 58.41% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $24.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $2.00. If an investor was to purchase shares of ACAD stock at the current price level of $24.85/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $25.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 8.65% if the stock gets called away at the April 8th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red:
Considering the fact that the $25.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 8.05% boost of extra return to the investor, or 68.38% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $24.85) to be 86%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 8th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 8th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $24.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $2.00. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 8th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $24.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $2.00. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 8th expiration. |
35759.0 | 2022-02-21 00:00:00 UTC | Will Acadia Pharmaceuticals (ACAD) Report Negative Earnings Next Week? What You Should Know | ACAD | https://www.nasdaq.com/articles/will-acadia-pharmaceuticals-acad-report-negative-earnings-next-week-what-you-should-know-0 | nan | nan | Acadia Pharmaceuticals (ACAD) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2021. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 28. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This drugmaker is expected to post quarterly loss of $0.24 per share in its upcoming report, which represents a year-over-year change of +42.9%.
Revenues are expected to be $134.68 million, up 11.3% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Acadia?
For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -5.37%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Acadia will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Acadia would post a loss of $0.27 per share when it actually produced a loss of $0.09, delivering a surprise of +66.67%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Acadia doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (ACAD) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2021. How Have the Numbers Shaped Up for Acadia? For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. | Acadia Pharmaceuticals (ACAD) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2021. How Have the Numbers Shaped Up for Acadia? For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. | For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. Acadia Pharmaceuticals (ACAD) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2021. How Have the Numbers Shaped Up for Acadia? | Acadia Pharmaceuticals (ACAD) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2021. How Have the Numbers Shaped Up for Acadia? For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. |
35760.0 | 2022-02-16 00:00:00 UTC | Noteworthy Wednesday Option Activity: PAG, MU, ACAD | ACAD | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-pag-mu-acad | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Penske Automotive Group Inc (Symbol: PAG), where a total of 2,133 contracts have traded so far, representing approximately 213,300 underlying shares. That amounts to about 59.3% of PAG's average daily trading volume over the past month of 359,615 shares. Particularly high volume was seen for the $100 strike call option expiring August 19, 2022, with 1,000 contracts trading so far today, representing approximately 100,000 underlying shares of PAG. Below is a chart showing PAG's trailing twelve month trading history, with the $100 strike highlighted in orange:
Micron Technology Inc. (Symbol: MU) options are showing a volume of 133,232 contracts thus far today. That number of contracts represents approximately 13.3 million underlying shares, working out to a sizeable 58.7% of MU's average daily trading volume over the past month, of 22.7 million shares. Especially high volume was seen for the $65 strike put option expiring September 16, 2022, with 10,079 contracts trading so far today, representing approximately 1.0 million underlying shares of MU. Below is a chart showing MU's trailing twelve month trading history, with the $65 strike highlighted in orange:
And Acadia Pharmaceuticals Inc (Symbol: ACAD) saw options trading volume of 8,309 contracts, representing approximately 830,900 underlying shares or approximately 55.5% of ACAD's average daily trading volume over the past month, of 1.5 million shares. Especially high volume was seen for the $30 strike call option expiring June 17, 2022, with 2,407 contracts trading so far today, representing approximately 240,700 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $30 strike highlighted in orange:
For the various different available expirations for PAG options, MU options, or ACAD options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $30 strike call option expiring June 17, 2022, with 2,407 contracts trading so far today, representing approximately 240,700 underlying shares of ACAD. Below is a chart showing MU's trailing twelve month trading history, with the $65 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) saw options trading volume of 8,309 contracts, representing approximately 830,900 underlying shares or approximately 55.5% of ACAD's average daily trading volume over the past month, of 1.5 million shares. Below is a chart showing ACAD's trailing twelve month trading history, with the $30 strike highlighted in orange: For the various different available expirations for PAG options, MU options, or ACAD options, visit StockOptionsChannel.com. | Below is a chart showing MU's trailing twelve month trading history, with the $65 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) saw options trading volume of 8,309 contracts, representing approximately 830,900 underlying shares or approximately 55.5% of ACAD's average daily trading volume over the past month, of 1.5 million shares. Especially high volume was seen for the $30 strike call option expiring June 17, 2022, with 2,407 contracts trading so far today, representing approximately 240,700 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $30 strike highlighted in orange: For the various different available expirations for PAG options, MU options, or ACAD options, visit StockOptionsChannel.com. | Below is a chart showing MU's trailing twelve month trading history, with the $65 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) saw options trading volume of 8,309 contracts, representing approximately 830,900 underlying shares or approximately 55.5% of ACAD's average daily trading volume over the past month, of 1.5 million shares. Especially high volume was seen for the $30 strike call option expiring June 17, 2022, with 2,407 contracts trading so far today, representing approximately 240,700 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $30 strike highlighted in orange: For the various different available expirations for PAG options, MU options, or ACAD options, visit StockOptionsChannel.com. | Below is a chart showing MU's trailing twelve month trading history, with the $65 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) saw options trading volume of 8,309 contracts, representing approximately 830,900 underlying shares or approximately 55.5% of ACAD's average daily trading volume over the past month, of 1.5 million shares. Below is a chart showing ACAD's trailing twelve month trading history, with the $30 strike highlighted in orange: For the various different available expirations for PAG options, MU options, or ACAD options, visit StockOptionsChannel.com. Especially high volume was seen for the $30 strike call option expiring June 17, 2022, with 2,407 contracts trading so far today, representing approximately 240,700 underlying shares of ACAD. |
35761.0 | 2022-02-16 00:00:00 UTC | Here's How Much a $1000 Investment in Acadia Pharmaceuticals Made 10 Years Ago Would Be Worth Today | ACAD | https://www.nasdaq.com/articles/heres-how-much-a-%241000-investment-in-acadia-pharmaceuticals-made-10-years-ago-would-be | nan | nan | For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Acadia Pharmaceuticals (ACAD) ten years ago? It may not have been easy to hold on to ACAD for all that time, but if you did, how much would your investment be worth today?
Acadia Pharmaceuticals' Business In-Depth
With that in mind, let's take a look at Acadia Pharmaceuticals' main business drivers.
San Diego, CA-based ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders.
The company’s sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease (PD) psychosis. The drug was launched in May 2016. ACADIA’s top-line consists of only net product sales of Nuplazid in the United States.
In April 2021, the company suffered a setback, when the FDA issued a complete response letter (CRL) to the supplemental new drug application (sNDA) for Nuplazid for treating dementia-related psychosis. In December 2021, ACADIA announced that it plans to resubmit the sNDA for Nuplazid for the treatment of hallucinations and delusions associated with dementia focused on Alzheimer’s disease psychosis (“ADP”).
Notably, several additional studies on Nuplazid n targeting different CNS indications, such as dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway.
Meanwhile, in August 2018, ACADIA entered into a license agreement with Australian biopharmaceutical company Neuren Pharmaceuticals Limited and obtained exclusive North American rights to develop and commercialize trofinetide for Rett syndrome and other indications.
ACADIA’s top line mainly comprises U.S. sales of Nuplazid. The company recognized revenues worth $441.7 million in 2020 compared with $339.1 million in 2019.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Acadia Pharmaceuticals, if you bought shares a decade ago, you're likely feeling really good about your investment today.
According to our calculations, a $1000 investment made in February 2012 would be worth $14,745.95, or a 1,374.59% gain, as of February 16, 2022. Investors should keep in mind that this return excludes dividends but includes price appreciation.
In comparison, the S&P 500 gained 232.86% and the price of gold went up 3.02% over the same time frame.
Looking ahead, analysts are expecting more upside for ACAD.
ACADIA’s sole marketed drug, Nuplazid, has recorded strong sales since its launch. It’s top line consists of only net product sales of Nuplazid. The drug’s label-expansion program looks promising, with several studies that are currently underway. The company plans to file for Nuplazid label expansion in first quarter 2022. If approved, not only will the drug’s eligible patient population be expanded, but will boost sales in days ahead. However, heavy dependence on Nuplazid for revenues remains a worry. Also, the regulatory setback, wherein the FDA issued a complete response letter for Nuplazid’s label expansion, hurt the stock severely. Stiff competition in the target market also remains a woe. Shares of the company have underperformed the industry in the past year.
The stock has jumped 30.28% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 2 higher, for fiscal 2021; the consensus estimate has moved up as well.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | San Diego, CA-based ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. Meanwhile, in August 2018, ACADIA entered into a license agreement with Australian biopharmaceutical company Neuren Pharmaceuticals Limited and obtained exclusive North American rights to develop and commercialize trofinetide for Rett syndrome and other indications. What if you'd invested in Acadia Pharmaceuticals (ACAD) ten years ago? | ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report What if you'd invested in Acadia Pharmaceuticals (ACAD) ten years ago? It may not have been easy to hold on to ACAD for all that time, but if you did, how much would your investment be worth today? | Acadia Pharmaceuticals' Business In-Depth With that in mind, let's take a look at Acadia Pharmaceuticals' main business drivers. ACADIA’s sole marketed drug, Nuplazid, has recorded strong sales since its launch. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report | It may not have been easy to hold on to ACAD for all that time, but if you did, how much would your investment be worth today? ACADIA’s sole marketed drug, Nuplazid, has recorded strong sales since its launch. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report |
35762.0 | 2022-02-10 00:00:00 UTC | April 1st Options Now Available For Acadia Pharmaceuticals (ACAD) | ACAD | https://www.nasdaq.com/articles/april-1st-options-now-available-for-acadia-pharmaceuticals-acad | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new April 1st contracts and identified one put and one call contract of particular interest.
The put contract at the $26.00 strike price has a current bid of $1.80. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $26.00, but will also collect the premium, putting the cost basis of the shares at $24.20 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $26.78/share today.
Because the $26.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 6.92% return on the cash commitment, or 50.58% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $26.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $27.00 strike price has a current bid of $2.30. If an investor was to purchase shares of ACAD stock at the current price level of $26.78/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $27.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 9.41% if the stock gets called away at the April 1st expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $27.00 strike highlighted in red:
Considering the fact that the $27.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 8.59% boost of extra return to the investor, or 62.75% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $26.78) to be 86%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $27.00 strike highlighted in red: Considering the fact that the $27.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 1st expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $27.00 strike highlighted in red: Considering the fact that the $27.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 1st expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $26.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $27.00 strike price has a current bid of $2.30. Below is a chart showing ACAD's trailing twelve month trading history, with the $27.00 strike highlighted in red: Considering the fact that the $27.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 1st expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $26.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $27.00 strike price has a current bid of $2.30. Below is a chart showing ACAD's trailing twelve month trading history, with the $27.00 strike highlighted in red: Considering the fact that the $27.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 1st expiration. |
35763.0 | 2022-02-09 00:00:00 UTC | 4 Drug, Biotech Stocks Set to Beat Q4 Earnings Estimates | ACAD | https://www.nasdaq.com/articles/4-drug-biotech-stocks-set-to-beat-q4-earnings-estimates | nan | nan | Quite a few big pharma/biotech stocks have reported fourth-quarter earnings, and the results so far have been mixed. Most of these companies seem to have recovered from the adverse effects of the pandemic, and sales of key drugs for the majority are on track to improve as patient visits normalize. Sales of vaccines, diagnostic tests and antibody treatments for COVID-19 have been stupendous and boosted the top line of their respective companies. In fact, the rapid development of vaccines and antibody treatments for COVID-19 aided the economic recovery in 2021, barring a few setbacks. Regulatory and pipeline developments are back on track with new drug approvals as the economic situation improves.
While some uncertainty prevails due to new emerging variants, most bigwigs provided an encouraging outlook for 2022 and look well placed to counter any future challenges.
Among the big pharma companies that have reported so far, Johnson & Johnson and AbbVie beat earnings estimates but missed on sales. Merck beat on both counts. Lilly missed earnings estimates while beating on sales. Novartis results were disappointing as it missed on both counts. In the biotech space, Amgen AMGN outpaced earnings estimates but missed on sales. Bristol-Myers Squibb reported in-line fourth-quarter 2021 earnings while sales topped estimates on strong performance of key drugs. Biogen and Regeneron beat on both counts.
Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech and medical device companies.
Per the Earnings Trend report, as of Feb 2, 33.9% of the companies in the Medical sector, constituting nearly 53.7% of the sector’s market capitalization, have reported earnings. While 63.2% topped earnings estimates, 57.9% beat on sales. Earnings increased 10% year over year on 12.1% higher revenues. Overall, earnings for the Medical sector are expected to rise 18.4% on a 12.8% sales increase.
While the bigwigs are out with results, many companies are still left to report.
Zeroing in on the Winners
Here we have highlighted four drug/biotech companies, which are expected to beat on earnings in their upcoming quarterly results.
Earnings ESP is our proprietary methodology for determining the stocks that have the best chance to deliver an earnings surprise. Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.
According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be done with the help of the Zacks Stock Screener.
Our research shows that for stocks with this combination, the chance of an earnings surprise is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
4 Drug/Biotech Stocks That Match the Criteria
Vir Biotechnology, Inc’s VIR fourth-quarter results have likely been boosted by sales of its monoclonal antibody for the early treatment of COVID-19, sotrovimab. The company has a profit-sharing arrangement with GlaxoSmithKline for the sale of sotrovimab and earns collaboration revenues from the same. Additional government purchase contracts for doses of this treatment might have fueled the top line.
The combination of Vir’s Earnings ESP of +32.05% and a Zacks Rank #1 (Strong Buy) raises the possibility of an earnings surprise in the to-be-reported quarter. You can see the complete list of today’s Zacks #1 Rank stocks here.
Vir Biotechnology, Inc. Price and EPS Surprise
Vir Biotechnology, Inc. price-eps-surprise | Vir Biotechnology, Inc. Quote
Moderna’s MRNA COVID-19 vaccine sales are likely to have boosted the company’s top line during the fourth quarter, which might have propelled the bottom line as well. The U.S. authorization for booster dose for all adults might have led to additional sales.
The combination of Moderna’s Earnings ESP of +3.28% and a Zacks Rank #3 raises the possibility of an earnings surprise in the to-be-reported quarter. The company is scheduled to release earnings for the fourth quarter of 2021 on Feb 24.
Moderna, Inc. Price and EPS Surprise
Moderna, Inc. price-eps-surprise | Moderna, Inc. Quote
Jazz Pharmaceuticals’ JAZZ revenues in the fourth quarter have likely been driven by sales of new drugs and drugs added from the acquisition of GW Pharmaceuticals. Jazz’s sleep disorder portfolio looks solid, and the strong uptake of Xywav is likely to have fueled the top line.
The company has an Earnings ESP of +2.09% and a Zacks Rank of #3.
Jazz Pharmaceuticals PLC Price and EPS Surprise
Jazz Pharmaceuticals PLC price-eps-surprise | Jazz Pharmaceuticals PLC Quote
ACADIA’s ACAD sole marketed drug, Nuplazid, has recorded strong sales since its launch, and the same is likely to have boosted the top line in the fourth quarter. Solid volume growth in the third quarter fueled sales, and the same trend is expected to have prevailed in the to-be-reported quarter.
The company has an Earnings ESP of +7.26% and a Zacks Rank of #3.
ACADIA Pharmaceuticals Inc. Price and EPS Surprise
ACADIA Pharmaceuticals Inc. price-eps-surprise | ACADIA Pharmaceuticals Inc. Quote
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amgen Inc. (AMGN): Free Stock Analysis Report
Moderna, Inc. (MRNA): Free Stock Analysis Report
Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Vir Biotechnology, Inc. (VIR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Jazz Pharmaceuticals PLC Price and EPS Surprise Jazz Pharmaceuticals PLC price-eps-surprise | Jazz Pharmaceuticals PLC Quote ACADIA’s ACAD sole marketed drug, Nuplazid, has recorded strong sales since its launch, and the same is likely to have boosted the top line in the fourth quarter. ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. price-eps-surprise | ACADIA Pharmaceuticals Inc. Quote ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report | Jazz Pharmaceuticals PLC Price and EPS Surprise Jazz Pharmaceuticals PLC price-eps-surprise | Jazz Pharmaceuticals PLC Quote ACADIA’s ACAD sole marketed drug, Nuplazid, has recorded strong sales since its launch, and the same is likely to have boosted the top line in the fourth quarter. ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. price-eps-surprise | ACADIA Pharmaceuticals Inc. Quote ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report | Jazz Pharmaceuticals PLC Price and EPS Surprise Jazz Pharmaceuticals PLC price-eps-surprise | Jazz Pharmaceuticals PLC Quote ACADIA’s ACAD sole marketed drug, Nuplazid, has recorded strong sales since its launch, and the same is likely to have boosted the top line in the fourth quarter. ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. price-eps-surprise | ACADIA Pharmaceuticals Inc. Quote ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report | Jazz Pharmaceuticals PLC Price and EPS Surprise Jazz Pharmaceuticals PLC price-eps-surprise | Jazz Pharmaceuticals PLC Quote ACADIA’s ACAD sole marketed drug, Nuplazid, has recorded strong sales since its launch, and the same is likely to have boosted the top line in the fourth quarter. ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. price-eps-surprise | ACADIA Pharmaceuticals Inc. Quote ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report |
35764.0 | 2022-02-04 00:00:00 UTC | First Week of March 25th Options Trading For Acadia Pharmaceuticals (ACAD) | ACAD | https://www.nasdaq.com/articles/first-week-of-march-25th-options-trading-for-acadia-pharmaceuticals-acad | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the March 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new March 25th contracts and identified one put and one call contract of particular interest.
The put contract at the $22.00 strike price has a current bid of 95 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $22.00, but will also collect the premium, putting the cost basis of the shares at $21.05 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $22.78/share today.
Because the $22.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 61%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 4.32% return on the cash commitment, or 32.19% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $28.00 strike price has a current bid of 50 cents. If an investor was to purchase shares of ACAD stock at the current price level of $22.78/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $28.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 25.11% if the stock gets called away at the March 25th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red:
Considering the fact that the $28.00 strike represents an approximate 23% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 69%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 2.19% boost of extra return to the investor, or 16.36% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 101%, while the implied volatility in the call contract example is 102%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $22.78) to be 85%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 23% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the March 25th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 23% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the March 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new March 25th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $28.00 strike price has a current bid of 50 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 23% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the March 25th expiration. | At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new March 25th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 23% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the March 25th expiration. |
35765.0 | 2022-01-13 00:00:00 UTC | Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why | ACAD | https://www.nasdaq.com/articles/acadia-acad-up-more-than-20-in-past-3-months%3A-heres-why | nan | nan | Shares of Acadia Pharmaceuticals Inc. ACAD have rallied 24.2% in the past three months against the industry’s decrease of 13%.
Image Source: Zacks Investment Research
The company has made steady progress with its sole marketed drug, Nuplazid (pimavanserin), approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, in this time frame. The drug is the first and the only FDA-approved treatment for the given indication.
Acadia is planning to resubmit the supplemental new drug application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with dementia focused on Alzheimer’s disease psychosis (“ADP”) in the first quarter of 2022.
With this resubmission of the sNDA for pimavanserin, Acadia is now narrowing the focus of the proposed indication from dementia-related psychosis to ADP. Shares of the company rose on this news.
The company decided to resubmit the sNDA after the FDA issued a complete response letter (“CRL”) to the sNDA for Nuplazid for the treatment of hallucinations and delusions associated with dementia-related psychosis or DRP in April 2021.
This apart, Acadia has other promising pipeline candidates that are progressing well.
In December 2021, the company announced positive top-line data from the phase III Lavender study that evaluated the safety and efficacy of its pipeline candidate, trofinetide, for the treatment of Rett syndrome. The study met its co-primary endpoints.
Acadia, which expects to file a new drug application (“NDA”) for trofinetide to treat Rett syndrome around mid-2022, is planning to hold a pre-NDA meeting with the FDA in the first quarter of 2022.
Earlier this month, Acadia entered into a collaboration agreement with Stoke Therapeutics, Inc. STOK to discover, develop and commercialize novel RNA-based medicines for treating neurodevelopmental diseases of the central nervous system (“CNS”).
The partnership is looking to leverage Stoke’s RNA-based capabilities with Acadia’s expertise in neuroscience drug development for discovering multiple RNA-based treatments in severe and rare genetic neurodevelopmental diseases, including SYNGAP1 syndrome, Rett syndrome and an undisclosed neurodevelopmental target.
Acadia and Stoke will share all costs and profits equally for the SYNGAP1 program across the world.
The collaboration looks like a good strategic fit for Acadia to boost its pipeline of candidates being developed for treating various CNS disorders.
Acadia currently has no approved product in its portfolio other than Nuplazid. Hence, any regulatory setback for the drug will hurt the stock in the days ahead. Nuplazid has witnessed strong uptake since its launch. The company is also developing pimavanserin to treat other neuropsychiatric conditions. A potential label expansion is likely to boost sales of the drug in the days ahead and should drive the stock price.
However, competition remains stiff as several other companies, including Axsome Therapeutics AXSM, are also developing treatments to address various CNS disorders.
Axsome Therapeutics has several CNS product candidates, namely, AXS-05, AXS-07, AXS-09, AXS-12 and AXS-14, which are being developed for multiple CNS indications. A prospective approval for any of these candidates will induce competition for Acadia and its products.
Acadia Pharmaceuticals Inc. Price
Acadia Pharmaceuticals Inc. price | Acadia Pharmaceuticals Inc. Quote
Zacks Rank & Another Stock to Consider
Acadia currently carries a Zacks Rank #2 (Buy). A top-ranked stock in the biotech sector is AnaptysBio, Inc. ANAB, which has a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
AnaptysBio’s loss per share estimates have narrowed 0.3% for 2022 over the past 60 days. The stock has rallied 35.5% in the past year.
AnaptysBio’s earnings surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Axsome Therapeutics, Inc. (AXSM): Free Stock Analysis Report
AnaptysBio, Inc. (ANAB): Free Stock Analysis Report
Stoke Therapeutics, Inc. (STOK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Earlier this month, Acadia entered into a collaboration agreement with Stoke Therapeutics, Inc. STOK to discover, develop and commercialize novel RNA-based medicines for treating neurodevelopmental diseases of the central nervous system (“CNS”). Shares of Acadia Pharmaceuticals Inc. ACAD have rallied 24.2% in the past three months against the industry’s decrease of 13%. Acadia is planning to resubmit the supplemental new drug application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with dementia focused on Alzheimer’s disease psychosis (“ADP”) in the first quarter of 2022. | Acadia Pharmaceuticals Inc. Price Acadia Pharmaceuticals Inc. price | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Another Stock to Consider Acadia currently carries a Zacks Rank #2 (Buy). ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Shares of Acadia Pharmaceuticals Inc. ACAD have rallied 24.2% in the past three months against the industry’s decrease of 13%. | The partnership is looking to leverage Stoke’s RNA-based capabilities with Acadia’s expertise in neuroscience drug development for discovering multiple RNA-based treatments in severe and rare genetic neurodevelopmental diseases, including SYNGAP1 syndrome, Rett syndrome and an undisclosed neurodevelopmental target. Acadia Pharmaceuticals Inc. Price Acadia Pharmaceuticals Inc. price | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Another Stock to Consider Acadia currently carries a Zacks Rank #2 (Buy). Shares of Acadia Pharmaceuticals Inc. ACAD have rallied 24.2% in the past three months against the industry’s decrease of 13%. | Shares of Acadia Pharmaceuticals Inc. ACAD have rallied 24.2% in the past three months against the industry’s decrease of 13%. Acadia is planning to resubmit the supplemental new drug application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with dementia focused on Alzheimer’s disease psychosis (“ADP”) in the first quarter of 2022. With this resubmission of the sNDA for pimavanserin, Acadia is now narrowing the focus of the proposed indication from dementia-related psychosis to ADP. |
35766.0 | 2022-01-13 00:00:00 UTC | Analysts See 12% Upside For The Holdings of RXL | ACAD | https://www.nasdaq.com/articles/analysts-see-12-upside-for-the-holdings-of-rxl | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares Ultra Health Care ETF (Symbol: RXL), we found that the implied analyst target price for the ETF based upon its underlying holdings is $116.20 per unit.
With RXL trading at a recent price near $103.64 per unit, that means that analysts see 12.11% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of RXL's underlying holdings with notable upside to their analyst target prices are Agios Pharmaceuticals Inc (Symbol: AGIO), Blueprint Medicines Corp (Symbol: BPMC), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Although AGIO has traded at a recent price of $31.64/share, the average analyst target is 100.70% higher at $63.50/share. Similarly, BPMC has 42.19% upside from the recent share price of $81.50 if the average analyst target price of $115.89/share is reached, and analysts on average are expecting ACAD to reach a target price of $28.94/share, which is 30.73% above the recent price of $22.14. Below is a twelve month price history chart comparing the stock performance of AGIO, BPMC, and ACAD:
Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
ProShares Ultra Health Care ETF RXL $103.64 $116.20 12.11%
Agios Pharmaceuticals Inc AGIO $31.64 $63.50 100.70%
Blueprint Medicines Corp BPMC $81.50 $115.89 42.19%
Acadia Pharmaceuticals Inc ACAD $22.14 $28.94 30.73%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ProShares Ultra Health Care ETF RXL $103.64 $116.20 12.11% Agios Pharmaceuticals Inc AGIO $31.64 $63.50 100.70% Blueprint Medicines Corp BPMC $81.50 $115.89 42.19% Acadia Pharmaceuticals Inc ACAD $22.14 $28.94 30.73% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of RXL's underlying holdings with notable upside to their analyst target prices are Agios Pharmaceuticals Inc (Symbol: AGIO), Blueprint Medicines Corp (Symbol: BPMC), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, BPMC has 42.19% upside from the recent share price of $81.50 if the average analyst target price of $115.89/share is reached, and analysts on average are expecting ACAD to reach a target price of $28.94/share, which is 30.73% above the recent price of $22.14. | Three of RXL's underlying holdings with notable upside to their analyst target prices are Agios Pharmaceuticals Inc (Symbol: AGIO), Blueprint Medicines Corp (Symbol: BPMC), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, BPMC has 42.19% upside from the recent share price of $81.50 if the average analyst target price of $115.89/share is reached, and analysts on average are expecting ACAD to reach a target price of $28.94/share, which is 30.73% above the recent price of $22.14. ProShares Ultra Health Care ETF RXL $103.64 $116.20 12.11% Agios Pharmaceuticals Inc AGIO $31.64 $63.50 100.70% Blueprint Medicines Corp BPMC $81.50 $115.89 42.19% Acadia Pharmaceuticals Inc ACAD $22.14 $28.94 30.73% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Similarly, BPMC has 42.19% upside from the recent share price of $81.50 if the average analyst target price of $115.89/share is reached, and analysts on average are expecting ACAD to reach a target price of $28.94/share, which is 30.73% above the recent price of $22.14. Three of RXL's underlying holdings with notable upside to their analyst target prices are Agios Pharmaceuticals Inc (Symbol: AGIO), Blueprint Medicines Corp (Symbol: BPMC), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Below is a twelve month price history chart comparing the stock performance of AGIO, BPMC, and ACAD: Below is a summary table of the current analyst target prices discussed above: | ProShares Ultra Health Care ETF RXL $103.64 $116.20 12.11% Agios Pharmaceuticals Inc AGIO $31.64 $63.50 100.70% Blueprint Medicines Corp BPMC $81.50 $115.89 42.19% Acadia Pharmaceuticals Inc ACAD $22.14 $28.94 30.73% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of RXL's underlying holdings with notable upside to their analyst target prices are Agios Pharmaceuticals Inc (Symbol: AGIO), Blueprint Medicines Corp (Symbol: BPMC), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, BPMC has 42.19% upside from the recent share price of $81.50 if the average analyst target price of $115.89/share is reached, and analysts on average are expecting ACAD to reach a target price of $28.94/share, which is 30.73% above the recent price of $22.14. |
35767.0 | 2022-01-10 00:00:00 UTC | Acadia, Stoke To Jointly Develop RNA Treatments For Genetic Neuro-developmental Diseases | ACAD | https://www.nasdaq.com/articles/acadia-stoke-to-jointly-develop-rna-treatments-for-genetic-neuro-developmental-diseases | nan | nan | (RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) and Stoke Therapeutics, Inc. (STOK), said on Monday that they have signed a collaboration to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neuro-developmental diseases of the central nervous system.
The collaboration includes SYNGAP1 syndrome, Rett syndrome (MECP2), and an undisclosed neurodevelopmental target of mutual interest.
Under the terms of the deal, Stoke will receive an upfront payment of $60 million from Acadia and is eligible to receive up to $907 million in milestones as well as royalties on future sales.
For the SYNGAP1 program, the two parties will jointly share global research, development and commercialization responsibilities and share 50/50 in all worldwide costs and future profits.
In addition, Stoke is eligible to receive potential development, regulatory, first commercial sales and sales milestones.
For the Rett syndrome (MECP2) and the undisclosed neurodevelopmental program, Stoke will lead research and pre-clinical development activities, while Acadia will lead clinical development and commercialization activities.
Acadia will fully fund the research and pre-clinical development activities related to these two targets and Stoke is eligible to receive potential development, regulatory, first commercial sales and sales milestones as well as tiered royalty payments on worldwide sales starting in the mid-single digit range and escalating to the mid-teens based on revenue levels.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) and Stoke Therapeutics, Inc. (STOK), said on Monday that they have signed a collaboration to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neuro-developmental diseases of the central nervous system. For the Rett syndrome (MECP2) and the undisclosed neurodevelopmental program, Stoke will lead research and pre-clinical development activities, while Acadia will lead clinical development and commercialization activities. Acadia will fully fund the research and pre-clinical development activities related to these two targets and Stoke is eligible to receive potential development, regulatory, first commercial sales and sales milestones as well as tiered royalty payments on worldwide sales starting in the mid-single digit range and escalating to the mid-teens based on revenue levels. | For the Rett syndrome (MECP2) and the undisclosed neurodevelopmental program, Stoke will lead research and pre-clinical development activities, while Acadia will lead clinical development and commercialization activities. Acadia will fully fund the research and pre-clinical development activities related to these two targets and Stoke is eligible to receive potential development, regulatory, first commercial sales and sales milestones as well as tiered royalty payments on worldwide sales starting in the mid-single digit range and escalating to the mid-teens based on revenue levels. (RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) and Stoke Therapeutics, Inc. (STOK), said on Monday that they have signed a collaboration to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neuro-developmental diseases of the central nervous system. | For the Rett syndrome (MECP2) and the undisclosed neurodevelopmental program, Stoke will lead research and pre-clinical development activities, while Acadia will lead clinical development and commercialization activities. Acadia will fully fund the research and pre-clinical development activities related to these two targets and Stoke is eligible to receive potential development, regulatory, first commercial sales and sales milestones as well as tiered royalty payments on worldwide sales starting in the mid-single digit range and escalating to the mid-teens based on revenue levels. (RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) and Stoke Therapeutics, Inc. (STOK), said on Monday that they have signed a collaboration to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neuro-developmental diseases of the central nervous system. | (RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) and Stoke Therapeutics, Inc. (STOK), said on Monday that they have signed a collaboration to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neuro-developmental diseases of the central nervous system. For the Rett syndrome (MECP2) and the undisclosed neurodevelopmental program, Stoke will lead research and pre-clinical development activities, while Acadia will lead clinical development and commercialization activities. Acadia will fully fund the research and pre-clinical development activities related to these two targets and Stoke is eligible to receive potential development, regulatory, first commercial sales and sales milestones as well as tiered royalty payments on worldwide sales starting in the mid-single digit range and escalating to the mid-teens based on revenue levels. |
35768.0 | 2021-12-30 00:00:00 UTC | Interesting ACAD Put And Call Options For February 2022 | ACAD | https://www.nasdaq.com/articles/interesting-acad-put-and-call-options-for-february-2022-0 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the February 2022 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new February 2022 contracts and identified one put and one call contract of particular interest.
The put contract at the $22.50 strike price has a current bid of $1.20. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $22.50, but will also collect the premium, putting the cost basis of the shares at $21.30 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $23.99/share today.
Because the $22.50 strike represents an approximate 6% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 5.33% return on the cash commitment, or 45.27% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.50 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $1.55. If an investor was to purchase shares of ACAD stock at the current price level of $23.99/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $25.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 10.67% if the stock gets called away at the February 2022 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red:
Considering the fact that the $25.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 6.46% boost of extra return to the investor, or 54.84% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $23.99) to be 85%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the February 2022 expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the February 2022 expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $1.55. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the February 2022 expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $1.55. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the February 2022 expiration. |
35769.0 | 2021-12-23 00:00:00 UTC | Interesting ACAD Put And Call Options For February 2022 | ACAD | https://www.nasdaq.com/articles/interesting-acad-put-and-call-options-for-february-2022 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the February 2022 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new February 2022 contracts and identified one put and one call contract of particular interest.
The put contract at the $22.50 strike price has a current bid of 25 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $22.50, but will also collect the premium, putting the cost basis of the shares at $22.25 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $24.41/share today.
Because the $22.50 strike represents an approximate 8% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 1.11% return on the cash commitment, or 9.43% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.50 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $1.10. If an investor was to purchase shares of ACAD stock at the current price level of $24.41/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $25.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 6.92% if the stock gets called away at the February 2022 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red:
Considering the fact that the $25.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 4.51% boost of extra return to the investor, or 38.25% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $24.41) to be 85%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the February 2022 expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the February 2022 expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $1.10. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the February 2022 expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $1.10. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the February 2022 expiration. |
35770.0 | 2021-12-22 00:00:00 UTC | Acadia Pharmaceuticals Inc Shares Close the Day 20.8% Lower - Daily Wrap | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-inc-shares-close-the-day-20.8-lower-daily-wrap | nan | nan | Acadia Pharmaceuticals Inc (ACAD) shares closed today 20.8% lower than it did at the end of yesterday. The stock is currently down 49.3% year-to-date, down 51.0% over the past 12 months, and down 5.2% over the past five years. Today, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 1.8%.
Trading Activity
Shares traded as high as $27.19 and as low as $20.84 this week.
Shares closed 62.5% below its 52-week high and 36.8% above its 52-week low.
Trading volume this week was 45.3% higher than the 10-day average and 105.5% higher than the 30-day average.
Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4.
Technical Indicators
The Relative Strength Index (RSI) on the stock was between 30 and 70.
MACD, a trend-following momentum indicator, indicates an upward trend.
The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance
The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis
The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis
The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis
Per Group Comparative Performance
The company's stock price performance year-to-date lags the peer average by -274.5%
The company's stock price performance over the past 12 months lags the peer average by -293.4%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals Inc (ACAD) shares closed today 20.8% lower than it did at the end of yesterday. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. | Acadia Pharmaceuticals Inc (ACAD) shares closed today 20.8% lower than it did at the end of yesterday. Today, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 1.8%. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -274.5% The company's stock price performance over the past 12 months lags the peer average by -293.4% | Acadia Pharmaceuticals Inc (ACAD) shares closed today 20.8% lower than it did at the end of yesterday. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -274.5% The company's stock price performance over the past 12 months lags the peer average by -293.4% This story was produced by the Kwhen Automated News Generator. | Acadia Pharmaceuticals Inc (ACAD) shares closed today 20.8% lower than it did at the end of yesterday. Shares closed 62.5% below its 52-week high and 36.8% above its 52-week low. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. |
35771.0 | 2021-12-22 00:00:00 UTC | Why Acadia Pharmaceuticals Stock Climbed More Than 10% Wednesday | ACAD | https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-stock-climbed-more-than-10-wednesday | nan | nan | What happened
Acadia Pharmaceuticals (NASDAQ: ACAD), a mid-cap biotech company that focuses on neuroscience therapies, saw its shares rise 10.6% on Wednesday. The stock has been volatile, with a 52-week low of $15.68 and a 52-week high of $55.90, and is down more than 55% for the year.
Image source: Getty Images.
So what
It was a classic bounce back, as a reaction to a possible overreaction. The stock lost nearly $5 on Tuesday, dropping from its high of $25.29 and going for as low as $20.84. The catalyst for the fall was the concern investors had over the decision Acadia announced after the market closed on Monday. It plans to resubmit its supplemental New Drug Application (sNDA) for Nuplazid (pimavanserin), as a treatment for hallucinations and delusions associated with dementia. The company said it planned the resubmission, based on clinical data, for the first quarter of next year.
The company said the resubmission is intended to show that Nuplazid provides a clinically meaningful benefit to dementia patients, without damaging cognition or motor function.
The therapy is already approved to treat hallucinations and delusions connected with Parkinson's disease psychosis. But in April, Acadia received a Complete Response Letter from the Food and Drug Administration declining Nuplazid's use for dementia, noting problems with the studies for the drug in dementia patients, including a lack of statistical significance in some of the subgroups of patients in the study and too few patients with less-common dementia subtypes in the study.
Now what
While Nuplazid is the company's only marketed drug, it does have several other therapies in its pipeline, including trofinetide for Rett syndrome. The biotech company has already completed a phase 3 trial for trofinetide and says it plans to submit a New Drug Application in mid-2022. Acadia also has a two early-stage therapies, ACP-044, a non-opioid analgesic, and ACP-319, a drug designed to improve cognitive function and alleviate other neuropsychiatric symptoms associated with various central nervous system disorders. The company also is looking to expand Nuplazid's label as an anti-hallucination drug for schizophrenia patients.
Looking at the company's financials, it's clear that it needs to expand Nuplazid's label or hope that trofinetide is approved. The company did report $131.6 million in revenue in the third quarter, all from Nuplazid, and up 9% year over year. The company has significantly tightened its belt, but it is still losing money. It reported a net loss of $14.5 million in the quarter, compared to a loss of $84.7 million in the same period last year. The company has time to become profitable, however, with enough cash ($540 million) to last more than eight years at the current burn rate.
10 stocks we like better than Acadia Pharmaceuticals
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 16, 2021
Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Acadia Pharmaceuticals (NASDAQ: ACAD), a mid-cap biotech company that focuses on neuroscience therapies, saw its shares rise 10.6% on Wednesday. Acadia also has a two early-stage therapies, ACP-044, a non-opioid analgesic, and ACP-319, a drug designed to improve cognitive function and alleviate other neuropsychiatric symptoms associated with various central nervous system disorders. The catalyst for the fall was the concern investors had over the decision Acadia announced after the market closed on Monday. | What happened Acadia Pharmaceuticals (NASDAQ: ACAD), a mid-cap biotech company that focuses on neuroscience therapies, saw its shares rise 10.6% on Wednesday. But in April, Acadia received a Complete Response Letter from the Food and Drug Administration declining Nuplazid's use for dementia, noting problems with the studies for the drug in dementia patients, including a lack of statistical significance in some of the subgroups of patients in the study and too few patients with less-common dementia subtypes in the study. The catalyst for the fall was the concern investors had over the decision Acadia announced after the market closed on Monday. | But in April, Acadia received a Complete Response Letter from the Food and Drug Administration declining Nuplazid's use for dementia, noting problems with the studies for the drug in dementia patients, including a lack of statistical significance in some of the subgroups of patients in the study and too few patients with less-common dementia subtypes in the study. What happened Acadia Pharmaceuticals (NASDAQ: ACAD), a mid-cap biotech company that focuses on neuroscience therapies, saw its shares rise 10.6% on Wednesday. The catalyst for the fall was the concern investors had over the decision Acadia announced after the market closed on Monday. | * They just revealed what they believe are the ten best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! What happened Acadia Pharmaceuticals (NASDAQ: ACAD), a mid-cap biotech company that focuses on neuroscience therapies, saw its shares rise 10.6% on Wednesday. The catalyst for the fall was the concern investors had over the decision Acadia announced after the market closed on Monday. |
35772.0 | 2021-12-22 00:00:00 UTC | Health Care Sector Update for 12/22/2021: BVXV,ACAD,CODX,NVST | ACAD | https://www.nasdaq.com/articles/health-care-sector-update-for-12-22-2021%3A-bvxvacadcodxnvst | nan | nan | Health care stocks were finishing just under their intra-day highs this afternoon, with the NYSE Health Care Index rising 1.0% while the SPDR Health Care Select Sector ETF (XLV) also was up 0.8%.
The Nasdaq Biotechnology index, however, was sinking 0.7%.
In company news, BiondVax Pharmaceuticals (BVXV) raced 85% higher after the biopharmaceuticals firm said it was working with the Max Planck Society and the University Medical Center Gottingen in Germany to develop and commercialize nanosized antibodies to fight COVID-19 and part of a broader collaboration expected to be announced next month to commercialize nanosized antibodies for several other disease indications.
Acadia Pharmaceuticals (ACAD) rose more than 11% after Canaccord Genuity Wednesday raised its price target for the drug maker's shares by $4 to $30 apiece and reiterated its hold rating for the company's stock.
Envista Holdings (NVST) rose 7% after the dental supplies company Wednesday announced its purchase of Carestream Dental's intra-oral scanner business for $600 million, subject to regulatory approvals.
Co-Diagnostics (CODX) added 6.3% after the molecular diagnostics company Wednesday said it was acquiring Idaho Molecular and Advanced Conceptions after collaborating with the privately-held manufacturer on the development of its YourTest PCR device. Under terms of the proposed acquisition, Co-Diagnostics will issue about 4.7 million common shares of common stock along with warrants to buy up to 465,000 additional shares.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (ACAD) rose more than 11% after Canaccord Genuity Wednesday raised its price target for the drug maker's shares by $4 to $30 apiece and reiterated its hold rating for the company's stock. In company news, BiondVax Pharmaceuticals (BVXV) raced 85% higher after the biopharmaceuticals firm said it was working with the Max Planck Society and the University Medical Center Gottingen in Germany to develop and commercialize nanosized antibodies to fight COVID-19 and part of a broader collaboration expected to be announced next month to commercialize nanosized antibodies for several other disease indications. Co-Diagnostics (CODX) added 6.3% after the molecular diagnostics company Wednesday said it was acquiring Idaho Molecular and Advanced Conceptions after collaborating with the privately-held manufacturer on the development of its YourTest PCR device. | Acadia Pharmaceuticals (ACAD) rose more than 11% after Canaccord Genuity Wednesday raised its price target for the drug maker's shares by $4 to $30 apiece and reiterated its hold rating for the company's stock. In company news, BiondVax Pharmaceuticals (BVXV) raced 85% higher after the biopharmaceuticals firm said it was working with the Max Planck Society and the University Medical Center Gottingen in Germany to develop and commercialize nanosized antibodies to fight COVID-19 and part of a broader collaboration expected to be announced next month to commercialize nanosized antibodies for several other disease indications. Envista Holdings (NVST) rose 7% after the dental supplies company Wednesday announced its purchase of Carestream Dental's intra-oral scanner business for $600 million, subject to regulatory approvals. | Acadia Pharmaceuticals (ACAD) rose more than 11% after Canaccord Genuity Wednesday raised its price target for the drug maker's shares by $4 to $30 apiece and reiterated its hold rating for the company's stock. Health care stocks were finishing just under their intra-day highs this afternoon, with the NYSE Health Care Index rising 1.0% while the SPDR Health Care Select Sector ETF (XLV) also was up 0.8%. In company news, BiondVax Pharmaceuticals (BVXV) raced 85% higher after the biopharmaceuticals firm said it was working with the Max Planck Society and the University Medical Center Gottingen in Germany to develop and commercialize nanosized antibodies to fight COVID-19 and part of a broader collaboration expected to be announced next month to commercialize nanosized antibodies for several other disease indications. | Acadia Pharmaceuticals (ACAD) rose more than 11% after Canaccord Genuity Wednesday raised its price target for the drug maker's shares by $4 to $30 apiece and reiterated its hold rating for the company's stock. Health care stocks were finishing just under their intra-day highs this afternoon, with the NYSE Health Care Index rising 1.0% while the SPDR Health Care Select Sector ETF (XLV) also was up 0.8%. The Nasdaq Biotechnology index, however, was sinking 0.7%. |
35773.0 | 2021-12-21 00:00:00 UTC | Health Care Sector Update for 12/21/2021: AQST,ARDS,ACAD,ALDX | ACAD | https://www.nasdaq.com/articles/health-care-sector-update-for-12-21-2021%3A-aqstardsacadaldx | nan | nan | Health care stocks held small gains ahead of Tuesday's close, with the NYSE Health Care Index rising 0.4% and the Health Care Select Sector SPDR ETF (XLV) adding about 0.1%.
The Nasdaq Biotechnology index rose 0.3%.
In company news, Aquestive Therapeutics (AQST) shed more than 29% after saying the US Food and Drug Administration has told the company it will not be able to issue a decision on the company's Libervant seizure medication by the Dec. 23 regulatory deadline. In its notice to the company, the FDA did not provide a timeline for completing its review, adding it likely will not need more data.
Acadia Pharmaceuticals (ACAD) fell almost 21% after saying it expects to resubmit a supplemental new drug application for its pimavanserin drug candidate early next year with a narrowed indication as a treatment of hallucinations and delusions associated with Alzheimer's disease. The new submission likely will include data from two studies expected to meet their primary endpoints, in addition to analyses addressing concerns raised by US regulators in a complete response letter to the company.
Aldeyra Therapeutics (ALDX) shares sank 21% after the company said its reproxalap drug candidate failed to meet its primary endpoint in a phase 3 trial for dry eye disease.
Among gainers, Aridis Pharmaceuticals (ARDS) was 11% higher, easing from a nearly 71% advance earlier Tuesday that followed the biopharmaceuticals company saying its AR-701 monoclonal antibody cocktail was "broadly reactive" against the omicron and other COVID-19 variants with "no loss in affinity as compared to the original Wuhan strain."
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (ACAD) fell almost 21% after saying it expects to resubmit a supplemental new drug application for its pimavanserin drug candidate early next year with a narrowed indication as a treatment of hallucinations and delusions associated with Alzheimer's disease. The new submission likely will include data from two studies expected to meet their primary endpoints, in addition to analyses addressing concerns raised by US regulators in a complete response letter to the company. Aldeyra Therapeutics (ALDX) shares sank 21% after the company said its reproxalap drug candidate failed to meet its primary endpoint in a phase 3 trial for dry eye disease. | Acadia Pharmaceuticals (ACAD) fell almost 21% after saying it expects to resubmit a supplemental new drug application for its pimavanserin drug candidate early next year with a narrowed indication as a treatment of hallucinations and delusions associated with Alzheimer's disease. Health care stocks held small gains ahead of Tuesday's close, with the NYSE Health Care Index rising 0.4% and the Health Care Select Sector SPDR ETF (XLV) adding about 0.1%. The new submission likely will include data from two studies expected to meet their primary endpoints, in addition to analyses addressing concerns raised by US regulators in a complete response letter to the company. | Acadia Pharmaceuticals (ACAD) fell almost 21% after saying it expects to resubmit a supplemental new drug application for its pimavanserin drug candidate early next year with a narrowed indication as a treatment of hallucinations and delusions associated with Alzheimer's disease. Health care stocks held small gains ahead of Tuesday's close, with the NYSE Health Care Index rising 0.4% and the Health Care Select Sector SPDR ETF (XLV) adding about 0.1%. In company news, Aquestive Therapeutics (AQST) shed more than 29% after saying the US Food and Drug Administration has told the company it will not be able to issue a decision on the company's Libervant seizure medication by the Dec. 23 regulatory deadline. | Acadia Pharmaceuticals (ACAD) fell almost 21% after saying it expects to resubmit a supplemental new drug application for its pimavanserin drug candidate early next year with a narrowed indication as a treatment of hallucinations and delusions associated with Alzheimer's disease. Health care stocks held small gains ahead of Tuesday's close, with the NYSE Health Care Index rising 0.4% and the Health Care Select Sector SPDR ETF (XLV) adding about 0.1%. The new submission likely will include data from two studies expected to meet their primary endpoints, in addition to analyses addressing concerns raised by US regulators in a complete response letter to the company. |
35774.0 | 2021-12-21 00:00:00 UTC | Health Care Sector Update for 12/21/2021: ARDS,ACAD,ALDX | ACAD | https://www.nasdaq.com/articles/health-care-sector-update-for-12-21-2021%3A-ardsacadaldx | nan | nan | Health care stocks were edging higher Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR ETF (XLV) both up about 0.2%.
The Nasdaq Biotechnology index gained 0.1%.
In company news, Aridis Pharmaceuticals (ARDS) was more than 20% higher, easing from a nearly 71% advance earlier Tuesday that followed the biopharmaceuticals company saying its AR-701 monoclonal antibody cocktail was "broadly reactive" against omicron and other COVID-19 variants with "no loss in affinity as compared to the original Wuhan strain."
Acadia Pharmaceuticals (ACAD) shares fell more than 22% after the company said it expects to resubmit a supplemental new drug application for its pimavanserin drug candidate early next year with a narrowed indication for the potential treatment of hallucinations and delusions associated with Alzheimer's disease. The new submission is to include data from two studies expected to meet their primary endpoints in addition to analyses expected to address concerns raised by the US Food and Drug Administration in the agency's prior complete response letter to the company.
Aldeyra Therapeutics (ALDX) was sinking almost 52% after saying its reproxalap drug candidate failed to meet its primary endpoint in a phase 3 trial for dry eye disease.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (ACAD) shares fell more than 22% after the company said it expects to resubmit a supplemental new drug application for its pimavanserin drug candidate early next year with a narrowed indication for the potential treatment of hallucinations and delusions associated with Alzheimer's disease. In company news, Aridis Pharmaceuticals (ARDS) was more than 20% higher, easing from a nearly 71% advance earlier Tuesday that followed the biopharmaceuticals company saying its AR-701 monoclonal antibody cocktail was "broadly reactive" against omicron and other COVID-19 variants with "no loss in affinity as compared to the original Wuhan strain." Aldeyra Therapeutics (ALDX) was sinking almost 52% after saying its reproxalap drug candidate failed to meet its primary endpoint in a phase 3 trial for dry eye disease. | Acadia Pharmaceuticals (ACAD) shares fell more than 22% after the company said it expects to resubmit a supplemental new drug application for its pimavanserin drug candidate early next year with a narrowed indication for the potential treatment of hallucinations and delusions associated with Alzheimer's disease. Health care stocks were edging higher Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR ETF (XLV) both up about 0.2%. The new submission is to include data from two studies expected to meet their primary endpoints in addition to analyses expected to address concerns raised by the US Food and Drug Administration in the agency's prior complete response letter to the company. | Acadia Pharmaceuticals (ACAD) shares fell more than 22% after the company said it expects to resubmit a supplemental new drug application for its pimavanserin drug candidate early next year with a narrowed indication for the potential treatment of hallucinations and delusions associated with Alzheimer's disease. Health care stocks were edging higher Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR ETF (XLV) both up about 0.2%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (ACAD) shares fell more than 22% after the company said it expects to resubmit a supplemental new drug application for its pimavanserin drug candidate early next year with a narrowed indication for the potential treatment of hallucinations and delusions associated with Alzheimer's disease. Health care stocks were edging higher Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR ETF (XLV) both up about 0.2%. The Nasdaq Biotechnology index gained 0.1%. |
35775.0 | 2021-12-09 00:00:00 UTC | Interesting ACAD Put And Call Options For January 2022 | ACAD | https://www.nasdaq.com/articles/interesting-acad-put-and-call-options-for-january-2022 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the January 2022 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new January 2022 contracts and identified one put and one call contract of particular interest.
The put contract at the $22.50 strike price has a current bid of $2.00. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $22.50, but will also collect the premium, putting the cost basis of the shares at $20.50 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $22.88/share today.
Because the $22.50 strike represents an approximate 2% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 8.89% return on the cash commitment, or 64.89% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.50 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $1.55. If an investor was to purchase shares of ACAD stock at the current price level of $22.88/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $25.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 16.04% if the stock gets called away at the January 2022 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red:
Considering the fact that the $25.00 strike represents an approximate 9% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 6.77% boost of extra return to the investor, or 49.45% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $22.88) to be 80%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 9% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the January 2022 expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 9% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the January 2022 expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $1.55. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 9% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the January 2022 expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $1.55. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 9% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the January 2022 expiration. |
35776.0 | 2021-12-08 00:00:00 UTC | Is It Time to Buy the Nasdaq's 11 Worst-Performing Stocks of 2021? | ACAD | https://www.nasdaq.com/articles/is-it-time-to-buy-the-nasdaqs-11-worst-performing-stocks-of-2021 | nan | nan | It's been a great year for the overall market. The Nasdaq Composite (NASDAQINDEX: ^IXIC) is up a healthy 18% since the end of 2020, and is seemingly still going strong.
Not every Nasdaq-listed name, however, is participating in this rally despite the exchange's affinity for high-growth technology names. In fact, more than half of the Nasdaq's stocks are actually down year to date, even if only by a little. Of course, this spotty weakness has some bargain-hungry investors licking their chops.
Before plowing into one of these beaten-down tickers just because it's been beaten down, though, it might be wise to take a step back and look at the bigger picture.
Down, and maybe even out
Don't sweat the fact that the majority of Nasdaq-listed stocks are in the red through 2021 thus far. A bunch of those tickers are small-caps and micro-caps, which can often be expected to underperform en route to bankruptcy and/or a delisting. Limiting the look to the Nasdaq's mid-caps and bigger (market caps of more than $2 billion) dramatically improves the number of tickers that are up year to date. And, even among those remaining laggards, there are several one-off train wrecks most investors likely saw coming.
For instance, shares of ContextLogic (NASDAQ: WISH) (you know it as online shopping website wish.com) are down 82% since last December's public offering, as investors increasingly ignore the early hype surrounding that IPO and turn their focus on reality-rooted concerns regarding its actual growth prospects. It's an all-too-common tale. Meanwhile, while fitness equipment made by Peloton Interactive (NASDAQ: PTON) was all the rage when the pandemic was in full swing last year, the contagion's containment this year has deflated demand for its stock. Its shares are off 71% year to date.
Beyond ContextLogic's and Peloton's implosions, though, there are several identifiable themes among the Nasdaq's biggest 2021 losers to date.
One of those themes is extreme weakness among Chinese stocks, and Chinese technology stocks in particular. As of Monday, Chindata (NASDAQ: CD), iQIYI (NASDAQ: IQ), Pinduoduo (NASDAQ: PDD), and Kingsoft Cloud (NASDAQ: KC) were all down by more than 60% since the end of 2020.
Some of the weakness can be attributed to business-related headwinds, not the least of which are tougher comps created by a surge in business in the midst of last year's pandemic-prompted lockdowns. Mostly, though, blame China's ride-hailing company DiDi Global (NYSE: DIDI). DiDi ran afoul of several of China's regulatory agencies when it sought a public listing on a U.S. exchange in June, defying Beijing's scrutiny of the company underway at the time.
The decision reaccelerated a months-long crackdown of China's leading technology companies, ultimately leading to the recently planned delisting of DiDi Global's NYSE listing and relisting at a Hong Kong exchange. Some observers suggest DiDi's decision could be mirrored by other Chinese companies with U.S.-listed stocks, cutting off a key source of funding as well as a big source of demand for their shares. These stocks are simply trapped by uncertainty in the meantime.
Image source: Getty Images.
Several of the Nasdaq's biotechnology listings have also lost an inordinate amount of their value this year. As of Monday, Editas Medicine (NASDAQ: EDIT), Acadia Pharmaceuticals (NASDAQ: ACAD), AbCellera Biologics (NASDAQ: ABCL), and TG Therapeutics (NASDAQ: TGTX) are down by 60%, 65%, 65%, and 70% (respectively) since the end of 2020.
The reasons for these steep sell-offs are as varied as the four companies in question. In all four cases, though, the sell-offs are ultimately rooted in worries that these biopharma companies' flagship in-development drugs aren't apt to live up to once-lofty expectations.
TG Therapeutics' cancer-fighting umbralisib, for example, is scheduled to be scrutinized by the U.S. Food and Drug Administration (FDA)'s Oncologic Drugs Advisory Committee (or ODAC) before the agency makes a final decision on the therapy. The usually unnecessary step doesn't preclude the possibility of an eventual approval, but it does cast a shadow of doubt on the FDA's opinion of the drug's safety.
Finally, while a slew of biotech stocks are well into the red this year, several non-biotech Nasdaq-listed healthcare stocks are also deep in the hole. Shares of healthcare plan provider Clover Health Investments (NASDAQ: CLOV) are off by 74% as of early December. Health clinic chain 1Life Healthcare (NASDAQ: ONEM) and telehealth platform LifeStance (NASDAQ: LFST) are down 64% and 60%.
These particular plunges aren't tough to explain. Telehealth visits facilitated by LifeStance last year, for example, aren't quite as necessary now that COVID-19 vaccines are making a dent in the pandemic. Clover Health shares are down big-time, but much like ContextLogic, this stock is suffering the post-IPO blues stemming from its well-hyped debut via a special purpose acquisition company (or SPAC) merger completed in January.
1Life Healthcare shares are down so much mostly because it was up so much in 2020, also whipped around by the unusual circumstances created by the coronavirus pandemic. The thing is, those unusual circumstances are why you should view all of these losses (along with the healthcare sector's overall 2021 weakness) as one bigger-picture trend.
Buy, sell, or hold?
So now what? Are these drubbings an opportunity, or a warning? As always, it depends.
The broad weakness from the healthcare sector is indeed a buying opportunity. Investors have sought out other sectors at the expense of healthcare stocks over the course of the past several months. All sectors constantly fall in and out of favor, though, so shopping for a new name from this group is a smart idea at this time.
^SPX data by YCharts
Just be picky when making those selections, as none of the four aforementioned Nasdaq-listed biotech stocks are worth the risk here. That's not to suggest these tickers can't rebound. It's simply to say their recent weakness is a warning of sorts that shouldn't be ignored. It's not unusual for developmental biotech names to crash and burn, having never really become what many investors hoped they might.
As for all the Nasdaq's Chinese stocks, the four in question here (along with most of the others not discussed) are indeed hands-off until further notice. Although not every one of them is destined for a delisting, every one of them is at serious risk of being scrutinized into submission by China's regulators. Without even having an inkling of what their future holds, the smart decision is simply steering clear if you're not in any of these names right now.
The possibility that the broad market itself could soon be bumping into an economic headwind, of course, only makes most of these laggards even less ownable here.
10 stocks we like better than ContextLogic Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and ContextLogic Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 10, 2021
James Brumley has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Editas Medicine and Peloton Interactive. The Motley Fool recommends AbCellera Biologics Inc., TG Therapeutics, and iQiyi. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As of Monday, Editas Medicine (NASDAQ: EDIT), Acadia Pharmaceuticals (NASDAQ: ACAD), AbCellera Biologics (NASDAQ: ABCL), and TG Therapeutics (NASDAQ: TGTX) are down by 60%, 65%, 65%, and 70% (respectively) since the end of 2020. For instance, shares of ContextLogic (NASDAQ: WISH) (you know it as online shopping website wish.com) are down 82% since last December's public offering, as investors increasingly ignore the early hype surrounding that IPO and turn their focus on reality-rooted concerns regarding its actual growth prospects. DiDi ran afoul of several of China's regulatory agencies when it sought a public listing on a U.S. exchange in June, defying Beijing's scrutiny of the company underway at the time. | As of Monday, Editas Medicine (NASDAQ: EDIT), Acadia Pharmaceuticals (NASDAQ: ACAD), AbCellera Biologics (NASDAQ: ABCL), and TG Therapeutics (NASDAQ: TGTX) are down by 60%, 65%, 65%, and 70% (respectively) since the end of 2020. The decision reaccelerated a months-long crackdown of China's leading technology companies, ultimately leading to the recently planned delisting of DiDi Global's NYSE listing and relisting at a Hong Kong exchange. The Motley Fool recommends AbCellera Biologics Inc., TG Therapeutics, and iQiyi. | As of Monday, Editas Medicine (NASDAQ: EDIT), Acadia Pharmaceuticals (NASDAQ: ACAD), AbCellera Biologics (NASDAQ: ABCL), and TG Therapeutics (NASDAQ: TGTX) are down by 60%, 65%, 65%, and 70% (respectively) since the end of 2020. As of Monday, Chindata (NASDAQ: CD), iQIYI (NASDAQ: IQ), Pinduoduo (NASDAQ: PDD), and Kingsoft Cloud (NASDAQ: KC) were all down by more than 60% since the end of 2020. Finally, while a slew of biotech stocks are well into the red this year, several non-biotech Nasdaq-listed healthcare stocks are also deep in the hole. | As of Monday, Editas Medicine (NASDAQ: EDIT), Acadia Pharmaceuticals (NASDAQ: ACAD), AbCellera Biologics (NASDAQ: ABCL), and TG Therapeutics (NASDAQ: TGTX) are down by 60%, 65%, 65%, and 70% (respectively) since the end of 2020. In fact, more than half of the Nasdaq's stocks are actually down year to date, even if only by a little. The broad weakness from the healthcare sector is indeed a buying opportunity. |
35777.0 | 2021-12-07 00:00:00 UTC | Acadia Rises 21.8% on Positive Lavender Study Results | ACAD | https://www.nasdaq.com/articles/acadia-rises-21.8-on-positive-lavender-study-results | nan | nan | Shares of Acadia Pharmaceuticals Inc. (ACAD) rallied 21.8% in Monday’s extended trading session after the biopharmaceutical company revealed positive top-line results for the Phase 3 Lavender study of its drug, trofinetide, to treat Rett syndrome.
Rett syndrome is a rare, debilitating neurological disorder found primarily in females. It is caused by mutations on the X chromosome on a gene called MECP2. Rett syndrome causes problems in brain function that are responsible for cognitive, sensory, emotional, motor and autonomic function.
Study Findings
The 12-week placebo-controlled study was undertaken on 187 girls and young women aged 5-20 years. The results reflect a statistically significant improvement over placebo for both co-primary endpoints, which included caregiver and physician assessments.
Further, the drug displayed statistically significant separation over placebo on the key secondary endpoint, the Communication and Symbolic Behavior Scales Developmental Profile Infant-Toddler Checklist. (See Acadia stock chart on TipRanks)
However, side effects such as diarrhea and vomiting were witnessed in 17.2% of patients, as compared to 2.1% of patients in the placebo group. Acadia also informed that over 95% of participants have elected to roll over to the Lilac open-label extension study.
Official Comment
The Senior Vice-President, Chief Scientific Officer and Head of Rare Disease at Acadia, Kathie Bishop (Ph.D.), said, “The consistent efficacy across primary and key secondary endpoints in the Lavender study demonstrates the potential of trofinetide to treat Rett syndrome… We look forward to continuing this important work and potentially delivering an FDA-approved treatment for this rare and devastating disease.”
In the first quarter of 2022, Acadia plans to attend a pre-NDA meeting with the U.S. Food and Drug Administration, seeking to submit a New Drug Application around mid-year 2022.
See Insiders’ Hot Stocks on TipRanks >>
Stock Rating
Following the news, JMP Securities analyst Jason Butler reiterated a Buy rating on Acadia and raised the price target to $39 (101% upside potential) from $35.
Butler noted, “Positive Phase 3 results for trofinetide in Rett Syndrome appear robust and meaningful, supporting the drug could play an important role in the high unmet need.”
“We now include what we view as a potentially conservative peak U.S. opportunity of ~$400-$500 million as we look to gain additional granularity on the opportunity in coming months, including feedback from prospective prescribers,” the analyst added.
The rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating based on 3 Buys and 6 Holds. The average Acadia price target of $25.50 implies 31.4% upside potential.
Hedge Fund Trading Activity
TipRanks’ Hedge Fund Trading Activity tool shows that confidence in Acadia is currently Neutral, as the cumulative change in holdings across 2 hedge funds that were active in the last quarter was a decrease of 2.3 million shares.
Related News:
Bright Health to Fund Growth by Raising $750M
vTv Therapeutics Announces Restructuring; Shares Gain
Merck Strikes Deal to Provide Molnupiravir to Canadian Government
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of Acadia Pharmaceuticals Inc. (ACAD) rallied 21.8% in Monday’s extended trading session after the biopharmaceutical company revealed positive top-line results for the Phase 3 Lavender study of its drug, trofinetide, to treat Rett syndrome. Official Comment The Senior Vice-President, Chief Scientific Officer and Head of Rare Disease at Acadia, Kathie Bishop (Ph.D.), said, “The consistent efficacy across primary and key secondary endpoints in the Lavender study demonstrates the potential of trofinetide to treat Rett syndrome… We look forward to continuing this important work and potentially delivering an FDA-approved treatment for this rare and devastating disease.” In the first quarter of 2022, Acadia plans to attend a pre-NDA meeting with the U.S. Food and Drug Administration, seeking to submit a New Drug Application around mid-year 2022. (See Acadia stock chart on TipRanks) However, side effects such as diarrhea and vomiting were witnessed in 17.2% of patients, as compared to 2.1% of patients in the placebo group. | Shares of Acadia Pharmaceuticals Inc. (ACAD) rallied 21.8% in Monday’s extended trading session after the biopharmaceutical company revealed positive top-line results for the Phase 3 Lavender study of its drug, trofinetide, to treat Rett syndrome. See Insiders’ Hot Stocks on TipRanks >> Stock Rating Following the news, JMP Securities analyst Jason Butler reiterated a Buy rating on Acadia and raised the price target to $39 (101% upside potential) from $35. Hedge Fund Trading Activity TipRanks’ Hedge Fund Trading Activity tool shows that confidence in Acadia is currently Neutral, as the cumulative change in holdings across 2 hedge funds that were active in the last quarter was a decrease of 2.3 million shares. | Official Comment The Senior Vice-President, Chief Scientific Officer and Head of Rare Disease at Acadia, Kathie Bishop (Ph.D.), said, “The consistent efficacy across primary and key secondary endpoints in the Lavender study demonstrates the potential of trofinetide to treat Rett syndrome… We look forward to continuing this important work and potentially delivering an FDA-approved treatment for this rare and devastating disease.” In the first quarter of 2022, Acadia plans to attend a pre-NDA meeting with the U.S. Food and Drug Administration, seeking to submit a New Drug Application around mid-year 2022. Hedge Fund Trading Activity TipRanks’ Hedge Fund Trading Activity tool shows that confidence in Acadia is currently Neutral, as the cumulative change in holdings across 2 hedge funds that were active in the last quarter was a decrease of 2.3 million shares. Shares of Acadia Pharmaceuticals Inc. (ACAD) rallied 21.8% in Monday’s extended trading session after the biopharmaceutical company revealed positive top-line results for the Phase 3 Lavender study of its drug, trofinetide, to treat Rett syndrome. | Shares of Acadia Pharmaceuticals Inc. (ACAD) rallied 21.8% in Monday’s extended trading session after the biopharmaceutical company revealed positive top-line results for the Phase 3 Lavender study of its drug, trofinetide, to treat Rett syndrome. See Insiders’ Hot Stocks on TipRanks >> Stock Rating Following the news, JMP Securities analyst Jason Butler reiterated a Buy rating on Acadia and raised the price target to $39 (101% upside potential) from $35. (See Acadia stock chart on TipRanks) However, side effects such as diarrhea and vomiting were witnessed in 17.2% of patients, as compared to 2.1% of patients in the placebo group. |
35778.0 | 2021-12-07 00:00:00 UTC | Health Care Sector Update for 12/07/2021: HQY, ACAD, BHG, XLV, IBB | ACAD | https://www.nasdaq.com/articles/health-care-sector-update-for-12-07-2021%3A-hqy-acad-bhg-xlv-ibb | nan | nan | Health care stocks were advancing premarket Tuesday.
The Health Care SPDR (XLV) was 0.56% higher while the iShares NASDAQ Biotechnology Index (IBB) was recently up more than 1%.
HealthEquity (HQY) was shedding over 27% in value after it reported a non-GAAP EPS of $0.35 in Q3, down from $0.41 a year earlier, but meeting analyst estimates in a Capital IQ survey.
ACADIA Pharmaceuticals (ACAD) was gaining more than 16% in value after saying patients in its Phase 3 trial of trofinetide for the treatment of Rett syndrome showed improvements in core symptoms, including being able to respond to a choice or having more freedom from repetitive hand movements.
Bright Health Group (BHG) was over 12% higher after it reiterated its 2021 revenue guidance of $4.1 billion to $4.2 billion and said it expects 2022 revenue to rise to $6.3 billion to $6.5 billion.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals (ACAD) was gaining more than 16% in value after saying patients in its Phase 3 trial of trofinetide for the treatment of Rett syndrome showed improvements in core symptoms, including being able to respond to a choice or having more freedom from repetitive hand movements. The Health Care SPDR (XLV) was 0.56% higher while the iShares NASDAQ Biotechnology Index (IBB) was recently up more than 1%. HealthEquity (HQY) was shedding over 27% in value after it reported a non-GAAP EPS of $0.35 in Q3, down from $0.41 a year earlier, but meeting analyst estimates in a Capital IQ survey. | ACADIA Pharmaceuticals (ACAD) was gaining more than 16% in value after saying patients in its Phase 3 trial of trofinetide for the treatment of Rett syndrome showed improvements in core symptoms, including being able to respond to a choice or having more freedom from repetitive hand movements. Health care stocks were advancing premarket Tuesday. The Health Care SPDR (XLV) was 0.56% higher while the iShares NASDAQ Biotechnology Index (IBB) was recently up more than 1%. | ACADIA Pharmaceuticals (ACAD) was gaining more than 16% in value after saying patients in its Phase 3 trial of trofinetide for the treatment of Rett syndrome showed improvements in core symptoms, including being able to respond to a choice or having more freedom from repetitive hand movements. HealthEquity (HQY) was shedding over 27% in value after it reported a non-GAAP EPS of $0.35 in Q3, down from $0.41 a year earlier, but meeting analyst estimates in a Capital IQ survey. Bright Health Group (BHG) was over 12% higher after it reiterated its 2021 revenue guidance of $4.1 billion to $4.2 billion and said it expects 2022 revenue to rise to $6.3 billion to $6.5 billion. | ACADIA Pharmaceuticals (ACAD) was gaining more than 16% in value after saying patients in its Phase 3 trial of trofinetide for the treatment of Rett syndrome showed improvements in core symptoms, including being able to respond to a choice or having more freedom from repetitive hand movements. Health care stocks were advancing premarket Tuesday. The Health Care SPDR (XLV) was 0.56% higher while the iShares NASDAQ Biotechnology Index (IBB) was recently up more than 1%. |
35779.0 | 2021-12-07 00:00:00 UTC | Good Stocks To Invest In Right Now? 4 Health Care Stocks To Check Out | ACAD | https://www.nasdaq.com/articles/good-stocks-to-invest-in-right-now-4-health-care-stocks-to-check-out | nan | nan | 4 Top Health Care Stocks Worth Watching Now
Health care stocks have and continue to make headway in the stock market now amidst the current pandemic. From firms directly dealing with the global coronavirus outbreak to day-to-day health care providers, investors have plenty of options. For starters, investors appear to be reacting positively to the latest findings on the Omicron variant. While this may just be preliminary data, the variant appears to be more tamed in terms of severity than initially expected. Even so, some of the biggest names in the health care industry are already looking for solutions.
In fact, GlaxoSmithKline (NYSE: GSK) and Vir Biotechnology (NASDAQ: VIR) provided a crucial update on this front earlier today. Namely, data suggests that their coronavirus vaccine, sotrovimab, retains effectiveness against the Omicron variant. On top of that, the duo also notes that the drug is also effective against “all other variants of concern defined to date by the WHO”. At the same time, there seems to be no shortage of newcomers in the industry as well. As of today, Alvotech, an Iceland-based biopharma firm, is now looking to go public via a $2.25 billion SPAC deal. With all that said, could one of these health care stocks be worth watching in thestock market today
Best Health Care Stocks For Your December 2021 Watchlist
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD)
Novavax Inc. (NASDAQ: NVAX)
Cellectis (NASDAQ: CLLS)
Intellia Therapeutics Inc. (NASDAQ: NTLA)
Acadia Pharmaceuticals Inc.
First up, we have Acadia Pharmaceuticals, a biotech company with more than 25 years of experience in the industry. It has been at the forefront of health care, bringing vital solutions to people who need them most. Also, the company has developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Specifically, its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia, and Rett syndrome. ACAD stock currently trades at $21.42 as of 2:26 p.m. ET and is up by over 10% on today’s opening bell so far.
Investors are likely responding to news that the company posted yesterday. Diving in, Acadia announced positive top-line results from its pivotal Phase 3 Lavender study. The study evaluated the efficacy and safety of trofinetide in 187 girls and young women aged 5-20 years with Rett syndrome. The 12-week placebo-controlled study demonstrated a statistically significant improvement over placebo for both co-primary endpoints. Given this piece of information, will you consider watching ACAD stock right now?
Source: TD Ameritrade TOS
[Read More] Best Lithium Battery Stocks To Buy Now? 4 To Know
Novavax Inc.
Novavax is a health care company that develops vaccines to counter serious infectious diseases. Through the discovery and commercialization of innovative vaccines, the company has developed experimental vaccines to combat Covid, seasonal influenza, RSV, Ebola, MERS, and SARS. Its NanoFlu vaccine, for instance, is a quadrivalent influenza nanoparticle vaccine that has met all primary objectives in its Phase 3 clinical trial in older results. NVAX stock currently trades at $179.82 as of 2:26 p.m. ET and is up by over 26% on today’s opening bell.
On Tuesday, the head of the European Medicines Agency (EMA) says that it could soon approve the Covid vaccine developed by Novavax. Earlier in the month, the company also announced a statement for its Omicron variant response. It is conducting ongoing studies to evaluate multiple variants and is encouraged by its current and ongoing data. The company will also begin testing whether antibodies from previously vaccinated individuals can neutralize the Omicron variant, with lab-based data expected in the coming weeks. With the excitement surrounding Novavax, is NVAX stock worth adding to your portfolio right now?
Source: TD Ameritrade TOS
[Read More] Top Stocks To Buy Now? 4 Renewable Energy Stocks For Your Watchlist
Cellectis SA
Following that, we have Cellectis, a biopharmaceutical company that develops genome-edited chimeric antigen receptor T-cell technologies as a form of cancer immunotherapy. In essence, it is pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. It also has a platform to achieve therapeutic gene editing in hemopoietic stem cells for various genetic disorders. CLLS stock currently trades $9.43 as of 2:27 p.m. ET.
Last month, it expanded a collaboration with Cytovia Therapeutics of TALEN gene-edited iPSC-derived (induced pluripotent stem cells) Natural Killer and Chimeric Antigen Receptor Natural Killer cells to include new CAR target and development in China. “We are pleased to expand the collaboration with Cellectis to enable Cytovia to develop iNK products that will leverage the high-precision of TALEN® to perform gene-editing to minimize the risk of off-target effects and unlock the full potential of NK cells as a first line of defense against cancer,” says Cytovia CEO Dr. Daniel Teper. All things considered, is CLLS stock worth buying today?
Source: TD Ameritrade TOS
[Read More] Best Growth Stocks To Buy? 4 E-Commerce Stocks To Watch
Intellia Therapeutics Inc.
Another name to consider in the health care world now would be Intellia Therapeutics. For the most part, Intellia is a leading clinical-stage genome editing company. Through its groundbreaking work with CRISPR/Cas9 tech, the company aims to develop gene-editing therapies. The likes of which Intellia conducts tests on via two key approaches. Firstly, its in vivo program employs CRISPR treatments that are injected directly into patient bloodstreams. Secondly, Intellia’s ex vivo efforts involve the use of CRISPR to treat cancer and autoimmune diseases via engineered cells. Technical details aside, investors appear to be keen on NTLA stock now.
Evidently, the company’s shares currently trade at $119.74 as of 2:27 p.m. ET. This would be after gaining by over 110% year-to-date. Regardless, Intellia does not seem to have plans to slow down anytime soon. As of late November, the company revealed plans to expand its ongoing Phase 1 study NTLA-2001. Through this expansion, Intellia will be opening up enrollment into the trials for NTLA-2001 to “adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM). CEO Dr. John Leonard notes that ATTR is a “chronic, fatal disease” that impacts vital organ function. Could all this make NTLA stock worth keeping an eye on for you?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With all that said, could one of these health care stocks be worth watching in thestock market today Best Health Care Stocks For Your December 2021 Watchlist Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Novavax Inc. (NASDAQ: NVAX) Cellectis (NASDAQ: CLLS) Intellia Therapeutics Inc. (NASDAQ: NTLA) Acadia Pharmaceuticals Inc. First up, we have Acadia Pharmaceuticals, a biotech company with more than 25 years of experience in the industry. ACAD stock currently trades at $21.42 as of 2:26 p.m. Diving in, Acadia announced positive top-line results from its pivotal Phase 3 Lavender study. | With all that said, could one of these health care stocks be worth watching in thestock market today Best Health Care Stocks For Your December 2021 Watchlist Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Novavax Inc. (NASDAQ: NVAX) Cellectis (NASDAQ: CLLS) Intellia Therapeutics Inc. (NASDAQ: NTLA) Acadia Pharmaceuticals Inc. First up, we have Acadia Pharmaceuticals, a biotech company with more than 25 years of experience in the industry. ACAD stock currently trades at $21.42 as of 2:26 p.m. Diving in, Acadia announced positive top-line results from its pivotal Phase 3 Lavender study. | With all that said, could one of these health care stocks be worth watching in thestock market today Best Health Care Stocks For Your December 2021 Watchlist Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Novavax Inc. (NASDAQ: NVAX) Cellectis (NASDAQ: CLLS) Intellia Therapeutics Inc. (NASDAQ: NTLA) Acadia Pharmaceuticals Inc. First up, we have Acadia Pharmaceuticals, a biotech company with more than 25 years of experience in the industry. ACAD stock currently trades at $21.42 as of 2:26 p.m. Diving in, Acadia announced positive top-line results from its pivotal Phase 3 Lavender study. | With all that said, could one of these health care stocks be worth watching in thestock market today Best Health Care Stocks For Your December 2021 Watchlist Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Novavax Inc. (NASDAQ: NVAX) Cellectis (NASDAQ: CLLS) Intellia Therapeutics Inc. (NASDAQ: NTLA) Acadia Pharmaceuticals Inc. First up, we have Acadia Pharmaceuticals, a biotech company with more than 25 years of experience in the industry. ACAD stock currently trades at $21.42 as of 2:26 p.m. Diving in, Acadia announced positive top-line results from its pivotal Phase 3 Lavender study. |
35780.0 | 2021-12-07 00:00:00 UTC | Pre-market Movers: BJDX, MDB, CELZ, ISIG, ACAD… | ACAD | https://www.nasdaq.com/articles/pre-market-movers%3A-bjdx-mdb-celz-isig-acad... | nan | nan | (RTTNews) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.05 A.M. ET).
In the Green
Bluejay Diagnostics, Inc. (BJDX) is up over 25% at $3.22 MongoDB, Inc. (MDB) is up over 21% at $520.00 ACADIA Pharmaceuticals Inc. (ACAD) is up over 14% at $22.12 Palatin Technologies, Inc. (PTN) is up over 13% at $0.63 Vaxxinity, Inc. (VAXX) is up over 10% at $8.06 Eqonex Limited (EQOS) is up over 10% at $3.63 Moxian (BVI) Inc (MOXC) is up over 9% at $4.38 SuperCom Ltd. (SPCB) is up over 9% at $0.66 BIT Mining Limited (BTCM) is up over 8% at $6.99 VBI Vaccines Inc. (VBIV) is up over 8% at $2.39 monday.com Ltd. (MNDY) is up over 6% at $306.00
In the Red
Creative Medical Technology Holdings, Inc. (CELZ) is down over 19% at $1.79 Insignia Systems, Inc. (ISIG) is down over 15% at $12.74 Coupa Software Incorporated (COUP) is down over 12% at $152.31 Imperial Petroleum Inc. (IMPP) is down over 9% at $6.80 Code Chain New Continent Limited (CCNC) is down over 9% at $1.21 Valneva SE (VALN) is down over 6% at $45.23 China Jo-Jo Drugstores, Inc. (CJJD) is down over 6% at $0.42
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the Green Bluejay Diagnostics, Inc. (BJDX) is up over 25% at $3.22 MongoDB, Inc. (MDB) is up over 21% at $520.00 ACADIA Pharmaceuticals Inc. (ACAD) is up over 14% at $22.12 Palatin Technologies, Inc. (PTN) is up over 13% at $0.63 Vaxxinity, Inc. (VAXX) is up over 10% at $8.06 Eqonex Limited (EQOS) is up over 10% at $3.63 Moxian (BVI) Inc (MOXC) is up over 9% at $4.38 SuperCom Ltd. (SPCB) is up over 9% at $0.66 BIT Mining Limited (BTCM) is up over 8% at $6.99 VBI Vaccines Inc. (VBIV) is up over 8% at $2.39 monday.com Ltd. (MNDY) is up over 6% at $306.00 In the Red Creative Medical Technology Holdings, Inc. (CELZ) is down over 19% at $1.79 Insignia Systems, Inc. (ISIG) is down over 15% at $12.74 Coupa Software Incorporated (COUP) is down over 12% at $152.31 Imperial Petroleum Inc. (IMPP) is down over 9% at $6.80 Code Chain New Continent Limited (CCNC) is down over 9% at $1.21 Valneva SE (VALN) is down over 6% at $45.23 China Jo-Jo Drugstores, Inc. (CJJD) is down over 6% at $0.42 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.05 A.M. ET). | In the Green Bluejay Diagnostics, Inc. (BJDX) is up over 25% at $3.22 MongoDB, Inc. (MDB) is up over 21% at $520.00 ACADIA Pharmaceuticals Inc. (ACAD) is up over 14% at $22.12 Palatin Technologies, Inc. (PTN) is up over 13% at $0.63 Vaxxinity, Inc. (VAXX) is up over 10% at $8.06 Eqonex Limited (EQOS) is up over 10% at $3.63 Moxian (BVI) Inc (MOXC) is up over 9% at $4.38 SuperCom Ltd. (SPCB) is up over 9% at $0.66 BIT Mining Limited (BTCM) is up over 8% at $6.99 VBI Vaccines Inc. (VBIV) is up over 8% at $2.39 monday.com Ltd. (MNDY) is up over 6% at $306.00 In the Red Creative Medical Technology Holdings, Inc. (CELZ) is down over 19% at $1.79 Insignia Systems, Inc. (ISIG) is down over 15% at $12.74 Coupa Software Incorporated (COUP) is down over 12% at $152.31 Imperial Petroleum Inc. (IMPP) is down over 9% at $6.80 Code Chain New Continent Limited (CCNC) is down over 9% at $1.21 Valneva SE (VALN) is down over 6% at $45.23 China Jo-Jo Drugstores, Inc. (CJJD) is down over 6% at $0.42 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.05 A.M. ET). | In the Green Bluejay Diagnostics, Inc. (BJDX) is up over 25% at $3.22 MongoDB, Inc. (MDB) is up over 21% at $520.00 ACADIA Pharmaceuticals Inc. (ACAD) is up over 14% at $22.12 Palatin Technologies, Inc. (PTN) is up over 13% at $0.63 Vaxxinity, Inc. (VAXX) is up over 10% at $8.06 Eqonex Limited (EQOS) is up over 10% at $3.63 Moxian (BVI) Inc (MOXC) is up over 9% at $4.38 SuperCom Ltd. (SPCB) is up over 9% at $0.66 BIT Mining Limited (BTCM) is up over 8% at $6.99 VBI Vaccines Inc. (VBIV) is up over 8% at $2.39 monday.com Ltd. (MNDY) is up over 6% at $306.00 In the Red Creative Medical Technology Holdings, Inc. (CELZ) is down over 19% at $1.79 Insignia Systems, Inc. (ISIG) is down over 15% at $12.74 Coupa Software Incorporated (COUP) is down over 12% at $152.31 Imperial Petroleum Inc. (IMPP) is down over 9% at $6.80 Code Chain New Continent Limited (CCNC) is down over 9% at $1.21 Valneva SE (VALN) is down over 6% at $45.23 China Jo-Jo Drugstores, Inc. (CJJD) is down over 6% at $0.42 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.05 A.M. ET). | In the Green Bluejay Diagnostics, Inc. (BJDX) is up over 25% at $3.22 MongoDB, Inc. (MDB) is up over 21% at $520.00 ACADIA Pharmaceuticals Inc. (ACAD) is up over 14% at $22.12 Palatin Technologies, Inc. (PTN) is up over 13% at $0.63 Vaxxinity, Inc. (VAXX) is up over 10% at $8.06 Eqonex Limited (EQOS) is up over 10% at $3.63 Moxian (BVI) Inc (MOXC) is up over 9% at $4.38 SuperCom Ltd. (SPCB) is up over 9% at $0.66 BIT Mining Limited (BTCM) is up over 8% at $6.99 VBI Vaccines Inc. (VBIV) is up over 8% at $2.39 monday.com Ltd. (MNDY) is up over 6% at $306.00 In the Red Creative Medical Technology Holdings, Inc. (CELZ) is down over 19% at $1.79 Insignia Systems, Inc. (ISIG) is down over 15% at $12.74 Coupa Software Incorporated (COUP) is down over 12% at $152.31 Imperial Petroleum Inc. (IMPP) is down over 9% at $6.80 Code Chain New Continent Limited (CCNC) is down over 9% at $1.21 Valneva SE (VALN) is down over 6% at $45.23 China Jo-Jo Drugstores, Inc. (CJJD) is down over 6% at $0.42 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.05 A.M. ET). |
35781.0 | 2021-12-07 00:00:00 UTC | Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday | ACAD | https://www.nasdaq.com/articles/todays-biggest-pre-market-stock-movers%3A-10-top-gainers-and-losers-on-tuesday-3 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Good morning, trader! We’re beginning another busy day of trading with a breakdown of the biggest pre-market stock movers for Tuesday!
Source: Shutterstock
We’ve got earnings reports, clinical trials, insider buying, and more moving shares this morning.
Let’s get into that news below!
Pre-Market Stock Movers: 10 Top Gainers
Bluejay Diagnostics (NASDAQ:BJDX) stock is soaring more than 24% as retail traders take interest in the company.
MongoDB (NASDAQ:MDB) shares are rising over 21% with the release of its most recent earnings report.
ACADIA Pharmaceuticals (NASDAQ:ACAD) stock is surging close to 14% on positive results from a Phase 3 clinical trial.
Palatin Technologies (NYSEAMERICAN:PTN) shares are increasing more than 13% after getting a 5% price target late last month that has investors interested in the company.
Hycroft Mining Holding (NASDAQ:HYMC) stock is climbing over 12% as shares recover from a dip yesterday.
Creative Medical Technology (NASDAQ:CELZ) shares are sitting more than 11% higher as its public offering and uplisting closes today.
Vaxxinity (NASDAQ:VAXX) stock is gaining over 11% as shares rally following recent downward momentum.
Embark Technology (NASDAQ:EMBK) shares are getting a more than 11% boost one month after the company went public via a SPAC merger.
Eros STX Global (NYSE:ESGC) stock is jumping over 10% as retail traders take note of the shares this morning.
VBI Vaccines (NASDAQ:VBIV) shares are up more than 10% on insider buying from one of its executives.
7 A-Rated Biotechs to Buy for the Long Run
10 Top Losers
Insignia Systems (NASDAQ:ISIG) stock is pulling back over 16% after rallying on Monday due to strategic alternative news.
Coupa Software (NASDAQ:COUP) shares are falling more than 10% with the release of its Q3 fiscal 2022 earnings report.
Aemetis (NASDAQ:AMTX) stock is taking a nearly 10% beating after completing its change of state yesterday.
Code Chain New Continent (NASDAQ:CCNC) shares are dropping over 9% following a rally yesterday.
Imperial Petroleum (NASDAQ:IMPPP) stock is slipping more than 9% after making its public debut on Monday.
China Jo-Jo Drugstores (NASDAQ:CJJD) shares are decreasing over 8% after shares of the penny stock ran higher yesterday.
Valneva (NASDAQ:VALN) stock is dipping more than 7% as it continues negative movement with easing worries about the Covid-19 Omicron variant.
Co-Diagnostics (NASDAQ:CODX) shares are declining over 7% on no apparent news this morning.
Direxion Daily S&P Biotech Bear 3X Shares (NYSEARCA:LABD) are losing roughly 7% of their value in pre-market trading today.
Advanced Human Imaging (NASDAQ:AHI) stock closes out our pre-market stock movers down more than 6% after a rally yesterday.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals (NASDAQ:ACAD) stock is surging close to 14% on positive results from a Phase 3 clinical trial. Palatin Technologies (NYSEAMERICAN:PTN) shares are increasing more than 13% after getting a 5% price target late last month that has investors interested in the company. Eros STX Global (NYSE:ESGC) stock is jumping over 10% as retail traders take note of the shares this morning. | ACADIA Pharmaceuticals (NASDAQ:ACAD) stock is surging close to 14% on positive results from a Phase 3 clinical trial. Source: Shutterstock We’ve got earnings reports, clinical trials, insider buying, and more moving shares this morning. Pre-Market Stock Movers: 10 Top Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock is soaring more than 24% as retail traders take interest in the company. | ACADIA Pharmaceuticals (NASDAQ:ACAD) stock is surging close to 14% on positive results from a Phase 3 clinical trial. Pre-Market Stock Movers: 10 Top Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock is soaring more than 24% as retail traders take interest in the company. China Jo-Jo Drugstores (NASDAQ:CJJD) shares are decreasing over 8% after shares of the penny stock ran higher yesterday. | ACADIA Pharmaceuticals (NASDAQ:ACAD) stock is surging close to 14% on positive results from a Phase 3 clinical trial. Source: Shutterstock We’ve got earnings reports, clinical trials, insider buying, and more moving shares this morning. Pre-Market Stock Movers: 10 Top Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock is soaring more than 24% as retail traders take interest in the company. |
35782.0 | 2021-11-11 00:00:00 UTC | December 31st Options Now Available For Acadia Pharmaceuticals | ACAD | https://www.nasdaq.com/articles/december-31st-options-now-available-for-acadia-pharmaceuticals | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the December 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new December 31st contracts and identified one put and one call contract of particular interest.
The put contract at the $20.00 strike price has a current bid of $1.20. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $20.00, but will also collect the premium, putting the cost basis of the shares at $18.80 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $21.02/share today.
Because the $20.00 strike represents an approximate 5% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 6.00% return on the cash commitment, or 43.80% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $22.50 strike price has a current bid of $1.15. If an investor was to purchase shares of ACAD stock at the current price level of $21.02/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $22.50. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 12.51% if the stock gets called away at the December 31st expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $22.50 strike highlighted in red:
Considering the fact that the $22.50 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 5.47% boost of extra return to the investor, or 39.94% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $21.02) to be 79%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $22.50 strike highlighted in red: Considering the fact that the $22.50 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the December 31st expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $22.50 strike highlighted in red: Considering the fact that the $22.50 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the December 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new December 31st contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $22.50 strike price has a current bid of $1.15. Below is a chart showing ACAD's trailing twelve month trading history, with the $22.50 strike highlighted in red: Considering the fact that the $22.50 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the December 31st expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $22.50 strike price has a current bid of $1.15. Below is a chart showing ACAD's trailing twelve month trading history, with the $22.50 strike highlighted in red: Considering the fact that the $22.50 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the December 31st expiration. |
35783.0 | 2021-11-11 00:00:00 UTC | LABU, ALXO, ABBV, ACAD: Large Outflows Detected at ETF | ACAD | https://www.nasdaq.com/articles/labu-alxo-abbv-acad%3A-large-outflows-detected-at-etf | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $95.7 million dollar outflow -- that's a 12.8% decrease week over week (from 13,711,600 to 11,961,600). Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 1.5%, AbbVie Inc (Symbol: ABBV) is trading flat, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is higher by about 2.6%. For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average:
Looking at the chart above, LABU's low point in its 52 week range is $47.59 per share, with $185.61 as the 52 week high point — that compares with a last trade of $54.92. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 1.5%, AbbVie Inc (Symbol: ABBV) is trading flat, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is higher by about 2.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $95.7 million dollar outflow -- that's a 12.8% decrease week over week (from 13,711,600 to 11,961,600). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 1.5%, AbbVie Inc (Symbol: ABBV) is trading flat, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is higher by about 2.6%. For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $47.59 per share, with $185.61 as the 52 week high point — that compares with a last trade of $54.92. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 1.5%, AbbVie Inc (Symbol: ABBV) is trading flat, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is higher by about 2.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $95.7 million dollar outflow -- that's a 12.8% decrease week over week (from 13,711,600 to 11,961,600). For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $47.59 per share, with $185.61 as the 52 week high point — that compares with a last trade of $54.92. | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 1.5%, AbbVie Inc (Symbol: ABBV) is trading flat, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is higher by about 2.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $95.7 million dollar outflow -- that's a 12.8% decrease week over week (from 13,711,600 to 11,961,600). For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $47.59 per share, with $185.61 as the 52 week high point — that compares with a last trade of $54.92. |
35784.0 | 2021-11-09 00:00:00 UTC | Acadia Pharmaceuticals Inc (ACAD) Q3 2021 Earnings Call Transcript | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-inc-acad-q3-2021-earnings-call-transcript | nan | nan | Image source: The Motley Fool.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD)
Q3 2021 Earnings Call
Nov 8, 2021, 4:30 p.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good day, ladies and gentlemen, and welcome to the Acadia Pharmaceuticals Third Quarter 2021 Financial Results Conference Call. My name is Gigi, and I'll be your coordinator for today.
I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at Acadia. Please proceed.
10 stocks we like better than Acadia Pharmaceuticals
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of October 20, 2021
Mark Johnson -- Vice President, Investor Relations
[Technical Issues] today's call to discuss Acadia's third quarter 2021 financial results. Joining me on the call today from Acadia are Steve Davis, our Chief Executive Officer, who'll provide an overview of our Q3 2021 financial performance and a review of our business operation. Also joining us today is Brendan Teehan, our Chief Operating Officer and Head of Commercial, who'll provide updates on our commercial performance. Dr. Serge Stankovic, our President will discuss our pipeline progress; and our Interim Chief Financial Officer, Mark Schneyer will then discuss our financial results in more detail before turning it back to Steve for final remarks and opening the call for your question. I would also like to point out that we are using supplemental slides, which are available on the Events and Presentation section of our website.
Before we proceed, I would first like to remind you that during our call today, we'll be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements including goals, expectations, plans, prospects, growth potential, timing of events or future results are based on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially. These factors and other risks associated with our business can be found in our filings made with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of today's date.
I'll now turn the call over to Steve.
Stephen R. Davis -- Chief Executive Officer
Thank you, Mark. Good afternoon, everyone and thank you for joining us today. I'd like to start with a quick recap of our commercial performance followed by regulatory update for pimavanserin and a preview of our upcoming catalysts.
Please turn to Slide 4. First, I'd like to take a moment to remind everyone of our announcement last week that Brendan Teehan has been promoted to the position of Chief Operating Officer and Head of Commercial. Brendan has been a tremendous leader for our team, and I'm very excited to be able to further leverage his deep experience and strong capabilities. While Brendan will take you through our commercial update in greater detail in a minute, let me just say that on a macro level, the Parkinson's disease market continues to be significantly impacted as a result of the pandemic.
Despite these challenges, NUPLAZID has outperformed branded drugs in the space and for the third quarter of 2021, NUPLAZID achieved $131.6 million in net sales. This represents a 9% year-over-year increase with sequential and year-over-year volume growth. As shown in the graph on the left, our team has continued to execute with year-over-year and sequential growth each quarter since the beginning of the year. To be more precise, NUPLAZID has outperformed the market basket of top prescribed brands in Neurology and Parkinson's disease in the office-based setting. Similarly, NUPLAZID continued its strong outperformance in the long-term care channel.
Our strong relative performance underscores our team's ability to adapt and find ways to grow our brand. This includes our recently launched branded campaign targeting healthcare providers, which promotes NUPLAZID's unique safety profile specifically as it relates to the Parkinson's community. On the patient and caregiver front, we're in the process of launching a new DTC campaign aimed at solving one of our biggest COVID-related challenges, which is physicians not seeing as many PDP patients in-person. As such, this DTC campaign is aimed at patients and caregivers who are at home and is designed to activate them to have a conversation with their doctor about their symptoms of psychosis and potential treatment with NUPLAZID. Our growth initiatives, new leadership and strong relative performance give us confidence that we'll further accelerate the growth of NUPLAZID into 2022.
Now let's move to our regulatory update regarding our sNDA for pimavanserin on Slide 5. As you recall at our Type A End of Review Meeting, the FDA made it clear that today they are looking at individual subgroups of dementia rather than DRP as a single group. Accordingly, they stated that they believe our best path forward is to conduct an additional study in each subgroup where we seek approval. However, at that meeting, the FDA also stated based on additional analyses [Phonetic] we've shared with them that they are open to having another meeting to discuss whether there is a potential path to resubmission without an additional clinical study in any of the subgroups. This meeting is now scheduled and we expect to be able to report on the results of the meeting around year-end.
When we look at our dementia subgroup data, it is very clear that we have the most data for Alzheimer's disease, which represent somewhere between 60% and 80% of all dementia patients in the U.S. Our database includes two independent clinical studies providing evidence of pimavanserin antipsychotic efficacy in Alzheimer's disease psychosis, Study -019 and the HARMONY Study. Together, these studies demonstrate improvement in psychotic symptoms and reduction of risk of relapse of psychosis in ADP patients. At our upcoming meeting with the FDA, we look forward to sharing additional analyses we've done in response to feedback from the last meeting.
Serge will provide more details on this opportunity in his section. As we look ahead, I'd like to highlight some important near-term catalysts as shown on Slide 6. First, as I've noted, we look forward to providing an update from our meeting with the FDA around year-end. Second, we expect to announce top-line results from LAVENDER, our pivotal Phase 3 study for trofinetide in Rett syndrome later this quarter. And third, we expect to announce top-line results from a Phase 2 proof-of-concept study evaluating ACP-044 in postoperative pain following bunionectomy surgery in the first quarter of 2022. Finally, our Company is well poised for further expansion. We have a healthy balance sheet, a growing revenue base and best-in-class in-house R&D and commercial teams. Business development continues to be a key priority of our strategy and we continue to be very active on that front.
I would now like to turn the call over to Brendan to discuss our commercial performance.
Brendan Teehan -- Executive Vice President, Chief Operating Officer, Head of Commercial
Thank you, Steve. Today, I'd like to review our third quarter performance for NUPLAZID in Parkinson's disease psychosis, please turn to Slide 8. In the quarter, we delivered net sales of $131.6 million. This quarterly performance represents sequential demand growth fueled by new patient starts and continuing patients with strong adherence and compliance rates. I'd like to start with a further dive into the current macroenvironment that we're operating in.
As we've stated previously, the pandemic has disproportionately affected the Parkinson's disease patient population, significantly impacting the market. As shown on the slide, PD office visits and occupancy rates at long-term care facilities are still down significantly from pre-pandemic levels. Despite this, NUPLAZID has continued to grow meaningfully throughout the period with strong relative performance as compared to the overall Parkinson's disease and broader Neurology markets. More specifically, when we compare recent quarterly performance with pre-pandemic performance of 2019, we see the following, in the office-based setting, Carbidopa and Levodopa are down 4% and the top 10 Parkinson's brands on average are down 7% over that time period. And while the top 15 marketed Neurology products are up 15%, NUPLAZID is up fully 28% for that same time period.
Similarly, in the long-term care channel, Carbidopa and Levodopa are down 12% and the top 15 LTC brands are down on average 22%, while NUPLAZID has grown 8%. Perhaps the most important of all of these data points is the Carbidopa and Levodopa total prescription trend. These are the fundamental PD movement disorder medications and they have trended down during the pandemic. This decline clearly signifies just how challenged the PD market has been over the past two years. However, against the backdrop of this environment, NUPLAZID has continued to grow in both channels giving us confidence in our future growth.
We've had to adapt and utilizing novel analytics and thoughtful implementation of our tactics have found new opportunities to grow new patient starts. Our strong relative performance and continued growth across all channels underscores our commercial execution and gives us confidence that our tactics are working and will continue resonating in months ahead. Furthermore, our team is not simply waiting around for the macroenvironment to improve. We are buckling down and working even harder to ensure that we are interacting with in educating physicians, patients and their caregivers on PD psychosis and treatment with NUPLAZID.
Let's turn to Slide 9 to continue the discussion on what we are doing to further grow the brand. To continue to drive brand choice and growth in the second half of the year, we have introduced two new important campaigns, one focused principally on the healthcare provider or HCP audience and the other focused on engaging patients and caregivers. On this slide, I'd like to discuss our new HCP focused messaging platform that educates the treating community on the unique safety profile of NUPLAZID, specifically as it relates to the Parkinson's community. Our campaign is amplified across all promotional channels, including our field teams and is resonating well with HCPs. This messaging incorporates market research insights focused on HCP's treatment goals for Parkinson's patients experiencing psychosis and specifically on NUPLAZID's safety and tolerability profile in light of other important medical consideration. The most notable being the desire to avoid impacting motor function. Our messaging demonstrates a deep understanding of our clinicians' treatment goals by leveraging important clinical data to better educate physicians on NUPLAZID's safety and efficacy profile. While early in the roll-out of this campaign, this messaging is resonating with physicians and we see the opportunity to further increase diagnosis and capture a higher percentage of new PDP patients for NUPLAZID moving forward.
Slide 10 highlights our new direct-to-consumer campaign, which is intended to reach patients and caregivers at home and drive them to their physicians to have conversations about their symptoms of psychosis and treatment with NUPLAZID. This campaign should help solve one of our biggest COVID-related challenges, patients staying at home and not seeing their physicians in-person and therefore not adequately discussing their symptoms or new treatment options. Our campaign has been on air since mid-October. It tells an important patient caregiver-centered story about the impact of PD psychosis. The ad introduces NUPLAZID and its potential treatment benefits to both patients and their families. The ad also includes a critical component of disease awareness to help patients understand and recognize the signs and symptoms and prevalence of psychosis in patients living with Parkinson's disease. With the work our commercial team has been doing executing on the new message platform on the HCP side, this is the perfect time to introduce a new patient-centric campaign, drive new patients to their newly educated doctors and grow the NUPLAZID brand.
Of course, while we expect to see traction in the fourth quarter, the full benefit of these complementary campaigns will be mostly realized in next year's growth. The bottom-line, patients and caregivers are in need of better treatment options such as NUPLAZID and patients and caregivers need to recognize the symptoms of psychosis and its connection to Parkinson's disease. We are confident our campaigns will accomplish this.
I will now turn it over to Serge.
Serge Stankovic -- President
Thank you, Brendan, and good afternoon, everyone. As Steve mentioned, we have had a constructive dialog with the FDA and are looking forward to our upcoming meeting. While we continue to believe that evaluating pimavanserin as a treatment for the broad dementia-related psychosis indication is most appropriate, we understand the FDA's position and are preparing additional analysis [Phonetic] to support pimavanserin as a potential treatment by dementia subgroup.
Let's start the discussion on Slide 12 with an overview of our HARMONY data, specifically looking at the Alzheimer's disease subgroup, which as Steve mentioned is the most prevalent form of dementia. On the left side of the slide is an overview of pimavanserin antipsychotic efficacy observed overall and in the Alzheimer's [Phonetic] disease subgroup in the open-label portion of the HARMONY study, as well as the primary efficacy outcome in the double-blind portion. As we previously noted, HARMONY was not powered to show statistical significance by dementia subgroup. However, we did prospectively plan exploratory efficacy analysis of dementia subgroups. In the Alzheimer's disease subgroups, we see that Alzheimer's disease subjects who remain of pimavanserin were about 40% less likely to experience a relapse of psychotic symptoms compared with those on placebo has shown with hazard ratio of 0.62. Post-hoc analysis of the pimavanserin 34 milligram dose group, the dose currently approved for treating PDP patients showed about 50% risk reduction with a hazard ratio of 0.47.
For context, this magnitude of effect is in line with what has been observed in numerous relapse prevention studies of comparable design for approved drugs in various psychiatric indications such as schizophrenia or depression. In addition, this benefit is further supported by a number of complementary analysis, some examples of which are listed on the right hand side of the slide. These analysis consistently show the antipsychotic efficacy across different endpoints within the Alzheimer's disease subgroup, which clearly support the overall conclusion of the clinically meaningful benefit that pimavanserin demonstrated in the treatment of psychosis in Alzheimer's patients. Furthermore, these additional analysis also demonstrate and confirm pimavanserin's observed antipsychotic treatment effect across all dementia subgroups and thus provide further supportive evidence for the benefit of pimavanserin in Alzheimer's disease psychosis.
Please turn to Slide 13. In the upcoming meeting, we will also discuss with the FDA our positive -019 Study, a randomized, placebo-controlled study of pimavanserin for the treatment of symptoms of psychosis in Alzheimer's disease patients. The primary efficacy outcome was positive with p-value equal to 0.045. In a pre-specified analysis of Alzheimer's disease subjects with more severe psychotic symptoms, the magnitude of efficacy more than doubled with a p-value equal to 0.011.
In response to issues raised in the Complete Response Letter, Acadia has conducted multiple sensitivity and responder analysis that support the primary efficacy conclusion. Note that the responder analysis shown on the right of the slide also demonstrate that pimavanserin had even greater efficacy in those patients with a higher severity of psychosis. To recap, pimavanserin has been evaluated in ADP patients across two independent clinical studies, and in addition to positive and clinically meaningful efficacy has been well tolerated and importantly has not shown negative impact on cognition or motor function. In our next meeting with the FDA, we will share several analysis and a substantial data set demonstrating the potential utility of pimavanserin in the treatment of ADP in order to further examine the potential for resubmission without conducting additional clinical studies.
Now I would like to discuss our pivotal Phase 3 study evaluating trofinetide as a potential treatment for Rett syndrome on Slide 14. LAVENDER is a randomized, double-blind placebo-controlled study in approximately 180 young females age 5 to 20 with Rett syndrome, patients are evaluated for 12 weeks. The co-primary endpoints are Rett Syndrome Behavioral Questionnaire or RSBQ, a caregiver assessment tool and the Clinical Global Impression of Improvement or CGI-I, which is a physician assessment. We are currently on track to announce top-line results by year-end. And importantly, we have agreement with the FDA that positive results from LAVENDER in addition to supportive efficacy data from the previous Phase 2 study and the safety database we are collecting could be sufficient to support a new drug application.
Finally, let me remind you that there is nothing approved for the treatment of Rett syndrome. Rett is a devastating and burdensome disease for both the patients and their caregivers often requiring around-the-clock support. We have had several discussions with the key opinion leaders and experts in the field. They inform us that even a modest improvement of symptoms could make a significant and very meaningful difference in the ability to care for the patients and for their overall functioning. We look forward to announcing the results of this study in the near future.
Slide 15 shows a summary of our Phase 3 program evaluating pimavanserin for the treatment of the negative symptoms of schizophrenia, which includes two pivotal studies, our positive ADVANCE-1 Study and ADVANCE-2 which we initiated in the third quarter of last year. Please turn to Slide 16 for an update on our ACP-044 program. Our ongoing Phase 2 study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery is nearing enrollment completion. However, we now expect the results in the first quarter of 2022. This slight delay is due to slower than expected enrollment with the postponement of many elective surgeries during the summer COVID-19 Delta variant surge. In addition, as a reminder, earlier this year we initiated a Phase 2 study for patients suffering from pain associated with osteoarthritis and plan to provide an update on this study next year.
Slide 17 highlights a brief summary of our ACP-319 M1 PAM program for the potential treatment of schizophrenia and cognitive impairment in Alzheimer's disease. We recently initiated a multiple ascending dose study as our Phase 1 work continues for this program. Turning to Slide 18, at Acadia, we're committed to investing in therapies to address high unmet needs in CNS. Our clinical development pipeline has two late stage Phase 3 programs, as well as multiple early stage program. This year we have initiated multiple clinical studies, including ACP-044 in acute pain in Q1, ACP-044 in chronic pain in Q2, and most recently the ACP-319 multiple ascending dose study.
With that, I'll turn the call over to Mark.
Mark Schneyer -- Senior Vice President, Business Development, Chief Business and Interim Chief Financial Officer
Thank you, Serge. Today, I'll discuss our third quarter 2021 results, please turn to Slide 20. In the third quarter of 2021, we recorded $131.6 million in net sales, an increase of approximately 9% compared to $120.6 million of net sales in Q3 of 2020. Our net sales increase in Q3 2021 represents 3% volume growth year-over-year. The gross to net adjustment for Q3 2021 was 15.2%. Weeks of inventory in the channel at the end of the third quarter was slightly down. As a result, sequential demand growth of approximately 3% was slightly higher than sequential selling growth of approximately 1%.
Moving down the P&L, GAAP R&D expenses decreased to $58.6 million in the quarter compared to $120.1 million in Q3 2020. Recall last year, GAAP R&D expense included the $52.8 million upfront consideration and transaction costs related to our acquisition of CerSci Therapeutics. GAAP SG&A expenses were relatively flat at $81.7 million in the third quarter compared to $81.6 million in the third quarter of last year. Non-cash stock-based compensation expense during the quarter was $15.5 million compared to $21.4 million for the same period in 2020. Our cash balance at the end of the quarter was $540.3 million.
I'll now provide some additional color on our financial expectations and guidance ranges for the remainder of the year, please turn to Slide 21. As we mentioned previously, our commercial team is continuing to execute well and deliver quarter-over-quarter growth with strong relative performance in both channels. As a reminder, in the fourth quarter, we expect a much higher impact from gross to net as a result of accruing for the donut hole obligation associated with year-end inventory in the channel.
In addition, recall that last quarter we guided to gross to net being somewhere around 20% for the full-year. As we get closer to the end of the year, we have narrowed the top end of our full-year 2021 net sales guidance range to $480 million to $500 million from the previous range of $480 million to $515 million. Our net sales guidance assumes that inventory levels remain relatively flat in the channel as we approach the end of the year.
I'd like to provide a little bit more commentary on our net sales guidance. As we saw on Slide 8 of Brendan's presentation, our leading indicators of PD office visits and LTC occupancy rates has started to improve in the first half of the year. However, in the third quarter, they seem to have leveled off or declined. This is a reflection of the COVID-19 Delta variant surge we experienced in the summer. Our net sales guidance range factors and scenarios that depends on how long our leading indicators remain relatively flat versus how quickly they return to grow.
Moving on to the expense side for 2021, we have lowered our GAAP R&D guidance to be between $230 million and $245 million for the full-year from our previous range of $250 million to $270 million. And finally, we have slightly narrowed the top end of our GAAP SG&A full-year guidance range to be between $385 million to $405 million from $385 million to $415 million.
And with that, I'll turn the call back over to Steve.
Stephen R. Davis -- Chief Executive Officer
Thank you, Mark. Please turn to Slide 23. In closing, I'd like to remark on how proud I'm of our teams for their execution this year. Our commercial team has worked tirelessly all year on delivering pimavanserin to more Parkinson's patients and their families who are suffering from the symptoms of psychosis. They've achieved more with less and continue to push through the pandemic conditions. Our R&D team has executed during a time when patient enrollment is difficult. We're now poised to report out on two key clinical studies, Phase 3 results from LAVENDER, our trofinetide study in Rett syndrome and Phase 2 results from our ACP-044 study in postoperative pain. And, of course, we look forward to providing additional clarity regarding ADP around year-end. Finally, I would like to thank all of our employees for their commitment to our mission to elevate life.
I'll now open up the call for questions. Operator?
Questions and Answers:
Operator
[Operator Instructions] Please standby while we compile the Q&A roster. Our first question comes from the line of Neena Bitritto-Garg from Citi. Your line is now open.
Neena Bitritto-Garg -- Citi -- Analyst
Hey guys, thanks for taking my question and congrats on the quarter. So just a question about the commercial performance of NUPLAZID. I guess, can you comment at all on the pace of new starts during the quarter versus Q2? And then also just on Q4, just from -- from Mark's commentary just now, it sounds like we should expect a higher gross to net and kind of similar patient dynamics quarter-over-quarter, I guess, should -- is it kind of safe for us to assume that Q4 could actually be kind of a down quarter? Thanks.
Stephen R. Davis -- Chief Executive Officer
Yeah, thanks for the questions, Neena. I'm going to ask Brendan answer the first question and Mark, the second.
Brendan Teehan -- Executive Vice President, Chief Operating Officer, Head of Commercial
Neena, thanks for the question. The question regarding new patient starts in the third quarter, we are seeing new patient starts that are approaching the pre-pandemic levels, so largely comparable in between the quarters. As we head into the fourth quarter with DTC and our increased -- and our efforts with our HCP campaign, we would expect to continue growth moving into 2022.
Stephen R. Davis -- Chief Executive Officer
Thanks, Brendan. Mark?
Mark Schneyer -- Senior Vice President, Business Development, Chief Business and Interim Chief Financial Officer
Yeah, Neena, thanks for the question. I think with the range of scenario -- of guidance that we put out for net sales, there's -- I think what I want to point out is, there is volume growth across that full range. But yes we are with an expected higher gross to net adjustment for the fourth quarter at the lower end of that range, the implication for fourth quarter net sales has got -- reported net sales at the bottom end of the range would be lower than the third quarter reported net sales.
Neena Bitritto-Garg -- Citi -- Analyst
Got it. Thanks, guys. I appreciate it.
Operator
Thank you. Our next question comes from the line of Cory Kasimov from JPMorgan. Your line is now open.
Gavin Scott -- JPMorgan -- Analyst
Hi, this is Gavin on for Cory. We had a question actually on DRP regulatory review, Carano [Phonetic] is expected to invest their drug candidate for DRP, but are now planning to launch a Phase 3 next year in ADP specifically, have you had any feedback from the agency about how they're broadly thinking about the DRP setting relative to the independent components as this development would seem to -- to help your case?
Stephen R. Davis -- Chief Executive Officer
Gavin, I didn't hear the second part of that question, could you repeat that part?
Gavin Scott -- JPMorgan -- Analyst
I just said that this development would seem to help your case?
Stephen R. Davis -- Chief Executive Officer
Got it, OK, thanks. Well look, we can't obviously comment on what other people's interactions are with the FDA. I would just simply say that the FDA has made it clear to us that they think the correct way to assess this population based upon reviewing our data is on a subgroup by subgroup basis. So that's what we're focused on, that's what we'll be focused on at the next meeting.
Operator
Thank you. Our next question comes from the line of Ritu Baral from Cowen. Your line is now open.
Ritu Baral -- Cowen -- Analyst
Hi, guys. Thanks for taking the question. I did want to follow up on that last question, I guess, I was going to ask it a slightly different way. As you approach this meeting and come out on the far side, if the FDA does prove immovable, is an ADP specific trial sort of the best next option, and so far as you clearly have treatment effect, it would just take a well powered study to address as you mentioned 60% to 80% of the overall DRP population? And then further as you plan to discuss -019, can you remind us -- I believe the FDA sort of changed its mind on whether they considered -019 a well-controlled study and I think that was around sort of like the whole quote-unquote, administrative single center aspect of it. Can you remind us of what their interpretation of well-controlled was versus Acadia's conduct of the study? Thanks.
Stephen R. Davis -- Chief Executive Officer
Yeah, thanks for the question, Ritu. I'm going to take the first part, I'm going to ask Serge to answer the -019 portion of the question. Serge, if you have any other comments regarding the HARMONY, please chime in as well. So just to recap very briefly, we received a CRL in April, and through that process and our Type A meeting, the FDA made it clear that they are looking at dementia-related psychosis on a subgroup by subgroup basis as I mentioned a second ago.
At our Type A meeting, we presented data to the -- that was intended to demonstrate both a consistency of response on drug-treated patients versus placebo-controlled patients or placebo-treated patients. And also cluster analyses that broke down the individual components of the SAPS-H+D scale, which was used throughout the study, it's used for enrollment entry criteria, it was used during the 12-week response period and then during the six-month randomized portion of the study.
And when we broke that down on individual components, what we saw again was a very consistency of response irrespective of underlying subgroups. So across each of those elements, patients looked pretty much the same when they came into the study, they looked -- they responded in a very similar way during the 12-week open-label period and then they responded -- those on drug that has responded in a very similar way during the randomized portion of the study.
The one area where we did see difference was in the placebo group on patients that have both comorbid Parkinson's disease and trench [Phonetic] dementia. And in that group, we saw a more rapid relapse in that group relative to patients sub -- placebo patients in other subgroups, and we attribute that to the fact that these patients were taking dopaminergic therapies for their motor function and that is known to, can exacerbate psychotic symptoms.
So at the conclusion of that meeting, the FDA said we get your points, we think you made some valid points, we want to reiterate we think the best way to study this population is on a subgroup by subgroup basis, and we think your best path forward is to run an additional study in each of the subgroups that you were seeking approval, however, didn't get to complete the conversation. It's a one-hour meeting, of course, through dialog back and forth before the meeting, and they said, we would be very open to having another meeting with you if you like to further discuss the potential for resubmitting without an additional clinical study.
And so what we're telling you today is, we think the subgroup where that is -- where there's the greatest potential of doing that is in Alzheimer's disease psychosis. That's the group that was about 70% of the population in our HARMONY study, also epidemiologically it represents about 70% of dementia patients and we also have our Study -019 that Serge will speak to in a second, where we had a very positive result in the Alzheimer's dementia psychosis population. And so for all those reasons, as we said, we're very focused now on this next meeting in taking new analyses that we've done since the last meeting that focuses on the Alzheimer's disease psychosis population. So we look forward to having that meeting, obviously, that's the next step we need to have a meeting, and as soon as we have, we'll be able to give further guidance about next steps. Serge, do you want to address the -019 Study.
Serge Stankovic -- President
Yes, thank you. In respect to -019 Study, just a reminder, our Alzheimer's disease psychosis study that was conducted in the care homes, in a number of care homes in the UK, FDA raised certain issues that in the Complete Response Letter, they expressed concern that makes it difficult for them to consider this study adequate and well-controlled study. These issues by the FDA can be roughly categorized into two buckets, one is related to the design of the study and the others are related to conduct of the study or the protocol deviations that were recorded and reported in the study.
In respect to design, two specific issues were emphasized, one that this is a single center study, and the second is that the secondary outcome measures, there was no Type 1 error control for the secondary outcomes. We believe that we can and intend to address these concerns, particularly from the perspective that in our understanding none of these are requirements for the adequate and well-controlled study. Just as a reminder as I said, this study is done under coordination of a single investigator in the UK, but it was done in a number of care homes or nursing homes throughout the broader UK, London area.
From the perspective of the conduct, we also intend to address not only in detail the, specifically the protocol deviations that are reported, and by the way, they are reported in the study report from very beginning and we discussed them, but we will further elaborate on the specifics and timing and their ability to impact the study per se and the interpretation of the results, but also we will provide a number of additional sensitivity analysis that are intended to demonstrate that these protocol deviations did not impact the overall conclusions of the study in anyway.
So in short, we are -- from the data perspective, we have a level of comfort that we can address these concerns raised by the FDA and that is exactly what we intend to do in the -- in our meeting, as well as in -- eventually in the resubmission. And we believe that following that, this study can and should be considered adequate and well-controlled study and supportive in the overall as an independent evidence of efficacy of pimavanserin in the Alzheimer's disease psychosis.
Ritu Baral -- Cowen -- Analyst
Got it, thanks.
Operator
Thank you. Our next question comes from the line of Charles Duncan from Cantor Fitzgerald. Your line is now open.
Charles Duncan -- Cantor Fitzgerald -- Analyst
Yes, hi, good afternoon, Steve and team. First of all, thanks for taking our question and congrats on a solid quarter. I wanted to ask you one commercial question and then one pipeline question. Regarding the commercial question, I guess I'm thinking about the two new campaigns for HCPs and direct-to-consumer, and I think Brendan suggested that higher percentage of PDP diagnosis would be the goal. I guess I'm wondering if you could provide us some color on where you're at today and where you'd like to be in say 12 months?
Stephen R. Davis -- Chief Executive Officer
Sure. Brendan, go ahead.
Brendan Teehan -- Executive Vice President, Chief Operating Officer, Head of Commercial
Excuse me, Charles, thank you very much for the question. First I'd say, we're excited about both campaigns. The HCP campaign is focused on drawing attention to the ability to improve psychosis while not impacting motor function. We know that our patients are going to see their HCPs principally because of their Parkinson's disease and we need to weave in the story about Parkinson's disease psychosis and the need to treat. We've done market research on the campaign. HCPs are responding very favorably to it. They demonstrate an interest, a higher interest in prescribing NUPLAZID as a function of telling the story that way.
The second campaign more focused on patients and caregivers, you can see in the DTC story, which is to, first of all, highlight NUPLAZID as the solution to Parkinson's disease psychosis, but every bit is importantly to make sure that those patients and caregivers understand that this is a normal part of their Parkinson's disease experience, and thus it's important to bring that situation to their HCP's attention. So we are using those in a complementary fashion. We've been very proud of the DTC campaigns up to now and how that has engaged patients and caregivers with their treaters in that conversation and we're very confident that, that will happen again here.
Charles Duncan -- Cantor Fitzgerald -- Analyst
Okay. And then second question is for Serge on the pipeline, perhaps you just answered this in addressing Ritu's question, but I'm wondering if you could provide us a little bit more color on the new analyses that have been conducted, are they primarily around efficacy or they -- are they around safety? I mean, Brendan just mentioned a lack of impact on motor function and it would seem to me that would be important, as well as cognition in the ADP population. So what kind of analyses have you conducted? And then secondarily, when would you be able to update this, would the meeting happen by the end of the year or would you be in a position to update by the end of this year or so?
Stephen R. Davis -- Chief Executive Officer
Yeah, Serge, please go ahead.
Serge Stankovic -- President
Yes, thanks, Charles. Let me just get one by one. In regard to new analyses, I'll start first of all by stating something that we previously also stated that questions raised in the Complete Response Letter were related to the way of how the efficacy evidence in the patient population should be derived, and the -- as Steve said, what is the appropriate way of evaluating efficacy in dementia patients with psychosis whether as a group or as by dementia subtype.
So as you can imagine, most of the discussion that we have is around that evidence efficacy in patient population. And in this specific case, we are preparing a number of analyses that are specifically designed to whether it's natural to start with a subgroup that is the largest subgroup of Alzheimer's disease psychosis, whether we are providing a broader additional analyses, and I'll comment on that just in a second. But also I don't want to address your question about safety, and that is there were issues related to safety, because the pimavanserin safety profile is unchanged and all the additional data that we have provided in the supplemental NDA did not open any new questions in regard to the safety of pimavanserin.
That calls as well for the certain safety benefit that we see with pimavanserin and that is related to the motor function and specifically in this patient population with dementia to lack of negative impact in -- in cognition -- in cognitive functioning. And, of course, that is a part, it was a part of our supplemental NDA submission, it's also a part of this discussion where we certainly are providing the information in that respect. In regard to specifically Alzheimer's disease psychosis and the additional evidence that, that can be looked at in three -- grouped in three different groups. One is related to the primary and secondary outcome, and that is of the reduction in relapse, as well as reduction in the upper clause [Phonetic] discontinuation in this specific group, where we are providing variety of ways of looking into that analyses and demonstrating the benefit that is clinically meaningful and substantive.
As I mentioned in the prepared remarks, between 40% and 50% reduction, where we're also providing not only the overall in the Alzheimer's group, but also specifically in the larger group of patients that received 34 milligram, which is a dose we -- recommended dose and the approved dose in PDP and recommended dose in DRP or Alzheimer's disease psychosis. Second group analyses is following the -- different ways of measuring severity of psychotic symptoms in all of the patients following randomization either to continue active treatment with pimavanserin or to discontinue pimavanserin and switch to placebo or to placebo. We are following over time, the severity of symptoms in these two groups of patients both on the scale for psychotic symptoms for hallucinations and delusions, as well as in the Clinical Global Impression of Change and Improvement, where we are looking at and demonstrating that patients that remaining on treatment continue -- overall continue with the benefit of pimavanserin in terms of control of psychotic symptoms.
We are also looking on the relationship of the dose and drug exposure, pharmacokinetic exposure and the efficacy of the drug as another way of looking of the -- that the effects that we're seeing and benefit that we're seeing in patients that are receiving pimavanserin is real true effect and not spurious finding. And the third group of evidence is really related to the broader overview of the response across different dementia subtypes and characterization of psychotic symptoms prior to treatment, following the treatment with one purpose, and that is to demonstrate the benefits that we're seeing across the subgroup is another supportive evidence that what we're seeing in Alzheimer's disease psychosis subgroup is a real effect. And finally, I would just mention that we're also looking at categorical presentation of response across different categories of patients, specifically in the Alzheimer's disease psychosis and confirming again both overall and in the 34 milligram group, the substantive evidence of benefit in treating patients with pimavanserin. So I hope this helps on the -- on a broader scale.
Charles Duncan -- Cantor Fitzgerald -- Analyst
Definitely. Look forward to hearing the response from the agency, hopefully, they allocate more than an hour to you and forget about the timing of the response, we'll just hear when we hear it.
Serge Stankovic -- President
Yeah, well, I'm sorry, I will address that, I just slipped my mind. We are saying that we -- meeting is scheduled, we will have the meeting and anticipate that we will receive minutes from that meeting around year-end. Just because we're talking about year-end holidays, it's a little bit difficult for us to confidently say that, that whether we will receive the minutes before the end of the year or maybe just after the end year and therefore, we are characterizing that around year-end.
Charles Duncan -- Cantor Fitzgerald -- Analyst
Very good. Thanks for the added color, Serge.
Serge Stankovic -- President
You're welcome.
Operator
Thank you. Our next question comes from the line of Yatin Suneja from Guggenheim Partners. Your line is now open.
Yatin Suneja -- Guggenheim Partners -- Analyst
Thank you. Hey, guys, thank you for taking my question. Just a few question on trofinetide. So you guys are looking at two or a co-primary endpoint, could you comment on what sort of agreements you have with the FDA if you hit on one and what exactly you are aiming to show both on RSBQ and CGI-I? And the second question I have is that could you also confirm to us or let us know if all patients have entered the OLE portion of the study or are there any patients who decided to enter -- to not enter the OLE after the 12-week treatment period?
Stephen R. Davis -- Chief Executive Officer
Yeah, thanks much for the question. Serge, do you want to take both of those?
Serge Stankovic -- President
Yeah, thanks, Yatin. First in terms of the co-primary measure, as we have disclosed to actually having the actual data from the study, I think I would hesitate to speculate on different scenarios that may occur, obviously, what we are focused on is obtaining a positive result and statistical separation of both the Rett Syndrome Behavioral Questionnaire Scale and on the Clinician Scale. Rest assured, we are certainly preparing for all different scenarios in the background, but I don't think it would serve any good purpose for us to speculate what would be -- what would happen if it happens.
From the -- on the second point, vast majority of patients -- we, of course, don't provide again the specific numbers, but I can say that vast majority of patients have rolled over into the open-label extension of the study. And therefore, I think that's -- that hasn't been an issue from the perspective of the further safety exposures on the patient -- for the patients in this program.
Yatin Suneja -- Guggenheim Partners -- Analyst
Got it. Just one more clarifying question on the timeline, could you just maybe let us know how long it might take for you to analyze the data once the trial is completing, just trying to get a sense that if these data could sort of get pushed to January?
Serge Stankovic -- President
I can just say that we are on track to report top-line results from this study before the end year, there hasn't been a change in that respect.
Yatin Suneja -- Guggenheim Partners -- Analyst
Got it. Good luck with that. Thank you.
Serge Stankovic -- President
Thank you.
Operator
Thank you. Our next question comes from the line of Marc Goodman from SVB Leerink. Your line is now open.
Marc Goodman -- SVB Leerink -- Analyst
Serge, you explained nicely what new data you're going to be given to the FDA when you do the meeting, but I'm just curious there were a couple of slides that you went over with us today, has the FDA even seen that data, that subgroup data of Alzheimer's?
Serge Stankovic -- President
Yes, Marc, thanks for the question. We have in the previous meeting discussed some of this, so they have seen some of the data, discussion in the general terms of what we should be providing have been discussed, but some of the output on some of this analyses hasn't. So it's sort of a mixture in that regard. But they have -- we have provided them with a good general idea what direction we are moving in that respect, and we'll be providing much more color in the next meeting in terms of the output and specific data.
Marc Goodman -- SVB Leerink -- Analyst
Right, OK. And then just separately commercial question, can you just give us a sense of how the reps in the office has just changed relative to second quarter and how -- in the third quarter and then how fourth quarter has changed, just give us a sense of the past four months how that's changed?
Stephen R. Davis -- Chief Executive Officer
Yeah, thanks for the question, Marc. Brendan, do you want to take that?
Brendan Teehan -- Executive Vice President, Chief Operating Officer, Head of Commercial
Sure. Marc, thanks for the question. We have seen improved access rates for our representatives both in the community and LTC setting. So I think we previously reported very much in line with what we've seen in the industry. We're up around 70% of visits being face to face, it varies a little bit between community and LTC, but we are encouraged by what we're seeing so far in the early fourth quarter.
Marc Goodman -- SVB Leerink -- Analyst
And where were we three months ago?
Brendan Teehan -- Executive Vice President, Chief Operating Officer, Head of Commercial
So we would -- we were reporting in the 60%, 65% range, so it's continuing to arc up.
Marc Goodman -- SVB Leerink -- Analyst
Thank you.
Stephen R. Davis -- Chief Executive Officer
Maybe just to again say a little bit more, it's very low at the beginning of the year for us and everyone else. And what we've seen in the industry is month by month from the beginning of this year, those numbers were really going up on a very continual and meaningful basis [Technical Issues]. With the Delta variant, you saw that slowdown quite a bit. So where we stand today is, as Brendan mentioned about 70% of our details are in-person, about 30% are virtual. And I think as we see the impact of the Delta variant kind of pull all the way through and you guys are all seeing the same press that we are, I think we're probably approaching that point now, we'll see the impact of the Delta variant pass as well.
Marc Goodman -- SVB Leerink -- Analyst
Thanks.
Operator
Thank you. Our next question comes from the line of Gregory Renza from RBC Capital Markets. Your line is now open.
Gregory Renza -- RBC Capital Markets -- Analyst
Hey, good afternoon, Steve and team. My congratulations on the quarter and thanks for taking my question. Steve, just to follow up on the regulatory update that -- that's expected and as you proceed with engaging the FDA, I know you -- in the past, you have characterized that the stance as more of an agree to disagree position with respect to the totality of DRP versus the subgroups, and I'm just curious, if you can comment quickly on how that's evolved if that changes you're going into the subgroup meeting or the meeting on the subgroup with respect to starting with Alzheimer's disease, and just your level of enthusiasm that that's the right way to proceed with the DRP indication going forward? Thank you very much.
Stephen R. Davis -- Chief Executive Officer
Let me take -- thanks for the question, Greg. Let me take a little bit of running start at it. There is no drug approved to treat dementia-related psychosis, there is no drug approved to treat Alzheimer's disease psychosis, so we're breaking ground. We today have undoubtedly the largest safety database in dementia-related psychosis patients or Alzheimer's disease psychosis patients. In addition, we've done really groundbreaking work in terms of trying to determine how to treat these patients.
Our view has not changed. We still believe that the best way to study this population is looking at dementia-related psychosis as a whole, reasons for that described very thoroughly before.The underlying etiology is relevant as it relates to the dementia itself, but as it relates to psychosis, the symptoms are very similar, they respond in a very similar way, and we think that is the best way to study population. However, in this groundbreaking area, where there is very little data to go on, we understand that reasonable minds [Phonetic] can differ and the FDA does not share that view.
Their view is that we should be looking at things and they should be looking at things on a subgroup by subgroup basis. So recognizing that, we have pivoted to focus on that for the next meeting, describe the history of the CRL dialog we've had, and I would just simply say at this point in time that FDA, this includes the Division of Psychiatry, as well as the Office of Neuroscience have been very engaged. It's a very important topic to them, of course, it's a very important topic to us as well. And together, we expect that this next meeting to come to a conclusion. We are eager to make a decision and move forward. And if they remain engaged in the way that they have been up to this point, I think the prospects are very good. But I'll simply say, again, this is a new area where there's a lot of virgin territory that has not been encountered before. Having said that, when we look at our data in ADP, that is Alzheimer's disease psychosis, we think that data represents a strong case for the utility of pimavanserin from both an efficacy, as well as a safety and tolerability perspective for utility in those -- in that patient population. We need to have that meeting with FDA to see if we can find alignment around that.
Gregory Renza -- RBC Capital Markets -- Analyst
Thanks, Steve. I appreciate the color.
Operator
Thank you. Our next question comes from the line of Ami Fadia from Needham. Your line is now open.
Ami Fadia -- Needham -- Analyst
Great, thanks for taking my question. I had a follow-up on DRP and want to ask the question in a slightly different way, is the point of contention with the FDA around whether or not there is adequate data in the Alzheimer's disease sub population or whether or not the Phase 2 study can be viewed as acceptable as part of registrational package, if you could give us your best sort of view on that? And then I have a different question.
Stephen R. Davis -- Chief Executive Officer
Well, I'll try to give you a little bit of additional color and then Serge feel free to jump in if anything else you want to add. I think when we designed our Phase 3 program and we aligned with the FDA about how to pursue that program, we and the FDA aligned around a design that was not to study Alzheimer's disease psychosis or dementia with Lewy body psychosis or Parkinson's dementia psychosis, it was to study all of these subgroups as one single group, and so that's the Phase 3 program we ran.
Today, as I've just described, the FDA has a perspective that we should be looking at things or they are looking at things on a subgroup by subgroup basis. And so from that perspective, we're in a situation that is a little bit atypical because we're talking about now a group that was not -- where we did not design the study to show statistically significant data on a subgroup basis, but we have very clinically meaningful results in that subgroup. And Serge described I think very thoroughly, we've looked at things from a multitude of cross-sectional perspectives to see if we have consistency in that data and we do.
We also have our -019 study that was focused on just Alzheimer's disease psychosis patients, we have a positive study there, as Serge has described, we need to have further dialog with FDA around the perspective of that being an adequate and well-controlled study. So that's where the pieces on the chessboard are. We're very eager to have the next meeting with FDA to see if we can align around the data to the data that we have.
Serge Stankovic -- President
Yeah, if I just may add, I think it's very important to remember that with everything that Steve said that we did not set out to study Alzheimer's disease psychosis subgroup or any other subgroup specifically, but more as a group that now that we are aligning out the evidence for benefit in that specific subgroup, this has to be taken in the context of actually us having two positive studies. One positive study is -019 study and the second positive study is DRP study, and looking at the subgroup of Alzheimer's disease psychosis is in the context of the robustly positive overall evidence or efficacy. This is a very different situation that if you would look on the study that failed on its primary analyses and then you're looking at a subgroup and seeing whether there is a benefit in the subgroup, completely different, and from that perspective, much more persuasive and convincing in terms of evidence. So we believe that there is independent evidence to two separate studies demonstrating benefit in this particular subgroup of dementia.
Ami Fadia -- Needham -- Analyst
Great, that was very helpful. My second question is on trofinetide, and you answered a question earlier about the co-primary endpoints and the clinical meaningfulness of those, I understand that any type of improvement would be welcome in this patient population, however, as we think about the chronic nature of treatment and the possible requirements of other supportive care for these patients, how would you think about pricing the drug should it get approved?
Stephen R. Davis -- Chief Executive Officer
Yeah, thanks much for the question. I think as much as I'd like to answer the question, I think it would just be premature and imprudent for us to comment on pricing at this juncture. The next step, of course, in that program is to open the envelope, determine the results and if they're -- if we have results that support an application, we'll file it and look forward to moving forward. I would just simply say that as is the case with NUPLAZID, we would seek to price the drug based on the value that we're delivering. It is in the Rett syndrome population, it's a very, very unfortunate situation, where it's -- the extraordinarily high disease burden, and if we can help improve the lives of those patients and their caregivers, we think that'd be very important from a medical perspective.
Ami Fadia -- Needham -- Analyst
Got it. I appreciate that. Thank you.
Operator
Thank you. Our next question comes from the line of Paul Matteis from Stifel. Your line is now open.
Paul Matteis -- Stifel -- Analyst
Hey, thanks so much. I had a couple of questions on the refiling strategy and just the DRP data in general. I guess one is just kind of related to reconciling one thing we've had trouble wrapping our heads around and that is you speak to patients with DRP presenting similarly and responding similarly, but just going back to the forest plot, the hazard ratio in Parkinson's is around 0.1 and it's a lot higher in other subgroups except for Lewy body. So I was just kind of curious how you explain that and if that is not driven by biological differences and disease in your view?
And then second on the ADP subgroup, can you just speak to statistics or anything around that, that can kind of quantitatively bolster your case. I know you talked about a 40% relapse reduction, but the hazard ratio upper bounds is almost 1.5. So how do you think FDA will view that quantitatively speaking or if there is any sort of p-value that's tied to it? Thanks so much.
Stephen R. Davis -- Chief Executive Officer
Yeah, thanks much for the question. Serge, do you want to take those?
Serge Stankovic -- President
Yes. Let me address first question. Paul you characterized, well, the principal question about the difference that we see in the observed hazard ratio in Parkinson's disease psychosis versus the other subgroups of dementia, like Alzheimer's. And what I think the question is, is that really a reason for the biological difference in the response or there is something else going on here that we could point out to and think of, I will, first of all, say, when you just look to the relapse rates in patients on pimavanserin versus relapse rates in patients on placebo after randomization, what we see actually that relapse rates among dementia subtypes are very similar for the groups on pimavanserin, where the difference really is striking is in placebo where patients are randomized to discontinuation of treatment, it turns out that the Parkinson's disease patients relapse much faster at a faster rate than all other patients from group.
So we thought about that why is that happening, because it's on the active treatment, the relapse rates are fairly similar among different subtypes, and thought about what is unique about Parkinson's disease patients that is not present in other subtype. One thing that is unique is actually dopaminergic therapy, it is dopamine stimulating therapy or replacement therapy that these patients are on, all of them are on that, there is virtually just in the whole sample we have just one that wasn't. And when you look at and what is happening is that there additional sort of a stimulus that while the psychotic symptoms are controlled once you discontinue antipsychotic treatment in these patients, they relapse faster because they have this additional kind of promoting element in their concomitant therapy.
So we have presented -- when we intent to present some additional data to FDA in that regard, because we look this -- there are small samples, obviously, there is very few other patients that are not Parkinson's that are on dopamine stimulating therapy, but we can look at that and look at the patterns, and it seems that there is some confirmation of this hypothesis that we are -- so what we see in our data, it's not about biological difference, it is about confounding related to the concomitant therapy effects that we are seeing in this subgroup. So I hope that helps a little bit with your conundrum and reconciling these different hazard ratios.
And now, I'll ask you in regard to the second part of your question, it escaped my mind, while I was thinking and talking about this. So if you can remind me please?
Paul Matteis -- Stifel -- Analyst
Yeah, no worries, Serge, and thank you for the thoughts there, that was super interesting. As it relates to the ADP subgroup right, I mean, we see the 40% relapse reduction, but we also see the hazard ratio for the 95% confidence interval, the upper bounds almost 1.5, which would suggest this is really far away from statistical significance or at least there is -- it's telling you there is a ton of, I guess just sample size issue in the data and I'd be kind of curious how you think about that?
Serge Stankovic -- President
Well, the -- as Steve said, the study is not designed to test statistically separation in the subgroups, because we needed to have more patients in each of the subgroups in order to see that as a reasonable power. So confidence intervals that you're seeing are actually simply a consequence of the sample size that we have, smaller the sample size, larger the confidence intervals that you are talking about.
But what we are presenting the body of evidence related to Alzheimer's disease psychosis is a number of different analysis, some of them reached statis -- nominal statistical significance, some doesn't, but what is important point is consistency of that effect. The question is, is the 40% or 50% risk reduction that we are seeing, nobody argued, it's clinically meaningful and robust. The question is, is that a spurious finding or it is a real true effect.
And one way to demonstrate that, if you look to consistency of different analytical approaches, different outcome measures, different time points and point out to that consistency. And, let's say, sometimes it's not significant, sometimes it's significant nominally, because these are -- some of these are post-hoc analysis or not controlled for Type 1 error. But the point is, if you see something consistently, you start to be convinced that it is actually a true effect and true benefit rather than some spurious chance findings.
Paul Matteis -- Stifel -- Analyst
All right. Thank you so much, Serge.
Serge Stankovic -- President
Thank you.
Operator
Thank you. We have time for one more question. Our next question comes from the line of Jeff Hung from Morgan Stanley. Your line is now open.
Jeffrey Hung -- Morgan Stanley -- Analyst
Thanks for taking the question. For ACP-044, can you provide more granularity on when you expect to complete enrollment and when in the first quarter the data might readout? I guess when would you need to have the enrollment completed for the data in January versus data in March, just appreciate any color you can provide. Thanks.
Stephen R. Davis -- Chief Executive Officer
Yeah, thanks so much for the question, Jeff. Serge, do you want to take that?
Serge Stankovic -- President
Yes, happy to. Thanks, Jeff. What I will say is that we -- as I said, we are experiencing some headwinds, but it's a slight delay. We anticipate that we should be completing enrollment before the end of the year, by the end of the year, and therefore by sometimes within the first quarter or toward the end of first quarter, we should have top -line results. That's again as I'm saying is in the context of dependency, particularly sensitivity of this type of elective surgeries and enrollment there is always a certain level of uncertainty, but we are -- that's generally our expectation.
Jeffrey Hung -- Morgan Stanley -- Analyst
All right. Thank you.
Operator
Thank you. At this time, I'm showing no further questions. I would like to turn the call back over to Steve Davis for closing remarks.
Stephen R. Davis -- Chief Executive Officer
Great, thanks much, operator. Thanks again everyone for joining us today. We look forward to updating you on our progress next quarter.
Operator
[Operator Closing Remarks]
Duration: 75 minutes
Call participants:
Mark Johnson -- Vice President, Investor Relations
Stephen R. Davis -- Chief Executive Officer
Brendan Teehan -- Executive Vice President, Chief Operating Officer, Head of Commercial
Serge Stankovic -- President
Mark Schneyer -- Senior Vice President, Business Development, Chief Business and Interim Chief Financial Officer
Neena Bitritto-Garg -- Citi -- Analyst
Gavin Scott -- JPMorgan -- Analyst
Ritu Baral -- Cowen -- Analyst
Charles Duncan -- Cantor Fitzgerald -- Analyst
Yatin Suneja -- Guggenheim Partners -- Analyst
Marc Goodman -- SVB Leerink -- Analyst
Gregory Renza -- RBC Capital Markets -- Analyst
Ami Fadia -- Needham -- Analyst
Paul Matteis -- Stifel -- Analyst
Jeffrey Hung -- Morgan Stanley -- Analyst
More ACAD analysis
All earnings call transcripts
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Q3 2021 Earnings Call Nov 8, 2021, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen, and welcome to the Acadia Pharmaceuticals Third Quarter 2021 Financial Results Conference Call. I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at Acadia. | See the 10 stocks *Stock Advisor returns as of October 20, 2021 Mark Johnson -- Vice President, Investor Relations [Technical Issues] today's call to discuss Acadia's third quarter 2021 financial results. Operator [Operator Closing Remarks] Duration: 75 minutes Call participants: Mark Johnson -- Vice President, Investor Relations Stephen R. Davis -- Chief Executive Officer Brendan Teehan -- Executive Vice President, Chief Operating Officer, Head of Commercial Serge Stankovic -- President Mark Schneyer -- Senior Vice President, Business Development, Chief Business and Interim Chief Financial Officer Neena Bitritto-Garg -- Citi -- Analyst Gavin Scott -- JPMorgan -- Analyst Ritu Baral -- Cowen -- Analyst Charles Duncan -- Cantor Fitzgerald -- Analyst Yatin Suneja -- Guggenheim Partners -- Analyst Marc Goodman -- SVB Leerink -- Analyst Gregory Renza -- RBC Capital Markets -- Analyst Ami Fadia -- Needham -- Analyst Paul Matteis -- Stifel -- Analyst Jeffrey Hung -- Morgan Stanley -- Analyst More ACAD analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Q3 2021 Earnings Call Nov 8, 2021, 4:30 p.m. | Operator [Operator Closing Remarks] Duration: 75 minutes Call participants: Mark Johnson -- Vice President, Investor Relations Stephen R. Davis -- Chief Executive Officer Brendan Teehan -- Executive Vice President, Chief Operating Officer, Head of Commercial Serge Stankovic -- President Mark Schneyer -- Senior Vice President, Business Development, Chief Business and Interim Chief Financial Officer Neena Bitritto-Garg -- Citi -- Analyst Gavin Scott -- JPMorgan -- Analyst Ritu Baral -- Cowen -- Analyst Charles Duncan -- Cantor Fitzgerald -- Analyst Yatin Suneja -- Guggenheim Partners -- Analyst Marc Goodman -- SVB Leerink -- Analyst Gregory Renza -- RBC Capital Markets -- Analyst Ami Fadia -- Needham -- Analyst Paul Matteis -- Stifel -- Analyst Jeffrey Hung -- Morgan Stanley -- Analyst More ACAD analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Q3 2021 Earnings Call Nov 8, 2021, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen, and welcome to the Acadia Pharmaceuticals Third Quarter 2021 Financial Results Conference Call. | Operator [Operator Closing Remarks] Duration: 75 minutes Call participants: Mark Johnson -- Vice President, Investor Relations Stephen R. Davis -- Chief Executive Officer Brendan Teehan -- Executive Vice President, Chief Operating Officer, Head of Commercial Serge Stankovic -- President Mark Schneyer -- Senior Vice President, Business Development, Chief Business and Interim Chief Financial Officer Neena Bitritto-Garg -- Citi -- Analyst Gavin Scott -- JPMorgan -- Analyst Ritu Baral -- Cowen -- Analyst Charles Duncan -- Cantor Fitzgerald -- Analyst Yatin Suneja -- Guggenheim Partners -- Analyst Marc Goodman -- SVB Leerink -- Analyst Gregory Renza -- RBC Capital Markets -- Analyst Ami Fadia -- Needham -- Analyst Paul Matteis -- Stifel -- Analyst Jeffrey Hung -- Morgan Stanley -- Analyst More ACAD analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Q3 2021 Earnings Call Nov 8, 2021, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen, and welcome to the Acadia Pharmaceuticals Third Quarter 2021 Financial Results Conference Call. |
35785.0 | 2021-11-04 00:00:00 UTC | Noteworthy ETF Outflows: LABU, ALXO, ACAD, XLRN | ACAD | https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-labu-alxo-acad-xlrn-2021-11-04 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $92.3 million dollar outflow -- that's a 9.3% decrease week over week (from 15,061,600 to 13,661,600). Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is off about 8.7%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.5%, and Acceleron Pharma, Inc. (Symbol: XLRN) is higher by about 0.3%. For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average:
Looking at the chart above, LABU's low point in its 52 week range is $47.59 per share, with $185.61 as the 52 week high point — that compares with a last trade of $65.52. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is off about 8.7%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.5%, and Acceleron Pharma, Inc. (Symbol: XLRN) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $92.3 million dollar outflow -- that's a 9.3% decrease week over week (from 15,061,600 to 13,661,600). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is off about 8.7%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.5%, and Acceleron Pharma, Inc. (Symbol: XLRN) is higher by about 0.3%. For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $47.59 per share, with $185.61 as the 52 week high point — that compares with a last trade of $65.52. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is off about 8.7%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.5%, and Acceleron Pharma, Inc. (Symbol: XLRN) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $92.3 million dollar outflow -- that's a 9.3% decrease week over week (from 15,061,600 to 13,661,600). For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $47.59 per share, with $185.61 as the 52 week high point — that compares with a last trade of $65.52. | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is off about 8.7%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.5%, and Acceleron Pharma, Inc. (Symbol: XLRN) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $92.3 million dollar outflow -- that's a 9.3% decrease week over week (from 15,061,600 to 13,661,600). For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $47.59 per share, with $185.61 as the 52 week high point — that compares with a last trade of $65.52. |
35786.0 | 2021-10-21 00:00:00 UTC | ACAD December 3rd Options Begin Trading | ACAD | https://www.nasdaq.com/articles/acad-december-3rd-options-begin-trading-2021-10-21 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the December 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new December 3rd contracts and identified one put and one call contract of particular interest.
The put contract at the $17.50 strike price has a current bid of 95 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $17.50, but will also collect the premium, putting the cost basis of the shares at $16.55 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $18.00/share today.
Because the $17.50 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 5.43% return on the cash commitment, or 46.04% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $17.50 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $20.00 strike price has a current bid of 55 cents. If an investor was to purchase shares of ACAD stock at the current price level of $18.00/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $20.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 14.17% if the stock gets called away at the December 3rd expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $20.00 strike highlighted in red:
Considering the fact that the $20.00 strike represents an approximate 11% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 3.06% boost of extra return to the investor, or 25.91% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $18.00) to be 77%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $20.00 strike highlighted in red: Considering the fact that the $20.00 strike represents an approximate 11% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the December 3rd expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $20.00 strike highlighted in red: Considering the fact that the $20.00 strike represents an approximate 11% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the December 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new December 3rd contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $17.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $20.00 strike price has a current bid of 55 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $20.00 strike highlighted in red: Considering the fact that the $20.00 strike represents an approximate 11% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the December 3rd expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $17.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $20.00 strike price has a current bid of 55 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $20.00 strike highlighted in red: Considering the fact that the $20.00 strike represents an approximate 11% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the December 3rd expiration. |
35787.0 | 2021-10-19 00:00:00 UTC | How The Parts Add Up: IYY Headed For $124 | ACAD | https://www.nasdaq.com/articles/how-the-parts-add-up%3A-iyy-headed-for-%24124-2021-10-19 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Dow Jones U.S. ETF (Symbol: IYY), we found that the implied analyst target price for the ETF based upon its underlying holdings is $124.04 per unit.
With IYY trading at a recent price near $112.59 per unit, that means that analysts see 10.17% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IYY's underlying holdings with notable upside to their analyst target prices are Luminar Technologies Inc (Symbol: LAZR), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Bumble Inc (Symbol: BMBL). Although LAZR has traded at a recent price of $15.47/share, the average analyst target is 71.30% higher at $26.50/share. Similarly, ACAD has 43.94% upside from the recent share price of $17.60 if the average analyst target price of $25.33/share is reached, and analysts on average are expecting BMBL to reach a target price of $66.42/share, which is 30.30% above the recent price of $50.97. Below is a twelve month price history chart comparing the stock performance of LAZR, ACAD, and BMBL:
Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
iShares Dow Jones U.S. ETF IYY $112.59 $124.04 10.17%
Luminar Technologies Inc LAZR $15.47 $26.50 71.30%
Acadia Pharmaceuticals Inc ACAD $17.60 $25.33 43.94%
Bumble Inc BMBL $50.97 $66.42 30.30%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | iShares Dow Jones U.S. ETF IYY $112.59 $124.04 10.17% Luminar Technologies Inc LAZR $15.47 $26.50 71.30% Acadia Pharmaceuticals Inc ACAD $17.60 $25.33 43.94% Bumble Inc BMBL $50.97 $66.42 30.30% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYY's underlying holdings with notable upside to their analyst target prices are Luminar Technologies Inc (Symbol: LAZR), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Bumble Inc (Symbol: BMBL). Similarly, ACAD has 43.94% upside from the recent share price of $17.60 if the average analyst target price of $25.33/share is reached, and analysts on average are expecting BMBL to reach a target price of $66.42/share, which is 30.30% above the recent price of $50.97. | Three of IYY's underlying holdings with notable upside to their analyst target prices are Luminar Technologies Inc (Symbol: LAZR), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Bumble Inc (Symbol: BMBL). Similarly, ACAD has 43.94% upside from the recent share price of $17.60 if the average analyst target price of $25.33/share is reached, and analysts on average are expecting BMBL to reach a target price of $66.42/share, which is 30.30% above the recent price of $50.97. iShares Dow Jones U.S. ETF IYY $112.59 $124.04 10.17% Luminar Technologies Inc LAZR $15.47 $26.50 71.30% Acadia Pharmaceuticals Inc ACAD $17.60 $25.33 43.94% Bumble Inc BMBL $50.97 $66.42 30.30% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Similarly, ACAD has 43.94% upside from the recent share price of $17.60 if the average analyst target price of $25.33/share is reached, and analysts on average are expecting BMBL to reach a target price of $66.42/share, which is 30.30% above the recent price of $50.97. Three of IYY's underlying holdings with notable upside to their analyst target prices are Luminar Technologies Inc (Symbol: LAZR), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Bumble Inc (Symbol: BMBL). Below is a twelve month price history chart comparing the stock performance of LAZR, ACAD, and BMBL: Below is a summary table of the current analyst target prices discussed above: | iShares Dow Jones U.S. ETF IYY $112.59 $124.04 10.17% Luminar Technologies Inc LAZR $15.47 $26.50 71.30% Acadia Pharmaceuticals Inc ACAD $17.60 $25.33 43.94% Bumble Inc BMBL $50.97 $66.42 30.30% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYY's underlying holdings with notable upside to their analyst target prices are Luminar Technologies Inc (Symbol: LAZR), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Bumble Inc (Symbol: BMBL). Similarly, ACAD has 43.94% upside from the recent share price of $17.60 if the average analyst target price of $25.33/share is reached, and analysts on average are expecting BMBL to reach a target price of $66.42/share, which is 30.30% above the recent price of $50.97. |
35788.0 | 2021-10-07 00:00:00 UTC | November 26th Options Now Available For Acadia Pharmaceuticals | ACAD | https://www.nasdaq.com/articles/november-26th-options-now-available-for-acadia-pharmaceuticals-2021-10-07 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the November 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new November 26th contracts and identified one put and one call contract of particular interest.
The put contract at the $15.00 strike price has a current bid of 5 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $15.00, but will also collect the premium, putting the cost basis of the shares at $14.95 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $17.23/share today.
Because the $15.00 strike represents an approximate 13% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.33% return on the cash commitment, or 2.43% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $17.50 strike price has a current bid of 40 cents. If an investor was to purchase shares of ACAD stock at the current price level of $17.23/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $17.50. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 3.89% if the stock gets called away at the November 26th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $17.50 strike highlighted in red:
Considering the fact that the $17.50 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 2.32% boost of extra return to the investor, or 16.93% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $17.23) to be 77%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $17.50 strike highlighted in red: Considering the fact that the $17.50 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the November 26th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $17.50 strike highlighted in red: Considering the fact that the $17.50 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the November 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new November 26th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $17.50 strike price has a current bid of 40 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $17.50 strike highlighted in red: Considering the fact that the $17.50 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the November 26th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $17.50 strike price has a current bid of 40 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $17.50 strike highlighted in red: Considering the fact that the $17.50 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the November 26th expiration. |
35789.0 | 2021-10-06 00:00:00 UTC | LABU, ALXO, ACAD, XLRN: Large Inflows Detected at ETF | ACAD | https://www.nasdaq.com/articles/labu-alxo-acad-xlrn%3A-large-inflows-detected-at-etf-2021-10-06 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $115.2 million dollar inflow -- that's a 20.6% increase week over week in outstanding units (from 10,661,600 to 12,861,600). Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is off about 2%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is down about 0.3%, and Acceleron Pharma, Inc. (Symbol: XLRN) is lower by about 0.7%. For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average:
Looking at the chart above, LABU's low point in its 52 week range is $47.59 per share, with $185.61 as the 52 week high point — that compares with a last trade of $50.73. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is off about 2%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is down about 0.3%, and Acceleron Pharma, Inc. (Symbol: XLRN) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $115.2 million dollar inflow -- that's a 20.6% increase week over week in outstanding units (from 10,661,600 to 12,861,600). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is off about 2%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is down about 0.3%, and Acceleron Pharma, Inc. (Symbol: XLRN) is lower by about 0.7%. For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $47.59 per share, with $185.61 as the 52 week high point — that compares with a last trade of $50.73. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is off about 2%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is down about 0.3%, and Acceleron Pharma, Inc. (Symbol: XLRN) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $115.2 million dollar inflow -- that's a 20.6% increase week over week in outstanding units (from 10,661,600 to 12,861,600). For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $47.59 per share, with $185.61 as the 52 week high point — that compares with a last trade of $50.73. | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is off about 2%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is down about 0.3%, and Acceleron Pharma, Inc. (Symbol: XLRN) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $115.2 million dollar inflow -- that's a 20.6% increase week over week in outstanding units (from 10,661,600 to 12,861,600). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. |
35790.0 | 2021-09-29 00:00:00 UTC | Can These Former Biotech Growth Stocks Regain Their Form? | ACAD | https://www.nasdaq.com/articles/can-these-former-biotech-growth-stocks-regain-their-form-2021-09-29 | nan | nan | Biotech investing is a tumultuous process. Equities can stagnate for years while the multi-phase clinical process unfolds. And then, seemingly out of the blue, their share prices can explode higher following a positive trial result, regulatory outcome, or lucrative partnership. To come full circle, the once-high-flying equity tends to slowly but surely revert back to the mean due to the harsh reality of selling, marketing, and managing the lifecycle of a novel medication.
All that being said, biotech stocks in the middle of an important commercial launch or long-winded clinical trial can be powerful growth vehicles. Kadmon Holdings, for example, was essentially lost at sea until French pharma giant Sanofi swooped in to buy the company for a tidy $1.9 billion on a fully diluted basis. Biotech is chock-full of similar stories of early commercial stage companies floundering until a partner or suitor enters the picture. The lesson, if you will, is that investors shouldn't necessarily write off biopharma companies whose share prices have stagnated due to a commercial, clinical, or regulatory setback.
Acadia Pharmaceuticals (NASDAQ: ACAD) and Clovis Oncology (NASDAQ: CLVS) have both lagged behind the broader markets in a big way in 2021, even though they were super-charged growth stocks in the not-so-distant past. While there's no guarantee that either of these names will regain its prior form as a top growth stock, these two biotech companies do sport the type of key assets to spark a comeback. Here's a brief overview on the core value proposition of each of these stocks.
Image source: Getty Images.
Acadia: Patience will be key
Acadia's shares are down by a jaw-dropping 68% so far this year, which is in stark contrast to its nearly 1,000% gain from Jan., 1, 2013 to March 1, 2021. The drugmaker's shares cratered back in March in response to a regulatory setback for its flagship compound, pimavanserin, as a potential treatment for dementia-related psychosis. The drug is already approved by the Food and Drug Administration as a treatment for Parkinson's disease psychosis under the brand name Nuplazid. And although Acadia's management expects the drug to possibly achieve sales in excess of $500 million for Parkinson's disease psychosis in 2021, this second indication was widely believed to be the key to push it into blockbuster territory (sales topping $1 billion per year).
The real problem with Acadia's plunge was that shareholders were apparently banking on this label expansion to trigger a buyout offer (based on its enormous premium prior to this drop). Blockbuster psych meds, after all, are a rare commodity. That value proposition, unfortunately, appears to be on hold while Acadia figures out how to advance pimavanserin's dementia-related psychosis indication. A new trial may be required -- which would take years to complete -- or the FDA might allow the drug on the market in some kind of limited capacity (certain patient subgroups with dementia-related psychosis).
What's the verdict? If you are willing to hold this stock for a minimum of three years, my hunch (and it's only a hunch) is that you will be richly rewarded. Nuplazid's sales should continue to inch higher for Parkinson's disease psychosis, and the company does have several other assets in the clinic, after all. The bad news is that Acadia is unlikely to change the narrative around its stock anytime soon. Patience, in turn, will be required with this name.
Clovis: An odd distinction
Clovis Oncology isn't the first cancer company to have a rough time following an FDA approval. But the fact of the matter is the bulk of these companies tend to either find a partner or land a sizable buyout offer. Clovis, on the other hand, has failed on both of these fronts. As a result, its shares have lost a whopping 84% of their value over the past 36 months. The biotech's stock, in fact, has now given back all of its 445% gain (and then some) over the seven-year span from its initial public offering in 2011 to 2018. What's noteworthy about this story is that the company has actually earned three high-value indications for its Poly ADP-ribose Polymerase (PARP) inhibitor Rubraca during this period.
CLVS data by YCharts
Namely, Rubraca is currently approved as a maintenance treatment for adult patients with certain types of ovarian cancer, as a treatment for ovarian cancer patients with a deleterious BRCA mutation, and as a treatment for adult patients with a deleterious BRCA mutation associated metastatic castration-resistant prostate cancer.
Despite these regulatory wins, however, the drug's sales are on track to dip by approximately 4% this year relative to 2020. The core reason is that bigger pharmas like AstraZeneca are absolutely dominating the PARP market with their own drugs. Clovis is hoping to flip the script with multiple label expansions within the next six to 12 months, but that scenario is wholly dependent on the upcoming trial data.
Can Clovis recapture its mojo as a once-high-flying growth stock? The answer is obviously yes, but with a big caveat. The company needs Rubraca to hit on at least some of its other solid tumor indications. Ovarian and prostate cancer alone do not appear to be the drug's sweet spot based on how it's performing relative to other drugs on the market.
What's the upside potential? Rubraca could still become a blockbuster drug over the next three years. What this means is that Clovis' market cap of $552 million at present would look like a bargain in hindsight. On the flip side of the coin, Clovis doesn't have a whole lot of room for error. Any major clinical setbacks could spoil the biotech's potentially juicy comeback story.
10 stocks we like better than Clovis Oncology
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Clovis Oncology wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of September 17, 2021
George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The real problem with Acadia's plunge was that shareholders were apparently banking on this label expansion to trigger a buyout offer (based on its enormous premium prior to this drop). Acadia Pharmaceuticals (NASDAQ: ACAD) and Clovis Oncology (NASDAQ: CLVS) have both lagged behind the broader markets in a big way in 2021, even though they were super-charged growth stocks in the not-so-distant past. Acadia: Patience will be key Acadia's shares are down by a jaw-dropping 68% so far this year, which is in stark contrast to its nearly 1,000% gain from Jan., 1, 2013 to March 1, 2021. | Acadia Pharmaceuticals (NASDAQ: ACAD) and Clovis Oncology (NASDAQ: CLVS) have both lagged behind the broader markets in a big way in 2021, even though they were super-charged growth stocks in the not-so-distant past. Acadia: Patience will be key Acadia's shares are down by a jaw-dropping 68% so far this year, which is in stark contrast to its nearly 1,000% gain from Jan., 1, 2013 to March 1, 2021. And although Acadia's management expects the drug to possibly achieve sales in excess of $500 million for Parkinson's disease psychosis in 2021, this second indication was widely believed to be the key to push it into blockbuster territory (sales topping $1 billion per year). | Acadia Pharmaceuticals (NASDAQ: ACAD) and Clovis Oncology (NASDAQ: CLVS) have both lagged behind the broader markets in a big way in 2021, even though they were super-charged growth stocks in the not-so-distant past. And although Acadia's management expects the drug to possibly achieve sales in excess of $500 million for Parkinson's disease psychosis in 2021, this second indication was widely believed to be the key to push it into blockbuster territory (sales topping $1 billion per year). Acadia: Patience will be key Acadia's shares are down by a jaw-dropping 68% so far this year, which is in stark contrast to its nearly 1,000% gain from Jan., 1, 2013 to March 1, 2021. | Acadia Pharmaceuticals (NASDAQ: ACAD) and Clovis Oncology (NASDAQ: CLVS) have both lagged behind the broader markets in a big way in 2021, even though they were super-charged growth stocks in the not-so-distant past. Acadia: Patience will be key Acadia's shares are down by a jaw-dropping 68% so far this year, which is in stark contrast to its nearly 1,000% gain from Jan., 1, 2013 to March 1, 2021. And although Acadia's management expects the drug to possibly achieve sales in excess of $500 million for Parkinson's disease psychosis in 2021, this second indication was widely believed to be the key to push it into blockbuster territory (sales topping $1 billion per year). |
35791.0 | 2021-09-23 00:00:00 UTC | November 5th Options Now Available For Acadia Pharmaceuticals | ACAD | https://www.nasdaq.com/articles/november-5th-options-now-available-for-acadia-pharmaceuticals-2021-09-23 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the November 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new November 5th contracts and identified one put and one call contract of particular interest.
The put contract at the $16.00 strike price has a current bid of 5 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $16.00, but will also collect the premium, putting the cost basis of the shares at $15.95 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $17.17/share today.
Because the $16.00 strike represents an approximate 7% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.31% return on the cash commitment, or 2.65% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $16.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 15 cents. If an investor was to purchase shares of ACAD stock at the current price level of $17.17/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $18.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 5.71% if the stock gets called away at the November 5th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red:
Considering the fact that the $18.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 0.87% boost of extra return to the investor, or 7.42% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $17.17) to be 77%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the November 5th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the November 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new November 5th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $16.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 15 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the November 5th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $16.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 15 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the November 5th expiration. |
35792.0 | 2021-09-16 00:00:00 UTC | Oversold Conditions For Acadia Pharmaceuticals | ACAD | https://www.nasdaq.com/articles/oversold-conditions-for-acadia-pharmaceuticals-2021-09-16 | nan | nan | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $15.705 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 47.8. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares:
Looking at the chart above, ACAD's low point in its 52 week range is $15.6792 per share, with $57.46 as the 52 week high point — that compares with a last trade of $15.78.
Find out what 9 other oversold stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $15.705 per share. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $15.6792 per share, with $57.46 as the 52 week high point — that compares with a last trade of $15.78. | A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $15.6792 per share, with $57.46 as the 52 week high point — that compares with a last trade of $15.78. In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $15.705 per share. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $15.705 per share. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $15.6792 per share, with $57.46 as the 52 week high point — that compares with a last trade of $15.78. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $15.705 per share. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $15.6792 per share, with $57.46 as the 52 week high point — that compares with a last trade of $15.78. |
35793.0 | 2021-09-09 00:00:00 UTC | ACAD October 29th Options Begin Trading | ACAD | https://www.nasdaq.com/articles/acad-october-29th-options-begin-trading-2021-09-09 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 29th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new October 29th contracts and identified one put and one call contract of particular interest.
The put contract at the $16.00 strike price has a current bid of 50 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $16.00, but will also collect the premium, putting the cost basis of the shares at $15.50 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $16.48/share today.
Because the $16.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 3.12% return on the cash commitment, or 22.81% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $16.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $17.00 strike price has a current bid of 55 cents. If an investor was to purchase shares of ACAD stock at the current price level of $16.48/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $17.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 6.49% if the stock gets called away at the October 29th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $17.00 strike highlighted in red:
Considering the fact that the $17.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 3.34% boost of extra return to the investor, or 24.36% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $16.48) to be 77%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $17.00 strike highlighted in red: Considering the fact that the $17.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 29th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $17.00 strike highlighted in red: Considering the fact that the $17.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 29th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new October 29th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $16.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $17.00 strike price has a current bid of 55 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $17.00 strike highlighted in red: Considering the fact that the $17.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 29th expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $16.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $17.00 strike price has a current bid of 55 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $17.00 strike highlighted in red: Considering the fact that the $17.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 29th expiration. |
35794.0 | 2021-09-09 00:00:00 UTC | How Does Acadia Stock Performance In The Current Crisis Compare With That In 2008? | ACAD | https://www.nasdaq.com/articles/how-does-acadia-stock-performance-in-the-current-crisis-compare-with-that-in-2008-2021-09 | nan | nan | We believe that Acadia Pharmaceuticals stock (NASDAQ: ACAD), a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time. ACAD stock trades around $17 levels currently and it is, in fact, down 64% from its pre-Covid high of around $47 in February 2020 – before the coronavirus pandemic hit the world.
Acadia hasn’t had a great year thus far with its stock plummeting 68% year-t0-date. Much of this decline came in March after the U.S. FDA rejected the supplementary new drug application for Nuplazid, which is currently used to treat hallucinations associated with Parkinson’s disease psychosis (PDP), stating it lacked statistical significance in some of the subgroups of dementia. However, we continue to believe that ACAD stock is oversold now, and it is likely to see higher levels going forward. While the rejection of supplementary new drug application was surely negative, Nuplazid continues to see strong demand from PDP treatment. Moreover, Acadia says it will work with the FDA to resolve discrepancies in its application for dementia-related psychosis treatment. Apart from Nuplazid, the company also has three more programs in its pipeline, including Trofinetide, which is being investigated for the treatment of Rett Syndrome and it has peak sales potential of over $500 million.
While ACAD stock has seen lower levels during the current Covid-19 crisis, how did it fare in the 2008 crisis? In this note we focus on a comparative analysis of Acadia stock during the 2008 recession vs now in our interactive dashboard.
Timeline of 2020 Coronavirus Crisis:
12/12/2019: Coronavirus cases first reported in China
1/31/2020: WHO declares a global health emergency.
2/19/2020: Signs of effective containment in China and hopes of monetary easing by major central banks helps S&P 500 reach a record high
3/23/2020: S&P 500 drops 34% from the peak level seen on Feb 19, 2020, as Covid-19 cases accelerate outside China. Doesn’t help that oil prices crash in mid-March amid Saudi-led price war
Since 3/24/2020: S&P 500 rallies 103% from the lows seen on Mar 23, 2020, as the Fed’s multi-billion dollar stimulus package suppresses near-term survival anxiety and infuses liquidity into the system.
In contrast, here is how ACAD stock and the broader market fared during the 2007-08 crisis
Timeline of 2007-08 Crisis
10/1/2007: Approximate pre-crisis peak in S&P 500 index
9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08)
3/1/2009: Approximate bottoming out of S&P 500 index
12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008)
ACAD and S&P 500 Performance Over 2007-08 Financial Crisis
ACAD stock plummeted from from levels of about $16 in October 2007 (pre-crisis peak for the broader markets) to levels of $3 in September 2008 before plunging to under $1 in March 2009 (as the markets bottomed out), implying ACAD stock lost 95% from its peak. It saw a small recovery immediately post the 2008 crisis, to levels of over $1 by January 2010. In comparison, the S&P 500 Index saw a decline of 51% from its peak in September 2007 to its bottom in March 2009, followed by a sharp recovery of 48% by January 2010.
Acadia Fundamentals Over Recent Years Have Been Robust
Acadia’s revenues increased from $125 million in 2017 to $463 million for the last twelve-month period, led by increased sales of Nuplazid. The company is currently running into losses, partly due to higher R&D investments. That said, the losses have narrowed to $1.65 per share over the last twelve-month period, compared to a loss of $2.36 per share in 2017.
Does Acadia Have Sufficient Cash Cushion To Meet Its Obligations?
Acadia’s total debt rose from zero to around $66 million currently, while its total cash increased from $341 million in 2017 to $557 million currently. It utilized $136 million in cash for its operations over the last twelve-months period. The company has a comfortable liquidity position to meet its near term requirements.
Conclusion
Phases of Covid-19 Crisis:
Early- to mid-March 2020: Fear of the coronavirus outbreak spreading rapidly translates into reality, with the number of cases accelerating globally
Late-March 2020 onward: Social distancing measures + lockdowns
April 2020: Fed stimulus suppresses near-term survival anxiety
May-June 2020: Recovery of demand, with gradual lifting of lockdowns – no panic anymore despite a steady increase in the number of cases
Since late 2020: Weak quarterly results, but continued improvement in demand and progress with vaccine development buoy market sentiment. Multiple countries have undertaken large-scale vaccine programs for Covid-19, though new variants of coronavirus resulted in an uptick in active cases.
Overall, ACAD stock looks oversold and it is likely to see a rebound in the near term, in our view. Even if we look at the average of analysts price estimates of $26, it reflects over 50% upside from the current levels.
While ACAD stock can see a rebound, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for IDEXX vs Vertex.
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We believe that Acadia Pharmaceuticals stock (NASDAQ: ACAD), a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time. ACAD stock trades around $17 levels currently and it is, in fact, down 64% from its pre-Covid high of around $47 in February 2020 – before the coronavirus pandemic hit the world. Acadia hasn’t had a great year thus far with its stock plummeting 68% year-t0-date. | In contrast, here is how ACAD stock and the broader market fared during the 2007-08 crisis Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) ACAD and S&P 500 Performance Over 2007-08 Financial Crisis ACAD stock plummeted from from levels of about $16 in October 2007 (pre-crisis peak for the broader markets) to levels of $3 in September 2008 before plunging to under $1 in March 2009 (as the markets bottomed out), implying ACAD stock lost 95% from its peak. Acadia’s total debt rose from zero to around $66 million currently, while its total cash increased from $341 million in 2017 to $557 million currently. We believe that Acadia Pharmaceuticals stock (NASDAQ: ACAD), a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time. | In contrast, here is how ACAD stock and the broader market fared during the 2007-08 crisis Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) ACAD and S&P 500 Performance Over 2007-08 Financial Crisis ACAD stock plummeted from from levels of about $16 in October 2007 (pre-crisis peak for the broader markets) to levels of $3 in September 2008 before plunging to under $1 in March 2009 (as the markets bottomed out), implying ACAD stock lost 95% from its peak. Acadia Fundamentals Over Recent Years Have Been Robust Acadia’s revenues increased from $125 million in 2017 to $463 million for the last twelve-month period, led by increased sales of Nuplazid. We believe that Acadia Pharmaceuticals stock (NASDAQ: ACAD), a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time. | While ACAD stock has seen lower levels during the current Covid-19 crisis, how did it fare in the 2008 crisis? Overall, ACAD stock looks oversold and it is likely to see a rebound in the near term, in our view. We believe that Acadia Pharmaceuticals stock (NASDAQ: ACAD), a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time. |
35795.0 | 2021-09-07 00:00:00 UTC | LABU, ALXO, ACAD, XLRN: Large Outflows Detected at ETF | ACAD | https://www.nasdaq.com/articles/labu-alxo-acad-xlrn%3A-large-outflows-detected-at-etf-2021-09-07 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $190.4 million dollar outflow -- that's a 21.0% decrease week over week (from 13,311,600 to 10,511,600). Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 2%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.5%, and Acceleron Pharma, Inc. (Symbol: XLRN) is lower by about 0.5%. For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average:
Looking at the chart above, LABU's low point in its 52 week range is $42.2563 per share, with $185.61 as the 52 week high point — that compares with a last trade of $67.85. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 7%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 2%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.5%, and Acceleron Pharma, Inc. (Symbol: XLRN) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $190.4 million dollar outflow -- that's a 21.0% decrease week over week (from 13,311,600 to 10,511,600). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 2%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.5%, and Acceleron Pharma, Inc. (Symbol: XLRN) is lower by about 0.5%. For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $42.2563 per share, with $185.61 as the 52 week high point — that compares with a last trade of $67.85. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 2%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.5%, and Acceleron Pharma, Inc. (Symbol: XLRN) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $190.4 million dollar outflow -- that's a 21.0% decrease week over week (from 13,311,600 to 10,511,600). For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $42.2563 per share, with $185.61 as the 52 week high point — that compares with a last trade of $67.85. | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 2%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.5%, and Acceleron Pharma, Inc. (Symbol: XLRN) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $190.4 million dollar outflow -- that's a 21.0% decrease week over week (from 13,311,600 to 10,511,600). Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
35796.0 | 2021-09-06 00:00:00 UTC | Centene, ACADIA: Why These Out Of Favor Health Care Stocks Are Worth A Look | ACAD | https://www.nasdaq.com/articles/centene-acadia%3A-why-these-out-of-favor-health-care-stocks-are-worth-a-look-2021-09-06 | nan | nan | Our theme of Out Of Favor Health Care Stocks includes healthcare and pharma names that are seeing a disconnect between their financial performance and recent stock price returns. The theme remains down by about 27% year-to-date, compared to the S&P 500 which is up by a solid 21%. So why could these stocks be worth investing in? All the companies have grown revenue by at least 50% over the last three years, with operating margins also expanding, and despite this, have seen their stocks return less than 10% since early 2020, a period through which the S&P 500 has gained almost 40%. Although some of the companies in our theme have seen setbacks to their development pipelines, we think the risk-reward positioning should be favorable given the correction in most of the stocks. Moreover, there is the possibility that investors could rotate from richly valued stocks to value picks and beaten-down names and this could also help the stocks in our theme.
Within our theme, Centene (CNC) a full-line managed services company that services both government-sponsored and private insurance health care programs has been one of the better performers, with its stock rising by about 5% year-to-date. On the other side, ACADIA Pharmaceuticals stock (ACAD), down by 67% year-to-date, has been the weakest performer. This was largely due to the company’s flagship drug Nuplazid, which is currently used to treat hallucinations associated with Parkinson’s disease psychosis (PDP), seeing a regulatory setback on a proposed label expansion as a treatment for dementia-related psychosis, earlier this year.
[6/30/2021] Is There Deep Value In These Beaten Down Healthcare Stocks?
Our theme of Out Of Favor Health Care Stocks includes healthcare and pharma names that are seeing a disconnect between their financial performance and stock price returns. Specifically, the theme filters for healthcare companies that have grown revenue by at least 50% over the last three years, with operating margins also expanding, and despite this, have seen their stocks return less than 10% since early 2020. Overall, the theme remains down by about 29% year-to-date, compared to the S&P 500 which is up by about 15%. However, with coronavirus cases in the U.S. on the decline and healthcare spending on areas outside of Covid likely to pick up, the stocks in our theme could see some upside. Moreover, the broader market rotation from richly valued stocks to value picks could also help the stocks in our theme. Below is a bit more about how some of the stocks in our theme have been faring.
Sarepta Therapeutics (SRPT), a company that develops RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, has seen its stock decline by 54% year-to-date. The decline is due to unfavorable outcomes from clinical trials for one of its drugs, SRP-9001, used for treating Duchenne muscular dystrophy (DMD). However, the sell-off appears overdone, as there have been some positive developments for the stock, including the approval of Amondys 45, a drug used to treat certain patients with DMD. The company also has multiple other drugs in development that will likely help it gain share in the DMD treatment space over the coming years.
Vertex Pharmaceuticals (VRTX) stock is down by about 17% year-to-date, driven partly by the company’s move to abandon further development of VX-864 for alpha-1 antitrypsin deficiency (AATD) following phase 2 trials, as it noted that the drug was unlikely to provide substantial clinical benefit. However, the company’s most important drug, a 3-in-1 pill called ‘Trikafta,” which is used for the treatment of Cystic Fibrosis, has been seeing traction, generating about $3.9 billion in its first full year of sales in 2020. The stock could benefit as sales scale up further.
Neurocrine Biosciences (NBIX) is a biopharma company that develops treatments for neurological and endocrine-related disease disorders. The stock has remained roughly flat this year, as the phase two study of Luvadaxistat failed to achieve its primary endpoint of easing the negative symptoms of schizophrenia. Moreover, the company’s first FDA-approved drug Ingrezza, a treatment for Tardive Dyskinesia, faced headwinds due to the Covid pandemic, which impacted new patient starts. That said, with Covid cases off their highs and over half of U.S adults vaccinated, Ingrezza could see sales improve. Peak sales are estimated to be over $2 billion, compared to sales of $993 million in 2020.
[5/27/2021] Are These Healthcare Stocks Worth A Look?
Our theme of Out Of Favor Health Care Stocks includes healthcare and pharma stocks that have done reasonably well financially in recent years, although their stock prices have declined or underperformed due to setbacks in their development pipelines or due to Covid-19 related disruptions in the healthcare industry. The theme is down by about -33% year to date, compared to the S&P 500 which is up by about 12% over the same period. Below is a bit more about some of the companies in our theme, the reasons for their underperformance, and why we think they could be poised to recover.
ACADIA Pharmaceuticals (ACAD) a biopharmaceutical company focused on neuroscience drugs, has been the worst performer within our theme, with its stock down by 59% year-to-date. The underperformance comes as the company’s flagship drug Nuplazid, which is currently used to treat hallucinations associated with Parkinson’s disease psychosis (PDP), saw a regulatory setback on a proposed label expansion as a treatment for dementia-related psychosis in March. The company could still see an upside as Nuplazid continues to see strong demand from PDP treatment. Moreover, ACADIA says it will work with the FDA to resolve discrepancies in its application for dementia-related psychosis treatment.
Emergent Biosolutions (EBS), a specialty biopharmaceutical company, has seen its stock decline by about 36% this year. The sell-off comes as the company revealed that a “human error” in its Baltimore plant resulted in the contamination of a batch of Johnson & Johnson’s (NYSE: JNJ) Covid-19 vaccines, which it was helping to produce. The FDA asked the company to pause production and inspected the facility, making nine observations primarily on quality issues. That said, the worst is likely behind EBS stock now with the company recently noting that it was rectifying the issues, with production likely to resume “within days.” Considering the current pandemic and the shortage of vaccines globally, it’s likely that demand for the company’s services will hold up. Consensus estimates point to revenue growth of about 16% for this year.
Vertex Pharmaceuticals (VRTX) stock is down by about 12 % year-to-date, on account of mixed quarterly results and the company’s move to discontinue VX-814, a drug that was being investigated for a potential treatment for alpha-1 antitrypsin deficiency (AATD), last year. However, the company’s most important drug, a 3-in-1 pill called ‘Trikafta,” which is used for the treatment of Cystic Fibrosis, has been seeing traction, generating about $3.9 billion in its first full year of sales in 2020, and Vertex stock could benefit as sales scale up further.
[4/14/2021] Out Of Favor Healthcare Stocks To Watch
Our theme of Out Of Favor Health Care Stocks includes healthcare and pharma names that have done reasonably well financially in recent years, although their stock prices have declined or underperformed, on account of Covid-19 related disruptions in the healthcare industry, or due to setbacks in their development pipelines. The theme is down by about -26% year to date, compared to the S&P 500 which is up by about 10% over the same period. Below is a bit more about how some of the stocks in our theme have been faring.
Vertex Pharmaceuticals (VRTX) stock is down by about 3% year-to-date, on account of mixed results over Q4 and the company’s move to discontinue VX-814, a drug that was being investigated for a potential treatment for alpha-1 antitrypsin deficiency (AATD), last year. However, the company’s most important drug, a 3-in-1 pill called ‘Trikafta,” which is used for the treatment of Cystic Fibrosis, has been seeing traction, generating about $3.9 billion in its first full year of sales in 2020. The stock could benefit as sales scale up further.
Neurocrine Biosciences (NBIX) is a biopharma company that develops treatments for neurological and endocrine-related disease disorders. The stock has seen some headwinds, declining by about 14% year to date, as the phase two study of Luvadaxistat failed to achieve its primary endpoint of easing the negative symptoms of schizophrenia. Moreover, the company’s first FDA-approved drug Ingrezza, a treatment for Tardive Dyskinesia, faced headwinds due to the Covid pandemic, which impacted new patient starts. That said, with Covid cases off their highs and vaccinations picking up, Ingrezza could see sales improve. Peak sales are estimated to be over $2 billion, compared to sales of $993 million in 2020.
Centene (CNC) is a full-line managed services company that services both government-sponsored and private insurance health care programs. The stock has remained almost flat year-to-date, due to mixed quarterly earnings and some headwinds due to Covid-19. However, the stock could see gains in the medium term. Insurance companies specializing in government-sponsored Medicaid health programs could benefit, as President Joe Biden supports the Obamacare plan and potential reforms by Democrats in the healthcare sector could bode well for Centene.
[3/16/2021] Out Of Favor Health Care Stocks
Out Of Favor Health Care Stocks includes healthcare and pharma names that have done reasonably well financially in recent years, although their stock prices have lagged, due to Covid-19 related disruptions in the healthcare industry or due to some setbacks in their development pipelines. That said, the broader markets have seen significant sector rotation in recent weeks, with investors reallocating funds from expensive, high-growth tech stocks to value stocks and companies that could benefit as the Covid-19 pandemic wanes. It’s likely that some of the names in our theme could benefit from this trend as well. Here is a bit more about some of these companies have how they have been faring this year.
Centene (CNC) is a managed healthcare plan provider and is the largest Medicaid Managed Care Organization. The stock is down by about -2% year-to-date, due to mixed quarterly earnings and some headwinds due to Covid-19. However, with Covid-19 infections on the decline in the U.S. in recent weeks, and with Democrats achieving a U.S. government trifecta, the stock could see gains in the medium term.
Neurocrine Biosciences (NBIX) is a biopharma company that develops treatments for neurological and endocrine-related disease disorders. The company’s first FDA-approved drug Ingrezza, a treatment for Tardive Dyskinesia, is facing headwinds due to the Covid pandemic, which is impacting new patient starts. The stock is down by about -16% year-to-date.
Sarepta Therapeutics (SRPT) stock has declined by over 35% since early January due to unfavorable outcomes from clinical trials for one of its drugs, SRP-9001, used for treating Duchenne muscular dystrophy (DMD). However, the sell-off appears overdone, as there have been some positive developments for the stock, including the approval of Amondys 45, a drug used to treat certain patients with DMD.
See our theme Out Of Favor Health Care Stocks for a detailed look at the complete set of companies in the theme and our detailed selection criteria.
[2/22/2021] Sarepta, Neurocrine and Vertex
Our theme of Out Of Favor Health Care Stocks includes companies that have robust revenue growth and improving margins, and yet have not rallied much over the last year or so, due to Covid-19 related disruptions in the healthcare industry or due to some setbacks in their development pipelines. Below is a bit more about these stocks and why we think they could be good picks at current levels. See our theme Out Of Favor Health Care Stocks for a detailed look at the complete set of companies in the theme and our detailed selection criteria.
Sarepta Therapeutics stock (SRPT) has declined by over 50% since early January due to unfavorable outcomes from clinical trials for one of its drugs, SRP-9001, used for treating Duchenne muscular dystrophy (DMD). However, the stock looks attractive at current levels, considering that the company already had a couple of products that are already generating meaningful revenue, including Vyondys 53 and Exondys 51 which are both approved to treat DMD. Peak sales for Exondys 51’s are estimated to be upwards of $1 billion, compared to sales of $381 million in 2019, while Vyondys 53 can garner $250 million in peak sales. The company also reported a solid 41% sales growth in the first nine months of 2020. (Related: After A 50% Fall Sarepta Therapeutics Stock Now Looks Attractive)
Neurocrine Biosciences (NBIX) is a biopharma company that develops treatments for neurological and endocrine-related disease disorders. The company’s first FDA-approved drug Ingrezza, a treatment for Tardive Dyskinesia, is facing headwinds due to the Covid pandemic, which is impacting new patient starts. Although sales could remain lackluster for a few quarters, they should see gains in the medium to long run as Covid-19 cases moderate, with vaccine dosing in the U.S. rising. In fact, Ingrezza’s peak sales are estimated to be over $2 billion, compared to the sales of $753 million seen in 2019.
Vertex Pharmaceuticals’ (VRTX) current commercial drugs primarily deal with Cystic Fibrosis (CF), a genetic disease that affects the lungs and digestive system. The company’s most important drug, a 3-in-1 pill called ‘Trikafta,” was approved by the US FDA in late 2019 and generated about $3.9 billion in its first full year of sales in 2020. That said, the stock has underperformed as the biotech company discontinued the development of a drug for alpha-1 antitrypsin deficiency (AATD) last October. However, the company is developing another drug for the same disorder, with clinical data expected for the first half of 2021. Moreover, the company is likely to continue benefiting from a continued expansion of Trikafta sales.
Our first set of Out Of Favor Health Care picks, published on July 24, 2020 (see below), outperformed significantly, rising by over 55% on an equally weighted basis since our recommendation. In comparison, the S&P 500 is up by just about 20% over the same period. Stocks we picked back then include Novocure (NASDAQ: NVCR), ACADIA (NASDAQ: ACAD), Alexion (NASDAQ: ALXN), and Alkermes (NASDAQ: ALKS).
[1/15/2021] Neurocrine, Ionis and Vertex
Our theme of Out Of Favor Health Care Stocks includes health care stocks that have witnessed strong Revenue growth and improving fundamentals over the last few years but have underperformed in 2020, on account of clinical setbacks or due to Covid-19 related disruptions of the health care industry. Below is a bit more about these stocks, the reasons for their recent underperformance, and some near-term trends that could help with their recovery.
Neurocrine Biosciences (NBIX) is a biopharma company that develops treatments for neurological and endocrine-related disease disorders. The company’s first FDA-approved drug Ingrezza, a treatment for Tardive Dyskinesia, is facing headwinds due to the Covid pandemic, which is impacting new patient starts. Although sales could remain lackluster for a few quarters, it should see gains in the medium to long run. In fact, Ingrezza’s peak sales are estimated to be over $2 billion, compared to the sales of $753 million seen in 2019.
Ionis Pharmaceuticals (IONS) specializes in discovering and developing RNA-targeted therapeutics. The company’s primary drug is its spinal muscular atrophy (SMA) drug Spinraza which is licensed to Biogen. The stock has underperformed partly due to weak sales of Spinraza, with royalty Revenue for the drug declining in Q3 2020 due to the impact of Covid-19 on both new starts and maintenance doses, as well as increased competition. That said, Ionis is likely to return to growth over 2021, helping the stock.
Vertex Pharmaceuticals’ (VRTX) current commercial drugs primarily deal with Cystic Fibrosis (CF), a genetic disease that affects the lungs and digestive system. The company’s most important drug, a 3-in-1 pill called ‘Trikafta,” was approved by the US FDA in late 2019 and is likely to be a big driver of sales. That said, the stock underperformed as the biotech discontinued the development of a drug for alpha-1 antitrypsin deficiency (AATD) last October. However, the company is developing another drug for the same disorder, with clinical data expected for the first half of 2021.
BioMarin Pharmaceutical (BMRN) focused on enzyme replacement therapies. The stock underperformed with the U.S. FDA not approving its promising candidate valoctocogene roxaparvovec gene therapy for severe hemophilia A, which is in the late-stage pipeline, as it requested for two-year follow-up safety and efficacy data on all trial participants for Valrox. This means that the drug could probably be delayed to 2022. Valrox is a potential blockbuster with peak sales estimated to be over $3.5 billion in 2030. That said, the company still has six other approved drugs, and sales are poised to grow modestly over 2020 and 2021.
[12/31/2020] BioMarin, Alkermes, Ionis: Are These Health Care Stocks Set To Outperform In 2021
Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over 2020, partly due to Covid-19 related disruptions of the health care industry. However, with highly effective Covid vaccines being rolled out, the broader healthcare sector and economy should start returning to normal, potentially setting these stocks up for outperformance. Companies in our theme include Neurocrine Biosciences (NASDAQ:NBIX) – a biotech company that develops treatments for neurological and endocrine-related diseases and disorders, Ionis Pharmaceuticals (NASDAQ:IONS) – a pharma player engaged in RNA-targeted therapeutics, BioMarin Pharmaceutical (NASDAQ:BMRN) – a company focused on enzyme replacement therapies and Alkermes (NASDAQ:ALKS) – which focuses on drugs for central nervous system (CNS) diseases. View our theme on Out Of Favor Health Care Stocks for more details on the selection criteria and performance of these companies in recent years.
Our first set of out of favor health care stock picks, published on July 24, 2020 (see below), has outperformed significantly, rising by about 60% on an equally weighted basis since our recommendation. In comparison, the S&P 500 is up by just about 16% over the same period. The stocks we picked back then include Novocure (NASDAQ: NVCR), ACADIA (NASDAQ: ACAD), Alexion (NASDAQ: ALXN), and Alkermes (NASDAQ: ALKS).
[Updated 7/24/2020] Out Of Favor Healthcare Stocks
The performance of the healthcare sector has been mixed this year. While dental and surgery-related stocks have declined – as Covid-19 impacts sectors that require a close person-to-person contact, companies working on Covid-19 vaccines have outperformed significantly. On the other hand, the stocks of several high-growth companies that sell therapeutics that are relatively insulated from the pandemic have remained listless. In this analysis, we’ve picked a few healthcare names including Novocure (NASDAQ: NVCR), ACADIA (NASDAQ: ACAD), and Alexion (NASDAQ: ALXN) that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed this year. Overall, we believe these stocks could offer some growth and stability in the current environment, without being overpriced. See our analysis Out Of Favor Health Care Stocks That Are Still Poised For Gains for more details on the returns and performance of these stocks. Parts of the analysis are summarized below.
Alexion ($23 billion, -3% YTD) is a pharma company best known for Soliris, a drug used to treat atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria (PNH) – two rare disorders. The company has seen demand for Soliris grow, with revenues almost doubling from $2.6 billion in 2015 to $5 billion in 2019. Alexion’s pipeline also looks strong, with multiple drugs in phase 3 clinical trials including Ultomiris, which is its next-generation drug for PNH.
ACADIA Pharmaceuticals ($7 billion, +2% YTD) a biopharmaceutical company known for its flagship drug Nuplazid, which helps to treat the hallucinations associated with Parkinson’s disease psychosis (PDP). However, the stock gave up much of its year-to-date gains after Nuplazid recently failed in a trial for depression treatment. The company could still see an upside as Nuplazid continues to see strong demand from the PDP treatment, with total revenue rising steadily from about $17 million in 2016 to about $340 million last year.
Novocure ($7 billion, -20% YTD) is an oncology company that offers a novel therapy called Tumor Treating Fields, which uses electric fields to disrupt solid tumor cancer cell division. The company’s revenues have grown from around $33 million in 2015 to $350 million in 2019. While the TTF device is currently used for some types of brain cancer, late-stage trials are underway for its use in other conditions including lung carcinoma, ovarian cancer, and pancreatic cancer and this could drive future growth.
Alkermes ($3 billion, -4% YTD) is a biopharmaceutical company that focuses on drugs for diseases in the central nervous system including schizophrenia, depression, and multiple sclerosis. The company has been seeing steady demand growth, with revenue growing from around $0.6 billion in 2015 to about $1.2 billion in 2019.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market since 2016.
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On the other side, ACADIA Pharmaceuticals stock (ACAD), down by 67% year-to-date, has been the weakest performer. ACADIA Pharmaceuticals (ACAD) a biopharmaceutical company focused on neuroscience drugs, has been the worst performer within our theme, with its stock down by 59% year-to-date. Moreover, ACADIA says it will work with the FDA to resolve discrepancies in its application for dementia-related psychosis treatment. | On the other side, ACADIA Pharmaceuticals stock (ACAD), down by 67% year-to-date, has been the weakest performer. ACADIA Pharmaceuticals (ACAD) a biopharmaceutical company focused on neuroscience drugs, has been the worst performer within our theme, with its stock down by 59% year-to-date. Moreover, ACADIA says it will work with the FDA to resolve discrepancies in its application for dementia-related psychosis treatment. | On the other side, ACADIA Pharmaceuticals stock (ACAD), down by 67% year-to-date, has been the weakest performer. ACADIA Pharmaceuticals (ACAD) a biopharmaceutical company focused on neuroscience drugs, has been the worst performer within our theme, with its stock down by 59% year-to-date. Moreover, ACADIA says it will work with the FDA to resolve discrepancies in its application for dementia-related psychosis treatment. | ACADIA Pharmaceuticals (ACAD) a biopharmaceutical company focused on neuroscience drugs, has been the worst performer within our theme, with its stock down by 59% year-to-date. On the other side, ACADIA Pharmaceuticals stock (ACAD), down by 67% year-to-date, has been the weakest performer. Moreover, ACADIA says it will work with the FDA to resolve discrepancies in its application for dementia-related psychosis treatment. |
35797.0 | 2021-09-02 00:00:00 UTC | Interesting ACAD Put And Call Options For October 22nd | ACAD | https://www.nasdaq.com/articles/interesting-acad-put-and-call-options-for-october-22nd-2021-09-02 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new October 22nd contracts and identified one put and one call contract of particular interest.
The put contract at the $17.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $17.00, but will also collect the premium, putting the cost basis of the shares at $16.85 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $17.23/share today.
Because the $17.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.88% return on the cash commitment, or 6.44% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $17.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 50 cents. If an investor was to purchase shares of ACAD stock at the current price level of $17.23/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $18.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 7.37% if the stock gets called away at the October 22nd expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red:
Considering the fact that the $18.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 2.90% boost of extra return to the investor, or 21.18% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $17.23) to be 77%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 22nd expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new October 22nd contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $17.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 50 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 22nd expiration. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $17.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 50 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 22nd expiration. |
35798.0 | 2021-08-31 00:00:00 UTC | First Week of ACAD October 15th Options Trading | ACAD | https://www.nasdaq.com/articles/first-week-of-acad-october-15th-options-trading-2021-08-31 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the October 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new October 15th contracts and identified one put and one call contract of particular interest.
The put contract at the $16.00 strike price has a current bid of 55 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $16.00, but will also collect the premium, putting the cost basis of the shares at $15.45 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $17.48/share today.
Because the $16.00 strike represents an approximate 8% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 68%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 3.44% return on the cash commitment, or 27.88% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $16.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 95 cents. If an investor was to purchase shares of ACAD stock at the current price level of $17.48/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $18.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 8.41% if the stock gets called away at the October 15th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red:
Considering the fact that the $18.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 49%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 5.43% boost of extra return to the investor, or 44.08% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 79%, while the implied volatility in the call contract example is 89%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $17.48) to be 77%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the October 15th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the October 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new October 15th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $16.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 95 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the October 15th expiration. | At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new October 15th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the October 15th expiration. |
35799.0 | 2021-08-25 00:00:00 UTC | Relative Strength Alert For Acadia Pharmaceuticals | ACAD | https://www.nasdaq.com/articles/relative-strength-alert-for-acadia-pharmaceuticals-2021-08-25 | nan | nan | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $16.77 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 62.0. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares:
Looking at the chart above, ACAD's low point in its 52 week range is $16 per share, with $57.46 as the 52 week high point — that compares with a last trade of $17.06.
Find out what 9 other oversold stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $16.77 per share. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $16 per share, with $57.46 as the 52 week high point — that compares with a last trade of $17.06. | A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $16 per share, with $57.46 as the 52 week high point — that compares with a last trade of $17.06. In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $16.77 per share. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $16.77 per share. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $16 per share, with $57.46 as the 52 week high point — that compares with a last trade of $17.06. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $16.77 per share. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $16 per share, with $57.46 as the 52 week high point — that compares with a last trade of $17.06. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.